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Peroxisome Proliferator Activated Receptors (PPAR), part of the 48 member 
nuclear/steroid receptor superfamily of transcription factors, have critical roles in lipid 
and carbohydrate metabolism. While PPARγ regulates glucose levels and adipogenesis, 
PPARα is highly expressed in tissues involved in fatty acid metabolism where it regulates 
several key proteins in fatty acid oxidation and ketogenesis. Compounds that target 
PPARα and PPARγ are used extensively in the clinical setting to correct dyslipidemia 
and to restore glycemic balance in diabetes and atherosclerosis. However many of the 
drugs in current use have significant adverse effects. Therefore, there is a need for the 
discovery of more PPAR-active compounds with beneficial efficacy/risk profiles.  
Recently, natural variants of PPAR have been shown to be functionally significant 
and are important determinants of cardiovascular and metabolic health. In particular, a 
non-synonymous variant at the PPARA locus encoding a substitution of valine for alanine 
at residue 227 (V227A) in the hinge region of the PPARα has been observed in Singapore 
and other East-Asian populations with relatively high allelic frequencies.  This variant 
was associated with perturbations in plasma lipid levels and modulated the association 
between dietary polyunsaturated fatty acids and high density lipoprotein cholesterol.  The 
impact of this variant on the function of PPARα is unknown. 
To address the above issues, the objectives of this study were:  
1) To identify, isolate and structurally characterize PPAR active 
compounds from an anti-diabetic botanical, Pueraria Thomsonii (PT), 
and to characterize their functional effects in relevant cell models.  
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2) To examine the effects of the V227A variant on PPARα function and to 
elucidate the molecular mechanisms for any observed effects. 
Firstly, we demonstrated that extracts of PT can activate PPARα and PPARγ. 
Repeated bioassay guided fractionation resulted in the identification and isolation of the 
isoflavones, daidzin, daidzein, genistin, puerarin and 2’hydroxydaidzein, as bioactive 
compounds of PT. We characterized the effects of daidzein from PT and other 
isoflavones, calycosin, formononetin, genistein and biochanin A, using chimeric and full-
length PPAR constructs in vitro. Biochanin A and formononetin were potent activators of 
both PPAR receptors (EC50=1-4 μM) with PPARα/PPARγ activity ratios of 1:3 in the 
chimeric and almost 1:1 in the full length assay, comparable to that observed for 
synthetic dual PPAR-activating compounds under pharmaceutical development. There 
was a subtle hierarchy of PPARα/γ activities with biochanin A, formononetin and 
genistein being more potent than calycosin and daidzein in chimeric as well as full length 
receptor assays. At low doses only biochanin A and formononetin, but not genistein, 
calycosin or daidzein, activated PPARγ-driven reporter gene activity and induced 
differentiation of 3T3-L1 preadipocytes. Our data suggest the potential value of 
isoflavones, especially biochanin A, and their parent botanicals as anti-diabetic agents 
and for use in regulating lipid metabolism.   
Secondly, the functional significance of the V227A substitution was explored. 
The polymorphism significantly attenuated PPARα mediated transactivation of the 
CYP4A6 and mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCS2) 
genes, with polyunsaturated fatty acids and the fibrate, WY14,643, in a dominant-
negative manner.  Screening of a panel of PPARα coregulators revealed that V227A 
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enhanced recruitment of the nuclear corepressor, NCoR. Weaker transactivation activity 
of V227A can be restored by silencing NCoR, or by inhibition of its histone deacetylase 
activity. Deletion studies indicate that PPARα interacts with NCoR receptor-interacting 
domain 1 (ID1), but not ID2 or ID3. These interactions were dependent on the intact 
consensus nonapeptide nuclear receptor interaction motif in NCoR ID1, and were 
enhanced by the adjacent 24 N-terminal residues. Novel corepressor interaction 
determinants involving PPARα helices 1 and 2 were identified. The V227A substitution 
stabilized PPARα/NCoR interactions in the unliganded state, and caused defective 
corepressor/coactivator exchange in the presence of ligands, on the HMGCS2 promoter 
in hepatic cells. These results provide the first indication that defective function of a 
natural PPARα variant was due to increased corepressor binding.  
In all, our data suggest that the PPARα/NCoR interaction is physiologically 
relevant, and can produce a discernable phenotype when the magnitude of the interaction 
is altered by a naturally occurring variation. Our detailed mechanistic study of the 
PPARα V227A variant allows for the design of future human studies to identify other 
benefits and risks associated with this mutation. Furthermore, the identification and 
characterization of isoflavones, and their parent botanicals, with different PPARα/γ 
potencies suggest their value in the management of the epidemic of diabetes, 
dyslipidemia and the metabolic syndrome. 
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1.1 The Peroxisome Proliferator Activated Receptor 
1.1.1 The Nuclear Receptor Superfamily 
Nuclear receptors (NR) are members of a large superfamily of evolutionarily related 
DNA-binding transcription factors which have diverse, crucial roles in the regulation of 
growth, development and homeostasis (Chambon 2005; Evans 2005; Germain et al. 
2006). Since the isolation of cDNA encoding the Glucocorticoid Receptor (GR) 
(Hollenberg et al. 1985) and the Estrogen Receptor α (ERα) (Green et al. 1986; Greene et 
al. 1986), the sequencing of the human genome has so far led to the identification of 48 
nuclear receptors (Perissi and Rosenfeld 2005).  
Members of this superfamily can be broadly divided into subgroups on the basis 
of their pattern of dimerization (Germain et al. 2006) (Table 1.1). One group consists of 
the steroid receptors, including the Androgen Receptor (AR), the Mineralocorticoid 
Receptor (MR), the GR, the ERα and ERβ (Table 1.1). These steroid receptors function 
as homodimers and bind to a degenerate set of hexameric half-sites separated by 3 base 
pairs of spacer (IR3) on the DNA (Glass 1994). These specific DNA sequences are called 
hormone response elements (HRE) (Kumar et al. 1986). Except ER, the steroid receptors 
recognize the consensus DNA half-site sequence 5’-AGAACA-3’. ER binds in similar 
symmetric sites but with the consensus half-site sequence of 5’-AGGTCA-3’.  
Nearly all non-steroidal receptors recognize one or two copies of the consensus 
DNA half-site sequence 5’-AGGTCA-3’ that can be configured into a variety of 
structured motifs (Mangelsdorf and Evans 1995; Germain et al. 2006).  Among these 
receptors, a major group consists of receptors that form heterodimers with the Retinoid X 
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Receptor (RXR) (Table 1.1). The various RXR heterodimers can bind to direct repeats 
(DRs) with one to five base pairs of spacing, referred to as DR1 to DR5. The Peroxisome 
Proliferator Activated Receptor (PPAR), the Retinoid Acid Receptor (RAR), the Vitamin 
D Receptor (VDR) and the Thyroid Receptor (TR) heterodimerize with RXR on DR1 to 
DR4 respectively. RAR can also heterodimerize with RXR on DR5 (Mangelsdorf and 
Evans 1995). In addition, some NRs such as Rev-erb and Retinoid- related Orphan 
Receptor (ROR) binds DNA efficiently as monomers (Giguere et al. 1995; Harding and 
Lazar 1995). 
 
Table 1.1 DNA binding properties of homodimers and RXR heterodimers of nuclear 
receptors 
 















































Members of the NR superfamily share a common structural organization that is 
well-defined and has specific functions (Fig 1.1). The N-terminal transactivation domain 
(TAD) contains at least one ligand-independent activation function (AF-1) and is the least 
conserved among NR both in terms of length and sequence (Robinson-Rechavi et al. 
2003). So far, no crystal structure of the TAD has been elucidated (Germain et al. 2006).  
The most conserved region is the central DNA Binding Domain (DBD). The 
DBD allows the binding of ligand activated NR on HREs to elicit a biological response. 
Within the DBD, several sequence elements have been shown to determine HRE 
specificity, dimerization and facilitate contacts with the DNA backbone (Umesono and 
Evans 1989). The crystal structure of the GR homodimer on its cognate DNA (Luisi et al. 
1991) and subsequent studies revealed that this DBD consists of a highly conserved 66 
residues core made up of two typical cysteine-rich zinc finger motifs, two α helices and a 
COOH terminal (Gronemeyer et al. 2004).  
Between the DBD and the Ligand Binding Domain (LBD) is a less conserved 
region that behaves as a flexible Hinge between the two domains and may overlap onto 
the LBD (Robinson-Rechavi et al. 2003). Being the least studied, this region is thought to 
allow rotation of the DBD and permits the DBD and the LBD to adopt different 
conformations without creating steric hindrance (Germain et al. 2006). 
The largest domain is the moderately conserved LBD whose secondary structure 
of 12 α-helices is better conserved than the primary sequence (Robinson-Rechavi et al. 
2003). The LBD contains four structurally distinct but functionally linked surfaces 
(Germain et al. 2006): 1) a dimerization surface, which mediates interaction with partner 
LBDs, 2) a ligand binding pocket, which interacts with diverse lipophilic small molecules,  
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 Figure 1.1 Schematic illustration of the general structural and functional 
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3) a coregulator binding surface which binds regulatory protein complexes that modulate 
positively (by coactivators) or negatively (by corepressors) transcriptional activity, and 4) 
an activation function helix (AF-2) which mediates ligand dependent transactivation. NR 
crystal structures resolved show that the LBDs of these receptors form an anti-parallel α-
helical sandwich of 12 helices organized in three layers with a central hydrophobic ligand 
binding pocket (Nolte et al. 1998). Ligand binding to this pocket induces a structural 
change which favours the closure of the ligand binding pocket by helix 12 like a lid in a 
‘mouse trap’ model of ligand dependent activation. (Moras and Gronemeyer 1998). 
Despite the conserved fold of LBDs, the shape and size of the ligand binding pocket can 
vary greatly from receptor to receptor. This allow for selectivity of specific ligands for 
each receptor in the NR Superfamily (Germain et al. 2006). 
Collectively, these properties allows transactivation by members of the NR 
superfamily, especially homodimers, to occur in 5 major steps (Lefebvre et al. 2006): 1) 
ligand binding; 2) stable binding of liganded NR to HRE; 3) corepressors dismissal and 
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coactivators recruitment; 4) activation of transcription; and 5) either shut down or re-
initiation of transcription. 
 
1.1.2 The Peroxisome Proliferator Activated Receptor  
Peroxisome Proliferator Activated Receptors (PPARs) are members of the NR 
Superfamily. PPARs are transcriptional regulators involved in the regulation of key 
metabolic pathways in lipid metabolism, adipogenesis, and insulin sensitivity (Brown and 
Plutzky 2007).  
PPARα was first described as a receptor that is activated by peroxisomes 
proliferators in rodent hepatocytes (Issemann and Green 1990). Two additional related 
isotypes, PPARβ (also known as PPARδ) and PPARγ, have since been identified and 
characterized (Dreyer et al. 1992) (Fig 1.2). Due to different promoter usage within the 
same gene and subsequent alternative RNA splicing, there are two isoforms of PPARγ 
(Elbrecht et al. 1996). PPARγ2 has 28 amino acids more than the PPARγ1 isoform at the 
N-terminal domain. 
PPARs exhibit a broad but isotype specific tissue expression pattern that can 
account for the variety of cellular functions they regulate (Kliewer et al. 1994; Braissant 
et al. 1996). PPARα is expressed in tissues with high fatty acid catabolism such as the 
liver, the heart, the brown adipose tissue, the kidney, and the intestine (Mandard et al. 
2004). Of the three isotypes, PPARβ exhibits the broadest expression pattern (Feige et al. 
2006). Nonetheless, higher levels of PPARβ were noted in the brain, adipose and skin 
(Amri et al. 1995; Braissant et al. 1996). PPARγ2 is expressed primarily in adipose 
tissues while PPARγ1 is expressed in a broad range of tissue such as the gut, brain, 
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Figure 1.2 General structure of human PPAR 
Illustration of the four domain structures of PPAR with coordinates of each domain 
boundary given according to Desvergne and Wahli (1999). Purple bar represents the 
hinge which starts from the termination of DBD and extends into helix 2 of the LBD.  
TAD DBD LBD
1 101 166 195 468
1 72 137 167 441












vascular cells, and specific kinds of immune and inflammatory cells (Dreyer et al. 1992; 
Chawla et al. 1994; Tontonoz et al. 1994a; Tontonoz et al. 1994b; Zhu et al. 1995).  
Consistent with their distribution in tissues, PPARα is important in the 
transcription modulation of liver and skeletal muscle lipid metabolism (Lefebvre et al. 
2006). PPARβ, the least described PPAR isotype, enhances fatty acid catabolism and 
energy uncoupling in adipose tissue and muscle, and suppresses macrophage-derived 
inflammation (Barish et al. 2006). PPARγ is pivotal in adipose tissue differentiation, 
adipocyte specific functions and glucose metabolism (Michalik et al. 2006). 
PPARs function as a ligand activated transcription factor which control gene 
expression by binding to specific DNA sequence, called PPAR response elements 
(PPRE), as heterodimers with RXR in a ligand dependent manner. The first natural PPRE 
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identified was in the promoter of the acyl-CoA oxidase gene  (Tugwood et al. 1992) 
which contains a direct repeat of two core recognition motifs AGGTCA spaced by one 
nucleotide (DR1). Since then, sequence comparison of other natural PPREs has 
broadened the definition of a PPRE to include the following properties: an extended 5’ 
half site, an imperfect core DR1 and an adenine as the spacing nucleotide (Palmer et al. 
1995; IJpenberg et al. 1997; Juge-Aubry et al. 1997; Osada et al. 1997).  
Like members of the NR Superfamily, the first step of transactivation by PPARs 
involves ligand binding. PPARs are activated by a wide range of naturally occurring or 
metabolized lipids that are derived from the diet or from intracellular signaling pathways 
(Feige et al. 2006). These include saturated and unsaturated fatty acids and fatty acid 
derivatives such as prostaglandins and leukotrienes (Forman et al. 1995; Forman et al. 
1997; Kliewer et al. 1997; Krey et al. 1997). Synthetic ligands such as fibrates, the 
plasma lipid-lowering drug used in the treatment of hyperlipidaemia, activate PPARα 
(Forman et al. 1997) while thiazolidinediones, the insulin sensitizing drug for the 
treatment of type 2 diabetes, activate PPARγ (Lehmann et al. 1995).  
Crystal structure analyses of the PPAR LBD have revealed a three dimensional 
fold that is similar to other NRs (Nolte et al. 1998; Uppenberg et al. 1998; Xu et al. 1999; 
Xu et al. 2001). The PPAR LBD consists of 12 α-helices that form the characteristic three 
layer anti-parallel α-helical sandwich with a small four stranded β-sheet. However, some 
distinct differences are apparent (Nolte et al. 1998; Uppenberg et al. 1998). The core AF2 
in the apo-PPAR (unliganded) is folded against the ligand binding pocket in a 
conformation similar to that in the holoforms (liganded) of PPAR and other nuclear 
receptors.  Unlike other NRs, PPAR contains an additional helix 2’ which is found 
 10
between the first β strand and helix 3 (Gampe et al. 2000). This, together with a 
placement of helix 2 that differs from other NR tertiary structure, provides easy access to 
the hydrophobic pocket for ligands. The region between helix 2’ and helix 3 that 
corresponds to the Ω loop in RAR is extended, most thermally mobile and participates in 
the structural changes occurring upon ligand binding. Together, these structures define a 
large Y-shape hydrophobic ligand binding pocket which is larger in PPAR than in other 
receptors. While the ligand binding pocket is particularly large (~1300Å3), ligands only 
occupy 30-40% of this space. It is thus larger and more accessible than other known 
LBDs such as the TR which ~600Å3 cavity is largely occupied by its ligand, T3 of 
~530Å3 (Wagner et al. 1995). Collectively, these differences may contribute to the ability 
of PPAR to bind a wide range of synthetic and natural ligands at micromolar 
concentrations (Michalik et al. 2006).  
In the next two sections, focus will be on the detailed physiological roles of 
PPARα and PPARγ; and the synthetic and natural ligands which control them. This will 
be followed by a section which concentrates on the molecular mechanisms of 
transcription regulation in PPAR. Discussion in that section will be largely centered on 
PPARα although reference to PPARγ and PPARβ will be made where relevant. After 
which, a summary of PPARα polymorphisms will follow. Finally, this chapter will end 
with an outline on flavonoids and their botanical sources.   
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1.2 Physiological Aspects of PPAR 
1.2.1 PPARα 
PPARα controls intracellular lipid metabolism, lipoprotein metabolism and glucose 
homeostasis through direct transcriptional control of genes involved in fatty acid 
oxidation pathways (FAO) and fatty acid (FA) uptake; lipoprotein assembly and transport; 
and glucose homeostasis (Lefebvre et al. 2006). 
 
1.2.1.1 Lipid metabolism 
PPARα acts in the liver to reduce FA concentration through the control of key enzymes 
in FAO and FA uptake. Major enzymes of FA β-oxidation (peroxisomal and 
mitochondrial) and FA ω-oxidation (microsomal), together with proteins involved in the 
transport of FA, are increased in response to PPARα (Fig 1.3).  
In the peroxisomes, the β-oxidation pathway breaks down very-long-chain FA (of 
carbon atoms more than 20, >C20), as well as of other lipid derivatives such as 
eicosanoids or branched FAs, for further β-oxidation in the mitochondria. Major enzymes 
of the peroxisomal β-oxidation pathway, acyl-CoA synthetase (very-long and long chain 
FA) (Schoonjans et al. 1995), acyl-CoA oxidase (ACO) (short chained and branched FA) 
(Dreyer et al. 1992; Tugwood et al. 1992), L-bifunctional protein (Marcus et al. 1993) 
and 3-ketoacyl-CoA thiolase (Zhang et al. 1993) are regulated by PPARα.  
In the mitochondria, the β-oxidation pathways breaks down short-chain (<C8), 
medium-chain (C8-C12), and long-chain (C13-20) FA for energy in cellular processes 
through progressive shortening of FA into acetyl-CoA subunits. The acetyl-CoA subunits 
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Figure 1.3 PPARα in lipid metabolism 
 
Role of PPARα in lipid metabolism. Upon ligand activation, PPARα upregulates key 
enzymes (group of enzymes depicted by yellow squares) involved in the fatty acid (FA) 
β-oxidation (peroxisomal and mitochondrial) and ω-oxidation (microsomal) pathways. 
During fasting, final products of FA, the acetyl-CoA subunits, are converted to ketones 
by PPARα controlled HMGCS2 and other enzymes. PPARα also upregulates proteins of 
FA uptake (group of enzymes depicted by orange trapezium). The collective effect of 
increased FA oxidation and uptake by PPARα regulated genes lead to a decrease in 
intracellular FA concentration. Solid lines represent transport, broken lines represent 
enzymatic conversion which usually involves several steps.  
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 may be condensed into ketone bodies that serve as oxidizable energy substrates for 
extrahepatic tissues especially during starvation. Carnitine palmitoyl transferase 1A 
(CPT1A), the rate limiting enzyme that controls FA import into the mitochondria is 
regulated by PPARα in liver (Mascaro et al. 1998). Major enzymes of the mitochondria 
β-oxidation pathway, acyl-CoA synthetase (long chain FA) (Schoonjans et al. 1995) and 
very-long and medium-chain acyl-CoA dehydrogenase (Gulick et al. 1994; Aoyama et al. 
1998), are PPARα regulated.  During fasting or diabetes, the breakdown products of FA 
in the mitochondria, acetyl-CoA, are converted into ketone bodies. PPARα controls the 
expression of mitochondrial HMG-CoA synthase (HMGCS2), the key step in ketone 
body generation (Rodriguez et al. 1994).  
The CYP4A subclass of cytochrome P450 enzymes catalyze the ω-oxidation of 
FA in microsomes, a pathway that is particularly active in the fasted and diabetic states 
(Berger and Moller 2002), through hydroxylation of long chain saturated and unsaturated 
FAs for further β-oxidation in the peroxisome. Fibrates have been shown to activate 
expression of CYP4As and functional PPREs have been found in the promoters of 
CYP4A genes. (Aldridge et al. 1995; Kroetz et al. 1998)  
In FA transport, fatty acid translocase, (CD36), a glycoprotein that controls FA 
uptake in multiple cell types, is regulated by PPARα in the liver (Motojima et al. 1998). 
Similarly, the expression of the fatty acid transport protein (FATP-1) (Martin et al. 1997) 
and liver fatty acid binding protein (L-FABP) (Poirier et al. 2001), important proteins in 
the transport of FA across cell membrane, are upregulated by PPARα activation in 
hepatocytes. 
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Collectively, PPARα acts in the liver to reduce intracellular FA concentrations 
and likely contributing to a decrease in very-low-density-lipoprotein (VLDL) particle  
production and plasma triglyceride (TG) levels (Lefebvre et al. 2006). 
 
1.2.1.2 Lipoprotein metabolism 
In lipoprotein metabolism, VLDL and TG levels are reduced while high density 
lipoprotein (HDL) is increased upon PPARα activation by the lipid-lowering drug ligand 
of PPARα, fibrates.  
In TG breakdown, PPARα activation upregulates the expression of lipoprotein 
lipase (LPL) (Schoonjans et al. 1996a). LPL is a triacylglycerol hydrolase which 
hydrolyze TG from lipoprotein particles to FA. PPARα also controls TG degradation 
through the regulation of various apolipoprotein levels (Lefebvre et al. 2006). PPARα 
downregulates apolipoprotein C-III (apoC-III) in hepatocytes (Staels et al. 1995; Peters et 
al. 1997). apoC-III inhibits LPL activity and VLDL lipolysis. On the other hand, 
apolipoprotein A-V (apoA-V), a potent activator of lipolysis, is upregulated by PPARα 
(Vu-Dac et al. 2003).  
Apolipoprotein A-I (apoA-I) and A-II (apoA-II) are major  
components of HDL. HDL is protective against atherosclerotic vascular disease and are 
the main vehicle for reverse cholesterol transport (RCT) (Lefebvre et al. 2006). apoA-I 
and apoA-II gene expression is under direct transcriptional control of PPARα in-vitro 
(Vu-Dac et al. 1994; Hennuyer et al. 1999) and in humans (Vu-Dac et al. 1995; Watts et 
al. 2003). Interestingly, the murine apoA-I gene is negatively regulated by PPARα 
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agonists (Vu-Dac et al. 1998). The murine apoA-I lacks a functional PPRE in its 
promoter. Furthermore, PPARα agonists upregulate the expression of Rev-erb, an orphan 
receptor, which binds to the promoter of murine apoA-I to downregulate apoA-I 
expression.   
HDL particle size and lipid composition are modulated by the PPARα controlled 
phospholipid transfer protein (PLTP) (Tu and Albers 2001). Increase in PLTP and LPL 
also increase pre-β-HDL (Tu and Albers 2001; Fruchart and Duriez 2006). pre-β-HDL, is 
a key acceptor of cholesterol from peripheral cells during RCT (Fruchart 2001). 
Furthermore, PPARα agonists also induce the expression of adenosine triphosphate-
binding cassette transporter A1 (ABCA1) (Chinetti et al. 2001) and scavenger receptor BI 
(SR-BI) (Chinetti et al. 2000).  ABCA1 is an exporter of cholesterol from cells (eg. 
macrophage) while SR-BI are hepatic cell surface receptors that bind HDL with high 
affinity and mediate the selective uptake of cholesteryl esters from HDL into the liver 
(Fruchart 2001). Together, interaction of HDL with SR-BI and ABCA1 triggers 
cholesterol efflux from peripheral tissues and HDL particles direct cholesterol for hepatic 
excretion into the bile (Eriksson et al. 1999).  
Collectively, PPARα activation reduces TG levels through increased lipolysis and 
promotes HDL metabolism by increasing HDL formation to aid in the transport of 
cholesterol from peripheral tissues to the liver for breakdown.  
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 1.2.1.3 Glucose metabolism  
Severe hypoglycemia and hyperinsulinemia exhibited in PPARα null mice after fasting 
suggests a role for PPARα in glucose homeostasis (Kersten et al. 1999). Plasma glucose 
levels during fasting are affected by a combination of glucose synthesis, glycogen 
breakdown and glucose utilization (Mandard et al. 2004).  
PPARα activation reduces TG level. This causes a reduction in glucose synthesis 
because TG provides the pathway with the essential substrate, glycerol. Rate-limiting 
enzymes of glucose synthesis are phosphoenol pyruvate carboxykinase (PEPCK) and 
pyruvate carboxylase. While PEPCK contains a PPRE shown to be functional in 
adipocytes (Tontonoz et al. 1995), there is no observable difference in hepatic PEPCK 
expression between wild type and PPARα null mice, regardless of nutritional status 
(Kersten et al. 1999; Xu et al. 2002b). In contrast, pyruvate carboxylase is reduced in 
fasting PPARα null mice (Mandard et al. 2004). However, no PPRE has yet been 
identified on its promoter.    
Fasting induces the breakdown of glycogen into glucose through the induction of 
several hepatic enzymes such as glycerol-3-phosphate dehydrogenase and glycerol kinase. 
The expression of these enzymes, and of the glycerol transporters aquaporins 3 and 9, are 
PPARα dependent too (Patsouris et al. 2004).   
The pyruvate dehydrogenase kinase isoform 4 (PDK4) is an inhibitor of glucose 
utilization and is PPARα activated (Wu et al. 2001). During fasting, low levels of PDK4 
in PPARα null mice leads to an increase in its substrate, pyruvate dehydrogenase, and an 
increase in glucose utilization.  
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Response to fasting is also dependent on the pancreas, and PPARα null mice 
exhibit hyperinsulinemia due to inefficient suppression of insulin secretion upon fasting 
(Gremlich et al. 2005). PPARα activation in pancreatic islet β cells also increases 
pancreatic FAO and potentiates glucose-induced insulin secretion, suggesting that 
PPARα activation protects pancreatic islets from lipotoxicity (Ravnskjaer et al. 2005), a 
major causative factor for the development of type 2 diabetes mellitus (Lefebvre et al. 
2006).  
While PPARα activation of TRB3, an inhibitor of Akt/protein kinase B, 
negatively impacts on liver insulin signaling and perturbs glucose homeostasis (Koo et al. 
2004), the general marked hypoglycemic and hyperinsulinemic phenotype exhibited by 
PPARα null mice upon fasting indicates the role of PPARα as a key player in glucose 
homeostasis.  
 
1.2.3.4 PPARα null mice 
In rodents, PPARα activation leads to peroxisome proliferation and hepatocarcinoma, a 
property intrinsic to mouse PPARα but not observed in humans (Cheung et al. 2004), due 
in part to the ten fold lower expression of PPARα in human liver (Palmer et al. 1998; 
Berger and Moller 2002).  The phenotype of PPARα null mice fed on a normal diet is 
mild (Lee et al. 1995). However, fasting or inhibition of mitochondrial FA import 
severely impairs FA uptake and FAO, leading to sex-specific liver steatosis and cardiac 
lipid accumulation in male mice, hypoglycemia and hypothermia (Costet et al. 1998; 
Djouadi et al. 1998; Kersten et al. 1999). The induction of satiety in mice through 
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PPARα activation also suggest a role for PPARα in body weight control and indirectly 
supports the use of PPARα agonists to treat obesity (Fu et al. 2003).  
Collectively, the general positive effects of PPARα on energy metabolism reflects 
its ability to improve symptoms of the metabolic syndrome (obesity, insulin resistance 
and dyslipidemia) and also suggest that PPARα may be beneficial in the prevention or 
treatment of type 2 diabetes mellitus and its associated complications (Lefebvre et al. 
2006).  
 
1.2.2 PPARγ  
As a master modulator of adipocyte differentiation, PPARγ is required for the 
accumulation of adipose tissue and hence contributes to obesity (Lehrke and Lazar 2005). 
Crucial indication of the importance of PPARγ in human metabolism stemmed from its 
identification as the cognate receptor for the thiazolidinedione (TZD) class of insulin 
sensitizing drugs (Lehmann et al. 1995). Clinical studies involving TZDs such as 
pioglitazone and rosiglitazone suggest that the direct effects of these glucose-lowering 
agents on adipose tissue can contribute to improvements in hepatic and peripheral insulin 
sensitivity in patients with type 2 diabetes (Maeda et al. 2001; Yamauchi et al. 2001; Yu 
et al. 2002; Bajaj et al. 2004; Miyazaki et al. 2004), a disease of which insulin resistance 
is a hallmark (Gervois et al. 2007).  
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1.2.2.1 Insulin sensitization 
PPARγ regulation of insulin sensitivity involves the primary effects of this receptor on 
gene transcription in adipose tissue, where it is abundantly expressed (Mukherjee et al. 
1997b). In adipocytes, PPARγ regulates the expression of numerous genes such as 
adipocyte fatty acid binding protein (aP2) (Tontonoz et al. 1994b), PEPCK (Tontonoz et 
al. 1995), acyl-CoA synthetase (Schoonjans et al. 1995) and LPL (Schoonjans et al. 
1996b). PPARγ also increases lipid uptake by adipocytes through upregulation of FATP-
1 (Martin et al. 1997) and CD36 (Motojima et al. 1998). The collective effect of PPARγ 
upregulation is an increase in FA uptake and a decrease in lipolysis in adipocytes; and a 
reduction of free FA in the peripheral tissues.   
PPARγ also upregulates the secretion of adipocyte-specific proteins (adipokines) 
which either increase or decrease insulin sensitivity. Insulin sensitizing adipokines such 
as Acrp30/ adiponectin (Berger and Moller 2002) (Iwaki et al. 2003) decreases glucose, 
TG, and free FA (Berger and Moller 2002).  
In contrast, PPARγ inhibits the expression of insulin resistance adipokine such as 
tumour necrosis factor α (TNFα) (Hofmann et al. 1994). PPARγ also downregulates 
leptin, an adipokine that inhibits feeding and augments catabolic lipid metabolism (De 
Vos et al. 1996; Kallen and Lazar 1996). 
Selective PPRE-containing genes that are induced in adipose tissue are suppressed 
in skeletal muscle or liver (Berger and Moller 2002). For example, PPARγ mediated 
downregulation of PDK4 in muscle produces a net increase in glucose oxidation while 
selectively exerting a net decrease in glucose oxidation in the adipose tissue through 
upregulation of PDK4 there (Way et al. 2001).  
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Indeed, the net efficacy of PPARγ agonists involves direct actions on adipose 
cells, with secondary effects on key insulin responsive tissues such as skeletal muscle and 
liver (Berger and Moller 2002). Collectively, the beneficial metabolic effects of PPARγ is 
likely to involve a combination of enhance insulin mediated adipose tissue uptake, 
storage and breakdown of  FA (Oakes et al. 2001); an increase in circulating levels and/or 
action of insulin sensitizing adipokine (eg. Arcp30) and a decrease in insulin resistance 
causing adipokines (eg. TNFα, leptin, resistin (Steppan et al. 2001)). 
 
1.2.2.2 PPARγ null mice 
PPARγ null mice are not viable due to defects in placenta formation (Barak et al. 1999) 
while heterozygous PPARγ mice have reduced body size and weight, reduced insulin 
resistance and smaller adipocytes and fat depots (Kubota et al. 1999; Jaradat et al. 2001; 
Rieusset et al. 2004). In conditional knockout of PPARγ in specific tissues, mice lacking 
expression of PPARγ in adipose tissue have raised plasma levels of lipids, increased 
gluconeogenesis and developed insulin resistance (He et al. 2003).  
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1.3 Ligands of PPAR  
PPAR modulate metabolic and inflammatory pertubations that predispose one to 
cardiovascular diseases and type 2 diabetes. Indeed, hypolipidemic fibrates and the anti-
diabetic TZDs are drugs used in clinical practice that act via PPARα and PPARγ 
respectively. The pleiotropic actions of PPARs and the fact that chemically diverse PPAR 
agonists may induce distinct pharmacological responses have led to new concepts for 
drug design (Gervois et al. 2007). 
Several assays have been developed to identify and characterize PPAR ligands. 
Transactivation assays involve cotransfection of cells with a PPAR expression vector and 
a reporter construct containing a PPRE-driven gene reporter. However, in such assays, 
PPAR forms obligate heterodimers with RXR and activation of this heterodimeric 
complex might be due to ligands activating either RXR or PPAR. Thus, specific 
screening for PPAR ligand cannot be achieved. Alternatively, chimeric receptors 
consisting of the PPAR LBD and the yeast transcription factor Gal4 DBD have been 
utilized with a Gal4-responsive reporter plasmid. Activation of this chimeric reporter 
gene assay will more likely indicate the presence of a specific PPAR ligand. Recently, 
cell lines stably expressing this system has been reported and provides an additional tool 
for high throughput, cell based screening of PPAR ligands (Seimandi et al. 2005).  
Radiolabelled TZD and subsequently developed non-TZDs have been used in 
competitive PPAR ligand binding assays (Lehmann et al. 1995; Berger et al. 1996). 
PPAR scintillation proximity assays, using receptor LBDs attached to scintillant-
containing beads, allowed for high-throughput screening for ligands (Elbrecht et al. 1999). 
Most recently, a fluorescent energy transfer assay was implemented to evaluate the 
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ability of ligands to induce PPAR-cofactor interaction in a rapid, cell-free format (Zhou 
et al. 1998a). 
The prevalent point of view today is that PPARs act as lipid sensors that translate 
changes in lipid/fatty acid levels from the diet or from food deprivation into metabolic 
activity, leading to either fatty acid catabolism or lipid storage (Michalik et al. 2006). The 
endogenous ligands or mediators of these changes have not been characterized but are 
probably generated by fatty acid metabolism. Thus, the quest for "the" endogenous PPAR 
ligand is still ongoing (Lefebvre et al. 2006). 
 
1.3.1 PPARα ligands 
PPARα is activated naturally by a wide variety of saturated (palmitic acid), 
monounsaturated FA (oleic acid) and polyunsaturated FA (PUFA) (linoleic acid, 
linolenic acid and arachidonic acid) (Gottlicher et al. 1992; Keller et al. 1993; Forman et 
al. 1997; Kliewer et al. 1997; Xu et al. 1999) (Fig 1.4A). Notably, PPARα has the highest 
affinity for unsaturated FA among the subtypes and is also the only subtype that binds to 
a wide range of saturated FA (Xu et al. 1999). Comparison of the ligand-binding pocket 
of the three PPAR isotypes has revealed the following interesting characteristics. The 
PPARβ ligand binding pocket is significantly smaller than the pockets of PPARα and 
PPARγ. The pockets of PPARα and PPARγ  are similar to each other in shape and size. 
This difference might explain why PPARβ binds to less and more specific ligands than 
PPARα and PPARγ. The PPARα pocket is more lipophilic than the two others, and 
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Note: While the ligands shown here are mostly agonists, GW9662 is a PPARγ antagonist. 
suggests a possible explanation that certain potent PPARγ ligands do not bind PPARα; 
and that PPARα can bind the more lipophilic saturated FA. 
All these FA bind to PPARα directly with micromolar affinities. However, it is 
unclear whether the concentrations at which binding has been noted are physiologically 
relevant due to the variety, distribution pattern and affinity of  FA and FA derivatives for 
PPAR in the body (Michalik et al. 2006). Eicosanoids are a class of FA that are mainly 
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derived from arachidonic acid, either via the lipoxygenase pathway leading to the 
formation of leukotrienes and hydroxyeicosatetraenoic acids (HETEs) or via the 
cyclooxygenase pathway producing prostaglandins (PG) (Desvergne et al. 2006). The 
lipoxygenase metabolite 8(S)-HETE (Yu et al. 1995) and leukotriene B4 (Devchand et al. 
1996) were also identified as a submicromolar ligand for PPARα.  
Fibrates such as fenofibrate and clofibrate are lipid lowering drugs which are 
synthetic ligands of PPARα (Willson et al. 2000) (Fig 1.4A). WY14,643, the 2-
arylthioacetic acid analogue of clofibrate, is also a potent PPARα agonist (Berger and 
Moller 2002). In humans, fibrates are used at high doses (200–1200 mg/day) to achieve 
efficacious lipid-lowering activity at micromolar levels in vivo (Fruchart and Duriez 
2006). 
The ureidofibrate, GW2331, however, was found to be a nanomolar PPARα and 
PPARγ ligand (Brown et al. 1997), whereas the closely related ureidobutyric acid, 
GW9578 (Brown et al. 1999) and GW7647 (Brown et al. 2001) were found to be 
nanomolar PPARα agonist with potent PPARα-selective hypolipidemic activity in vivo. 
 
1.3.2 PPARγ ligands  
Unlike PPARα, PPARγ does not bind to saturated FA. Instead, PPARγ preferentially 
binds PUFA, including the essential FA linoleic acid, linolenic acid, arachidonic acid, 
and eicosapentaenoic acid at micromolar concentrations (Xu et al. 1999). Conversion of 
linoleic acid to 9-HODE and 13-HODE by 15-lipoxygenase can provide additional 
micromolar PPARγ agonists (Nagy et al. 1998). A prostaglandin derivative, 15-deoxy-
Δ12,14-Prostaglandin J2 (15dPGJ2) was also demonstrated to be a PPARγ agonist (Forman 
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et al. 1995; Kliewer et al. 1995) (Fig 1.4B). However, the physiologic relevance of this 
ligand is questionable since cellular concentrations cannot be accurately determined 
(Berger and Moller 2002).  
TZDs  such as rosiglitazone and pioglitazone (Fig 1.4B) are insulin sensitizing 
drugs and are PPARγ agonists (Lehmann et al. 1995; Berger et al. 1996; Willson et al. 
1996). GW2570 is a very potent non-TZD PPARγ-selective agonist that was shown to 
have antidiabetic efficacy in humans (Willson et al. 2000). In contrast, GW9662 is a 
PPARγ antagonist and also a PPARα partial agonist which binds irreversibly to the LBD 
of PPAR through covalent modification of cysteine (Leesnitzer et al. 2002) (Fig 1.4B).   
Unfortunately, PPARγ agonists can have undesirable clinical effects too. These 
include weight gain due to increased adiposity, edema, hemodilution, and plasma-volume 
expansion, which preclude their clinical application especially in patients with heart 
failure (Arakawa et al. 2004; Rangwala and Lazar 2004; Staels 2005).  
 
 1.3.2 Dual PPARα/PPARγ ligands 
In general, diabetic patients suffer from both hyperglycemia and dyslipidemia with their 
associated complications, such as peripheral neuropathy, kidney failure, retinopathy, and 
atherosclerosis, culminating in myocardial infarction and stroke (Plutzky 2003; Michalik 
et al. 2006). Thus, despite the negative effects of PPARγ agonist, positive clinical data on 
the use of PPARγ agonists for the treatment of diabetes and the use of PPARα agonists 
for the treatment of dyslipidemia and coronary heart disease makes it likely that dual 
PPARα and PPARγ agonists might provide broadly beneficial metabolic effects on these 
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patients through a simultaneous treatment of hyperglycemia, dyslipidemia and the 
associated cardiovascular risk factors (Staels and Fruchart 2005; Tenenbaum et al. 2005).  
Among the dual PPARα/PPARγ agonists developed, compounds that belong to 
the glitazar class were on the most advanced stage of development (Fievet et al. 2006). 
However, ragaglitazar (Lohray et al. 2001) was halted due to the detection of bladder 
tumors on long term carcinogenicity studies in rodents. Strikingly, a major concern of 
those attempting to develop novel PPAR targeted drugs is to avoid agents similar to 
present compounds that are carcinogenic in rodents (Michalik et al. 2006). Indeed, the 
U.S. Food and Drug Administration (FDA) has issued guidelines requiring that PPAR 
ligand clinical trials exceeding 6 months must be preceded by the successful completion 
of a 2 year carcinogenicity tests in rodents.  
Besides carcinogenicity, adverse effects of glitazar administration include weight 
gain, oedema, fluid retention, fatty infiltration in bone marrow, decrease in white blood 
cell count, anemia and raised levels of hepatic enzymes (Fievet et al. 2006). Indeed, while 
tesaglitazar was generally well tolerated in Phase II studies (Fagerberg et al. 2005), its 
development was recently halted due to the induction of impaired renal function (Fievet 
et al. 2006). Similarly, termination of muraglitazar recently was due to the existence of 
significant cardiovascular risks to treatment (Rubenstrunk et al. 2007). Collectively, the 
glitazars were associated with an excess incidence of the composite end-point death, 
major adverse cardiovascular events and congestive heart failure (Nissen et al. 2005). 
Challenged by today's global epidemic of obesity, research on PPAR modulators 
continues vigorously. Indeed, the ideal PPAR modulator remains highly anticipated. 
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1.4 Molecular mechanisms of PPAR activity 
There are several levels at which PPAR activity can be controlled especially in regards to 
PPARα. Besides the nature of the ligand used, transcriptional regulation can be affected 
by the action of AF-1 and AF-2, the dimerization of RXR on the PPRE, the regulation of 
PPAR expression, the post-translational modifications of PPAR; and the association with 
coregulators.  
 
1.4.1 Action of AF-1 and AF-2 
The AF-1 at the N-terminal of the PPAR TAD has been characterized. Interestingly, only 
the AF-1 of PPARα and PPARγ is ligand independent (Adams et al. 1997; Werman et al. 
1997; Juge-Aubry et al. 1999). Indeed, a truncated PPARα lacking the TAD had 60-70% 
lower transactivation function compared to the full length regardless of the presence of 
agonists (Hi et al. 1999). The AF-1 has been identified on residues 1-92 of  PPARα 
(Juge-Aubry et al. 1999). This AF-1 region on PPARα is acidic and the minimally 
essential region (residues 15-44) contains a helical motif that is implicated in 
transactivation function (Hi et al. 1999). In addition, the N-terminal domain is a major 
phosphorylation site (Gelman et al. 2005) and is thus unclear whether the AF-1 is an 
autonomous activation function or whether it primarily serves as a modulator of receptor 
activity by integrating various intracellular signaling pathways through post-translational 
modifications such as phosphorylation.  
Several PPARα and PPARγ AF-2 mutants showed reduced activity in the absence 
of ligand but maintained or increased ligand dependent activity. This observation 
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suggests a key role for the AF-2 domain in mediating the high basal activity of PPARs 
(Molnar et al. 2005). Interestingly, this constitutive activity which occurs in the absence 
of ligand is due to the interaction of PPARs with coactivators through intra- and inter-
molecular stabilization of helix 12 by four groups of residues (Molnar et al. 2005). The 
four different amino acid groups on PPARγ which contribute to the ligand independent 
stabilization of helix 12 in the LBD are: (i) Lys329 and Glu499, mediating a charge 
clamp-type stabilization of helix 12 via a coactivator bridge; (ii) Glu352, Arg425, and 
Tyr505, directly stabilizing the helix via salt bridges and hydrogen bonds; (iii) Lys347 
and Asp503, interacting with each other as well as contacting the coactivator; and (iv) 
His351, Tyr355, His477, and Tyr501, forming a hydrogen bond network. Except for 
His351 and Tyr355 that are responsible for ligand specific effects of PPARγ, these amino 
acids are highly conserved within the PPAR subfamily, suggesting that the same 
mechanism may apply for all three PPARs. Accordingly, the corresponding residues for 
PPARα are: (i) Lys292 and Glu462 (ii) Glu315, Arg388 and Tyr468 (iii) Lys310 and 
Asp464 (iv) His440 and Tyr464. Consistently, a phylogenetic analysis revealed that the 
helix 12 sequences from the three PPAR isotypes clustered with the homologous 
sequence from the constitutive androstane receptor, an orphan nuclear receptor with high 
constitutive activity which stabilizes its helix 12 in an active conformation using similar 
groups of residues.  
Enhancement of gene transcription in a ligand dependent manner is the most 
prominent feature of PPAR. However, recent studies have unveiled important insights 
regarding the high basal activity of the receptor in the absence of ligand. Nonetheless, it 
still remains debatable that the moderate PPAR activity in the absence of exogenous 
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ligand actually reflects a true ligand-independent action or a result of a weak 
concentration of agonist from either cellular metabolism or the culture medium (Feige et 
al. 2006).  
 
1.4.2 RXR dimerization 
It has been demonstrated recently, through live cell imaging, that the association of 
PPARs with RXR occurs independently of ligand binding and does not require DNA 
binding (Feige et al. 2005; Tudor et al. 2007). Although all three RXR isotype are 
reported to dimerize with PPARs, specific association with each RXR isotype seems to 
influence the recognition of target gene promoters (Juge-Aubry et al. 1997). PPAR 
prefers to bind RXRα and RXRγ on weak and strong binding elements respectively. The 
binding strength of the element is not dependent on the core DR1 sequence, which has a 
relatively uniform degree of conservation, but correlates with the extent of similarity of 
the 5'-flanking nucleotides and core sequence with respect to a consensus element. This 
5'-flanking sequence is essential for PPARα binding and thus contributes to subtype 
specificity. However, very little is known on the specificity of RXR isotype utilization by 
the different PPARs in vivo.  
Interestingly, PPAR/RXR heterodimers can induce transcription on PPAR target 
genes in response to either PPAR or RXR agonist alone. Moreover, treatment with PPAR 
and RXR agonists together potentiate the effects observed with each ligand alone 
(Kliewer et al. 1992; Gearing et al. 1993; Keller et al. 1993). This convergence of PPAR 
and RXR mediated effects was illustrated in vivo by the sensitization of diabetic mice to 
insulin by RXR agonists, an effect similar to the anti-diabetic action of PPARγ agonists 
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(Mukherjee et al. 1997a). However, the molecular mechanisms underlying transcriptional 
permissivity and synergy are not well understood in terms of cofactor recruitment by 
each partner of the heterodimers (Feige et al. 2006). Indeed, mutation of the PPARγ AF2 
abolishes the ability of RXR/PPARγ heterodimers to respond to ligands specific for either 
subunit. In contrast, the permissivity of PPAR/RXR to either of their ligands was not 
affected by mutation of RXR AF-2.  This indicates that binding of ligands to RXR may 
alter the conformation of the dimerization partner, PPAR, and modulate the activity of 
the heterodimer in a manner independent of the RXR ligand dependent AF-2 (Schulman 
et al. 1998). The interplay between PPARα AF-2 and RXR AF-2 together with 
coregulators is unclear.  
RXR homodimers have been shown to activate the PPRE of  the malic enzyme, 
PDK1, acyl-CoA oxidase and the bifunctional gene (IJpenberg et al. 2004). Moreover, in 
PPARα null mice, RXR homodimers can substitute for PPAR/RXR heterodimers to 
overcome the drastic effects of fasting observed in these animals. Indeed, in the presence 
of RXR agonists, coactivators (SRC-1 and TIF2) stabilizes the binding of RXR 
homodimers to PPREs. In contrast, p300 is unable to interact with the DNA-bound RXR 
homodimer, but readily forms a complex with PPAR/RXR regardless of the presence of 
ligand. This indicates that RXR homodimer formation onto PPREs requires selective and 
ligand-dependent interaction with specific coregulators. Although simplified with respect 
to the diversity of PPAR and RXR coregulators, this model reflects that relative levels of 
coregulator expression are important determinants mediating the specificity of the 
physiological response to PPAR or RXR agonists. 
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1.4.3 Protein regulation 
Human PPARα promoter activity is induced by PPARα itself and hepatocyte nuclear 
factor 4 (HNF4), a major regulator of gluconeogenesis. In contrast, the orphan receptor 
COUP-TFII antagonizes this action (Pineda Torra et al. 2002). Temporal expression of 
PPARα is also controlled by the circadian clock (Lemberger et al. 1996) through positive 
control by glucocorticoids (Lemberger et al. 1994; Steineger et al. 1994) and the clock 
gene Bmal1 (Oishi et al. 2005). Insulin downregulates PPARα expression (Steineger et al. 
1994) while leptin upregulates it (Zhou et al. 1998b). Glucose decreases PPARα 
expression in the pancreas, leading to diminished FA oxidation and TG accumulation 
(Roduit et al. 2000). Fasting in mice also induces PPARα expression (Kersten et al. 1999; 
Leone et al. 1999). Interestingly, male rats had higher levels of hepatic PPARα mRNA 
and protein than female rats and this is regulated by sex hormones (Jalouli et al. 2003). 
However, fasting increased hepatic PPARα mRNA levels to a similar degree in both 
sexes. Finally, synthetic PPAR ligands such as WY14,643 or fibrates increase the half-
life of the PPARα by preventing its ubiquitination and its subsequent degradation via the 
proteasome (Blanquart et al. 2002).  
 
1.4.4 Post-translational modification 
Post-translational modifications such as phosphorylation, ubiquitylation and sumoylation 
can affect transcription. Thus, a comprehensive study integrating the influence of such 




PPAR activity can be modulated through phosphorylation by major intracellular 
signaling cascades such as the mitogen-activated protein kinase (MAPK) or the protein 
kinases A and C (PKA and PKC) pathways (Feige et al. 2006). Several phosphorylation 
sites spanning all across the receptor have been identified and characterized. Collectively, 
the effects of PPAR phosphorylation mediate different mechanisms which include 
changes in the affinity for ligands, RXR, coregulators and target genes.  
Phosphorylation of PPARγ2 serine 112 by MAPK induces conformational 
changes which are transmitted to the LBD and result in weakened affinity for ligands 
(Shao et al. 1998), resulting in lower transcriptional activity (Hu et al. 1996). The 
interaction between PPARα and RXR is modulated by phosphorylation in the hinge 
region as mutation of the PKC phosphorylation sites T129 and S179 of PPARα reduces 
heterodimerization (Gray et al. 2005). Mutation of T129 also prevented PPARα from 
binding to DNA in vitro. The effects of phosphorylation on interactions with cofactors 
are illustrated by the MAPK-mediated phosphorylation of the AF-1 (at ser12 and ser21 
by p42 and p44 of MAPK) which activates PPARα in response to insulin, probably by 
relieving inhibition by corepressors (Juge-Aubry et al. 1999). Intriguingly, both these 
residues must be phosphorylated in order to activate transcription. This is in contrast to 
PPARγ2, which was mentioned previously to be phosphorylated at a single site that is not 
homologous to the sites described in PPARα. Phosphorylation by p38 of  MAPK on 
serine residues of the TAD of PPARα specifically enhances coactivation by the PPARγ 
coactivator-1α  (PGC-1α) (Barger et al. 2001), which interacts with the PPARα AF-2 
(Vega et al. 2000). Phosphorylation of the PPARα DNA binding domain, where PKA 
primarily acts on, regulate binding to response elements (Lazennec et al. 2000).  
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Finally, besides these direct effects of phosphorylation, PPAR activity can also be 
modulated by changing the expression level of the receptor. For example, the PKC and 
stress-associated kinase pathways induce the expression of the PPARα (Yaacob et al. 
2001).  Other means of regulating PPAR activity indirectly include the phosphorylation 
of RXR (Solomon et al. 1999).  
Ubiquitin is an 8 kDa protein which covalently binds to proteins to target them for 
degradation by the 26S proteasome. Ubiquitylation of proteins occurs on lysine residues. 
Surprisingly, little information is available on the mechanisms regulating PPAR 
degradation (Feige et al. 2006). Both PPARα and PPARγ can be targeted for degradation 
by ubiquitylation. The degradation of PPARγ is enhanced by ligand binding through a 
mechanism that requires an intact AF-2 structure and probably an active conformation of 
the receptor (Hauser et al. 2000). In contrast, PPARα agonists stabilize the PPARα and 
decreased its ubiquitylation and subsequent degradation (Hirotani et al. 2001; Blanquart 
et al. 2002).  
Together with the observations that phosphorylation events may influence 
ubiquitylation and degradation of PPARs (Floyd and Stephens 2002; Tsao et al. 2005), 
these results highlight the need for further integrated analyses linking ubiquitylation and 
proteasomal degradation to transcriptional activity.  
Small ubiquitin-like modifiers (SUMO) comprise a family of three 11 kDa 
proteins homologous to ubiquitin which can be reversibly conjugated to proteins through 
covalent binding to regulate various cellular mechanisms including transcriptional 
repression. Sumoylation occurs on lysine residues located in ΨKXE/D motifs (Ψ being a 
large hydrophobic residue and X any residue) (Feige et al. 2006). Till now, no detailed 
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work on sumoylation of PPARα has been carried out. In contrast, much of the current 
understanding of sumoylation on PPAR signaling is derived from work with PPARγ. 
PPARγ can be sumoylated on two different sites at lysines 77 and 365 (107 and 395 in 
PPARγ2) (Pascual et al. 2005). K77 sumoylation occurs in a ligand-independent manner 
and exerts inhibitory effects on the activity of the receptor (Ohshima et al. 2004; 
Yamashita et al. 2004; Pascual et al. 2005). In contrast, sumoylation at lysine 365 is 
ligand-dependent and leads to complex transrepressive effects on the iNOS promoter by 
promoting the interaction with the corepressor NCoR (Pascual et al. 2005).  
 
1.5 Molecular mechanisms of PPAR activity- Coregulators 
Coregulators are proteins which can repress (corepressors) or enhance (coactivators) 
nuclear receptor transcriptional activity by bridging transcription factors to the basic 
transcription machinery and by specifically modifying chromatin structure. While 
chromatin compaction and histone hypoacetylation mainly repress gene activation, 
remodeling and repositioning of nucleosomes allows binding of transcription factors and 
formation of the pre-initiation complex (McKenna and O'Malley 2002; Feige et al. 2006). 
Indeed, the regulation of a general transcription unit by nuclear receptors requires a vast 
number of coregulatory complexes that have various functions and enzymatic activities 
(Perissi and Rosenfeld 2005). The influence of coregulators on nuclear receptor signaling 




The nuclear receptor corepressor (NCoR) (Horlein et al. 1995) and the silencing mediator 
of retinoid and thyroid receptors (SMRT) (Chen and Evans 1995) were initially isolated 
as proteins mediating active repression by the thyroid hormone and retinoic acid 
receptors. NCoR and SMRT repress the activity of nuclear receptors in the absence of 
ligand or upon antagonist treatment until agonist binding induces their exchange for a 
coactivator complex to induce transcriptional activation (Privalsky 2004; Feige et al. 
2006).  
NCoR (Fig 1.5) and SMRT are paralogs of one another and function in a similar 
fashion (Ordentlich et al. 2001). NCoR is divided into a N-terminal portion having three 
distinct transcriptional repression domains (RD) and a C-terminal portion composed three 
nuclear receptor interaction domains (ID) (Privalsky 2004). Similarly, SMRT has fours 
RDs and two IDs. The RDs are docking surface that recruit additional components of the 
receptor complex, including histone deacetylases (HDACs), transducin-like protein 1 
(TBL-1), G protein pathway suppressor 2 (GPS2) and Sin3 (Goodson et al. 2005).  
While their repressive effects are essentially mediated through the recruitment of 
HDACs, like HDAC3 (Heinzel et al. 1997), interactions with the basal transcriptional 
machinery might also play a role (Muscat et al. 1998). Indeed, the N-terminal RD and the 
C-terminal receptor ID of NCoR are also part of the contact interface that directly 
mediates interaction with general transcription factors, and mediate signals from 
repressors to the basal machinery. This suggests that NCoR interacts with the central 
components of the transcriptional initiation process and locks them into a non-functional 
complex or conformation that is not conducive to transcription (Privalsky 2004). 
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Figure 1.5 A simplified schematic of the nuclear corepressor, NCoR 
 
A simplified representation of full length murine NCoR (2453 residues). The N-terminal 
of NCoR comprises three distinct transcriptional repression domains (RD) and the C-
terminal comprises three nuclear receptor interaction domains (ID). Dark grey boxes 
represent unique CoRNR box sequences within each ID, residues 2277-2285, 2073-2081, 







The interaction between PPARs with NCoR and SMRT in solution was 
documented by the isolation of NCoR as a PPARα and PPARβ interacting protein in 
yeast-two hybrid screens and by direct interactions with the three PPAR isotypes mostly 
in in vitro interaction assays (Dowell et al. 1999; Hu and Lazar 1999; Gurnell et al. 2000; 
Krogsdam et al. 2002; Stanley et al. 2003). Among the three PPAR isotypes, repression 
by PPARβ seems to play an important role since its association with NCoR and SMRT 
results in the strongest effects in transactivation (with PPARα being the weakest) 
(Krogsdam et al. 2002) but also because PPARβ can inhibit PPARα and PPARγ 
activation through corepressor and HDAC binding (Shi et al. 2002). Nonetheless, the 
physiological relevance of corepressor action on PPAR signaling remained controversial, 
especially for PPARα (Semple et al. 2005; Feige et al. 2006). While information on the 
action of corepressors on specific PPARα target gene is clearly lacking (Feige et al. 
2006), a clear role of corepressors on PPARγ mediated adipogenesis was only recently 
demonstrated (Guan et al. 2005; Yu et al. 2005).  
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Interestingly, the action of corepressors on endogenous PPARγ target genes is 
promoter specific. NCoR and SMRT were associated with the glycerol kinase (GyK) and 
oxidized LDL receptor 1 (OLR1) promoters in complex with PPARγ but absent from the 
aP2 promoter  (Chui et al. 2005; Guan et al. 2005). On the aP2 promoter, the 
PPARγ/RXR heterodimer was constitutively activated by the association of coactivators, 
such as SRC-1, even in the absence of exogenous ligand (Guan et al. 2005). The  
functional role of this corepressor-PPARγ interaction was further demonstrated in 
adipogenesis (Yu et al. 2005). Here, the significance of corepressors on PPARγ target 
genes during adipogenesis was demonstrated by the upregulation of adiponectin, perilipin 
and C/EBPα after NCoR and SMRT knockdown (Yu et al. 2005). Collectively, 
corepressors could provide a molecular switch to specifically silence PPAR target genes 
that do not require activation during key metabolic processes such as adipogenesis (Feige 
et al. 2006). Since this target gene specificity was observed within the same cell type 
(3T3-L1 cells), these results suggest that DNA binding may impose specific receptor 
conformations which determine affinity for corepressors and therefore possibly explain 
why corepressor binding was not observed in vitro on the ACO PPRE (Zamir et al. 1997; 
Feige et al. 2006).  
An important aspect of corepressor action is the response to antagonist binding as 
pharmacological inhibition of PPARs promises interesting therapeutic applications. To 
this respect, the crystal structure of the PPARα LBD bound to the antagonist GW6471 
and to a SMRT corepressor motif is particularly interesting as it revealed that antagonists 
promote a conformation of the receptor which prevents the correct positioning of helix 12 
and subsequent coregulator recruitment (Xu et al. 2002a).  
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Each ID in NCoR and SMRT contains a CoRNR box motif (or LXXI/HIXXXI/L) 
(where X is any residue) (Fig 1.5 and 1.6) that forms the core contact surface between 
corepressor and nuclear receptor (Hu and Lazar 1999; Perissi et al. 1999; Hu et al. 2001; 
Xu et al. 2002a). The CoRNR motif forms an extended α-helical domain that docks into a 
complementary groove formed by helices 3/4/5 in the LBD of the nuclear receptor. In 
contrast, the SRC-1 α-helical domain which docks in the similar groove is shorter (Xu et 
al. 2001). Differences in the CoRNR box motifs, in adjacent amino acids, and in the 
sequence of the helix 3/4/6 regions of the nuclear receptors contribute to the different 
affinities of various receptors for the different corepressor IDs (Cohen et al. 2001; 
Makowski et al. 2003).  Helix 12, located at the very C terminus, also plays an important 
but indirect role in the receptor/corepressor interaction (Privalsky 2004). The helix 12 of 
most nuclear receptors can form an extended conformation in the absence of hormone 
that allows access of corepressor to its docking site on helices 3/4/5.  The binding of 
hormone agonist can reorient this helix 12 to a sequestered position that occludes the 
corepressor docking surface, resulting in release of corepressor (Lin et al. 1997; Nagy et 
al. 1999; Zhang et al. 1999; Xu et al. 2002a). Interestingly, this same reorientation of 
helix 12 forms a new binding surface, made up of portions of helix 3/4/5 and 12, that can 
recruit the LXXLL motifs found in many coactivators (Darimont et al. 1998; Shiau et al. 
1998; Mak et al. 1999). Helix 12 therefore operates as a hormone-operated molecular 
toggle switch that regulates the equilibrium between corepressor recruitment and 
coactivators recruitment (Privalsky 2004). 
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Figure 1.6 Illustration of antagonist bound PPAR with corepressor and its 
comparison with agonist bound PPAR/coactivator 
 
Position of the AF-2 helix (orange bar) with antagonist (left panel) is different from that 
with agonist (middle panel). Both receptor interaction core consensus motif in 
corepressor (eg. NCoR) (red bar) and coactivator (SRC-1) (green bar) bind to the same 
groove of PPAR LBD formed by helices 3,4,5 (yellow bar). Superposition of the 
corepressor motif on the PPAR/agonist/coactivator complex (right-most panel) represents 
competition by the corepressor motif with the coactivator motif for AF-2 interaction due 






























Although not corepressors per se, heat shock protein 90 (hsp90) (Sumanasekera et 
al. 2003a; Sumanasekera et al. 2003b); hsp90 accessory protein XAP2 (Sumanasekera et 
al. 2003b) and ribosomal protein regulator of p53, rpL11, (Gray et al. 2006) have also 
been reported to repress PPARα activity, and interestingly, through interaction with the 
PPARα hinge.  
While NCoR and SMRT normally suppress in the absence of a ligand, another 
class of corepressors is recruited in a ligand dependent manner through LXXLL motifs 
and repress the activity of nuclear receptors by competing with coactivators and by 
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recruiting downstream effectors such as HDACs (White et al. 2004). The Receptor 
Interacting Protein 140 (RIP140) is one of such corepressors which can interact with 
PPARα and PPARγ (Miyata et al. 1998; Treuter et al. 1998). Furthermore, the recent 
identification of the ligand-dependent corepressor (LCoR) which represses the activity of 
several nuclear receptors in the presence of their agonists (Fernandes et al. 2003) suggests 
that the activity of such corepressors should be considered in the study of PPAR actions 
(Feige et al. 2006).  
 
1.5.2 Coactivators 
In contrast to the action of corepressors, coactivators turn on transcription by NR. The 
first group of coactivators is the switch/sucrose non-fermenting (SWI/SNF) complexes 
that change the location or conformation of nucleosomes and remodel chromatin by using 
energy from ATP hydrolysis (Feige et al. 2006). PPARγ2 has a direct requirement of 
SWI/SNF complexes on PPARγ target promoters to facilitate pre-initiation complex 
function in adipogenesis (Salma et al. 2004). Additionally, three members of the 
SWI/SNF family containing LXXLL motifs were also isolated in a PPARα interacting 
complex (PRIC) purified from liver extracts using full-length PPARα (Surapureddi et al. 
2002). Interestingly, besides gene activation, SWI/SNF has also been associated with 
gene repression (Perissi and Rosenfeld 2005). 
A second group of coactivators comprises factors which covalently modify 
histone tails by acetylation, methylation, phosphorylation or ubiquitylation. These 
modifications can occur in a large number of combinations, often in an interdependent 
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manner, and compose a hypothetical epigenetic code, referred to as histone code, which 
specifies the fate of the gene (Jenuwein and Allis 2001; Imhof 2003; Feige et al. 2006).  
Coactivators with histone acetyltransferase (HAT) activity include the 
homologous CREB binding protein (CBP) and p300 proteins. Transcriptional activation 
through CBP/p300 recruitment results in increased histone acetylation but also increased 
contacts with the basal transcription machinery (Kalkhoven 2004). p300 is also reported 
to harbor ubiquitin ligase activities (Grossman et al. 2003). PPARα-interacting domain of 
p300 was mapped to amino acids 39-117 which interacted strongly with PPARα but did 
not interact with RARγ or RXRα. Amino acids within the carboxyl terminus of PPARα 
as well as residues within the hinge region were required for ligand-dependent interaction 
with p300 (Dowell et al. 1997). The importance of CBP and p300 for PPAR action is also 
highlighted by the high affinity between PPARs and these cofactors. While PPARγ has a 
greater apparent affinity for CBP than for SRC-1, the steroid receptor ERα interacts 
preferentially with SRC-1 but very weakly with CBP (Zhou et al. 1998a). PPARα has a 
higher affinity for CBP than PGC-1α and SRC-1 (Mukherjee et al. 2002). In addition, it 
has been recently reported that interactions of p300/CBP coactivators with the LBDs of 
nuclear receptors are not limited to the canonical LXXLL motifs but involves both a 
longer contiguous segment around the motif and, for certain domains, an additional zone 
as shown with the LBD of PPARγ and RXRα (Klein et al. 2005). 
p160 proteins comprise a family of three related coactivators (SRC-1, TIF2 and 
SRC-3) (Leo and Chen 2000). These coactivators can also mildly acetylate histones 
(Chen et al. 1997; Spencer et al. 1997). However, their HAT activity is much weaker than 
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that of CBP/p300 and interactions with other cofactors suggest that its more important 
role is to bridge transcriptional complexes to the basal transcriptional machinery.  
The interaction of SRC-1 with PPARs is well documented in in vitro assays 
(DiRenzo et al. 1997). However, when the association of p160 proteins to PPARs is 
considered in the presence of PPAR, RXR and DNA response elements, p160 recruitment 
occurs in response to RXR ligands but not to PPAR agonists (Yang et al. 2000). Indeed, 
SRC-1 could be recruited to endogenous PPAR target genes by RXR homodimers in 
response to retinoid treatment but not by PPAR/RXR heterodimers (IJpenberg et al. 
2004). While the strong influence of SRC-1 and TIF2 on obesity and insulin sensitivity 
indicates that p160 cofactors may modulate PPARγ signaling (Picard et al. 2002), SRC-1 
knock-out mice retain normal PPARα signaling as β-oxidation and associated target 
genes can be induced by PPARα agonists (Qi et al. 1999). Nonetheless, this phenotype 
may have resulted from a compensation by the other p160 isotypes (Xu and Li 2003). 
Collectively, these results implies that probably SRC-1 and other p160 members are not 
bona fide PPAR coactivators but may play an indirect role in PPAR signaling through 
RXR (Feige et al. 2006). 
Histone methyltransferase (HMT) activity provided by proteins such as the 
coactivator-associated arginine methyltransferase 1 (CARM-1) or the protein arginine 
methyltransferase 1 (PRMT-1) enhances transcription. However, no study has addressed 
the influence of CARM-1 or PRMT-1 in PPAR signaling so far (Feige et al. 2006). 
Nonetheless, the importance of methylation for PPAR activity was briefly illustrated by 
the isolation of PRMT-2, a methyltransferase that could directly interact with PPARγ and 
enhance its transcriptional activity (Qi et al. 2002).  
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The PPARγ coactivator 1α (PGC-1α) is the prototype of another group of 
cofactors which act as molecular scaffolds to assemble activating complexes (Puigserver 
et al. 1999) and to couple transcription to mRNA splicing (Monsalve et al. 2000). PGC-
1α was isolated as a PPARγ interacting protein but coactivation of PPARα, PPARβ and 
other nuclear receptors was also reported (Feige et al. 2006). While PGC-1α interaction 
with PPARα and PPARβ is ligand-dependent and requires the AF-2 domain of the 
receptor and the first LXXLL motif of PGC-1α (Vega et al. 2000; Wang et al. 2003b), 
binding to PPARγ occurs in the absence of ligand and relies both on the PGC-1α N-
terminus and on a LXXLL motif (Puigserver and Spiegelman 2003; Wu et al. 2003).  
The PPARγ interacting protein (PRIP/RAP250) and the PRIP-interacting protein 
with methyltransferase domain (PIMT) are two coactivators acting as molecular scaffolds 
which cooperatively enhance PPARγ and RXR-mediated transcription (Zhu et al. 2000; 
Zhu et al. 2001). PRIP interacts in a ligand-dependent manner with both PPARα and 
PPARγ (Zhu et al. 2000), while PIMT was subsequently isolated as a PRIP interacting 
protein (Zhu et al. 2000). PRIP is important in PPAR signaling because PRIP null mouse 
embryonic fibroblast cannot sustain PPARγ-mediated adipogenesis and ligand-dependent 
recruitment of coactivators to the aP2 promoter during adipogenesis (Qi et al. 2003).  
The last class of cofactors consists of the mediator (Med1) /thyroid hormone 
receptor associated protein (TRAP220) /vitamin D receptor interacting protein 
(DRIP205)/ PPARγ binding protein (PBP) multi-subunit complex which plays an 
important role in bridging nuclear receptors to the general transcriptional machinery and 
in recruiting and activating Pol II (Lewis and Reinberg 2003; Feige et al. 2006). The PBP 
subunit which anchors mediator to nuclear receptors is only present in a subset of 
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mediator complexes which exist with different combinations of subunit arrangements 
(Zhang et al. 2005). Interestingly, a liver-specific inactivation of PBP mimics the liver 
phenotype of PPARα null mice (Jia et al. 2004).  
Several other PPARα coactivators for which the physiological relevance is still 
poorly understood have been characterized. Briefly, these coactivators include PRIC285 
(Surapureddi et al. 2002) and the CBP/p300 interacting transactivator with ED-rich tail 2 
(CITED-2) (Tien et al. 2004). Interestingly, CITED-2 coactivates PPARα and PPARγ but 
not PPARβ. 
 In addition to the various roles that groups of coregulators play, an extra layer of 
command was achieved through the control of phosphorylation status in various 
coregulators such as PGC-1α (Knutti et al. 2001; Puigserver et al. 2001), PBP (Misra et al. 
2002a), SRC-1 and TIF2 (Rowan et al. 2000; Lopez et al. 2001) or SMRT and NCoR 
(Hermanson et al. 2002; Jonas and Privalsky 2004).  
 
1.5.3 Dynamics of coregulator exchange on chromatin 
A key question that underlies the molecular mechanisms of PPAR action is how do 
multiple cofactors with different activities cooperate to initiate transcription (Feige et al. 
2006). Ligand binding is the crucial molecular event that switches the function of nuclear 
receptors from active repression to transcriptional activation (Perissi and Rosenfeld 2005). 
A combination of elegant structural and molecular studies of the interactions between 
nuclear receptors and coregulators has provided the evidence that hormone binding 
induces a conformational change in the ligand-binding domain of the receptor, which 
results in reduced affinity for corepressors and, simultaneously, enhanced affinity for 
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coactivators (Perissi and Rosenfeld 2005) (Fig 1.7A). Similarly, agonist binding to 
steroid receptors, such as ER, also induces the adoption of a specific conformation that 
favours coactivator binding, whereas antagonist binding promotes the interaction with 
corepressors (Perissi and Rosenfeld 2005). 
However, the classic model of static receptor/coregulator binding to promoters 
has recently been challenged because it has become clear that there are additional and 
unexpected layers of regulation in the molecular events which modulate the nuclear 
receptor ‘switch’ from repression to activation (Perissi and Rosenfeld 2005; Feige et al. 
2006).  
Much of the current paradigm shift has been due to advancements in experimental 
techniques. Using chromatin immunoprecipitation (ChIP), a technique used to 
specifically immunoprecipitate complexes of DNA with associated proteins to study 
chromatin occupancy by different transcription factors and the state of chromatin 
modification, various studies have shown that coregulator recruitment by NR occurs in an 
ordered manner and that promoter occupancy by NR is characterized by cycles of 
recruitment and release in a short time span (Perissi and Rosenfeld 2005).   
Using microscopy techniques to study protein behavior in live cells, a new 
concept on transcription regulation, in complement to the rapid oscillation of 
transcription factors on promoters, known as ‘genome scanning’ has emerged (Fig 1.7B). 
In live cell imaging, PPAR were observed to have low mobility. Indeed, they were not 
freely diffusing and this low mobility was due to interactions with coregulators (Tudor et 
al. 2007). Other than coregulator docking, PPARs may also transiently interact with 
rather immobile components such as chromatin (Feige et al. 2005). Thus, the ‘genome 
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scanning’ model was proposed where these interactions reflect a three-dimensional 
scanning of the genome performed until transcription factors reach a genuine enhancer 
site where they may reside for longer periods and initiate pre-initiation complex assembly 
(Phair et al. 2004; Gelman et al. 2006).  
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Figure 1.7 Models of PPAR action  
 
A) Ligand dependent corepressor/coactivator exchange. Some PPAR target genes are maintained 
in an inactive state in the absence of ligands by the PPAR/RXR heterodimer bound to corepressor. 
Presence of ligand (purple circle) allows dissociation and breakdown of corepressors and the 
recruitment of coactivators for transcriptional activation. B) Genome scanning (Feige et al. 2006; 
Gelman et al. 2006). Without ligand, PPAR and RXR are heterodimerized, recruit corepressors, 
and roam the nucleus where they interact transiently with chromatin, both on genuine PPREs and 
unspecific binding sites. Upon ligand binding, PPAR mobility is reduced due to its AF-2-
dependent binding to cofactors. PPAR/cofactor complexes may transiently bind to "non-specific" 
sites on chromatin, performing a three dimensional-scanning of the genome, until they encounter 
























1.6 Natural polymorphisms of the PPARα gene 
The gene (PPARA) encoding PPARα is located on the long arm of chromosome 22 
(Flavell et al. 2000; Lacquemant et al. 2000; Sapone et al. 2000; Vohl et al. 2000; Evans 
et al. 2001; Flavell et al. 2002; Tai et al. 2002; Tai et al. 2005; Tai et al. 2006). The 
PPARA locus is polymorphic in humans and several of these polymorphisms have been 
associated with variation in obesity, serum lipid concentrations and coronary artery 
disease (Naito et al. 2006). To date, 14 polymorphisms of PPARα have been reported 
(Flavell et al. 2000; Sapone et al. 2000):  P22R, R127Q, R131Q, D140Y, D140N, L162V, 
R178G, V227A, A268V, D304N, G395A, G395E, D409T, Q413L. Among these 
polymorphisms identified, only a common leucine to valine (L162V) substitution at 
PPARA has been shown to be functional, altering the transcriptional activation associated 
with fibrate treatment in vitro (Flavell et al. 2000; Vohl et al. 2000; Flavell et al. 2002; 
Tai et al. 2002).  
 
1.6.1 L162V 
L162V has been associated with relatively minor and inconsistent changes in the serum 
concentrations of lipids and lipoproteins (Gouni-Berthold et al. 2004). When examined in 
relation to plasma lipids, the presence of this polymorphism shows associations with total 
cholesterol, LDL-c and apolipoprotein B (Lacquemant et al. 2000; Vohl et al. 2000; Tai 
et al. 2002). However, no association was observed with either plasma triglyceride or 
HDL-c concentration (Low and Tai 2007).  
 49
Evidence is emerging that the benefits of PPARα activation in the prevention of 
cardiovascular events are dependent on the presence of insulin resistance and/or DM 
(Tenkanen et al. 1995; Rubins et al. 2002; Robins et al. 2003). Studies showed that the 
most benefits associated with fibrates such as gemfibrozil  (Tai et al. 2006), clofibrate 
(Anonymous 2000) and bezafibrate (Anonymous 1980) were observed in those with 
insulin resistance, diabetes mellitus (DM) or features associated with them. When 
subgroups with and without DM treated with gemfibrozil were compared (Tai et al. 2006), 
a lower prevalence of atherosclerosis and coronary pathology was seen in carriers of the 
V162 allele with DM. In contrast, in those without DM, the prevalence of atherosclerosis 
and coronary events with or without the V162 allele was the same.  
Besides the interaction of L162V with fibrates, a gene-diet interaction was also 
observed for L162V and PUFA consumption in regards to plasma lipoprotein levels. On a 
low PUFA diet, carriers of L162V have greater TG and apoC-III. Conversely, on a high 
PUFA diet, carriers of the L162V have lower apoC-III concentrations (Tai et al. 2005). 
Others examined L162V using a dietary intervention approach to test if plasma 
lipoprotein and lipid responsiveness modifications in the dietary ratio of polyunsaturated 
to saturated FA was influenced by this polymorphism. From a high PUFA diet, a gene-
diet interaction was observed whereby carriers of L162V had significant lower levels of 
apoA-I (Paradis et al. 2005).  
The L162V polymorphism was first identified in a Caucasian population (Flavell 
et al. 2000; Vohl et al. 2000) and later, in several populations from the Indian sub-
continent (Lacquemant et al. 2000). In a recent study, Chan et al (2005) reported that in 
Asian Indians in Singapore, the allele frequency remained much lower than amongst 
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Indians living in the Pondicherry district of India. Furthermore, the L162V polymorphism 
was found to be very rare in Singapore Chinese and Malays. Interestingly, another 
polymorphism which has not been described in non-oriental population, the V227A 
polymorphism, was found in Singapore Chinese with an allele frequency (0.04) similar to 
that reported in two independent Japanese study (0.04-0.05) (Yamakawa-Kobayashi et al. 
2002; Chan et al. 2006; Naito et al. 2006). None of the Japanese studies detected the 
L162V polymorphism in their population. In all, these studies confirm the differing 
genetic structure of the PPARA locus in various ethnic groups.  
 
1.6.2 V227A 
In association studies (Yamakawa-Kobayashi et al. 2002; Chan et al. 2006; Naito et al. 
2006), carriers of A227 allele consistently have lower levels of total cholesterol and 
triglycerides compared to that of non-carriers (Table 1.2).  This effect was more obvious 
in women compared to men.  Furthermore, the Singapore study identified a gene-diet 
interaction between the V227A polymorphism and dietary factors amongst Singapore 
Chinese women. In these subjects, the A227 allele was shown to modulate the association 
between dietary PUFA intake and serum HDL concentration. In women who carried the 
A227 allele, increasing dietary PUFA intake was associated with low HDL-c. This 
suggested that genetic variation at the PPARA locus may determine the lipid response to 
changes in PUFA intake. In addition, Naito et al (2006) reported that while non-alcohol 
drinkers with the A227 polymorphism have lower total cholesterol levels, this difference 
was not significant in carriers of the A227 allele who are drinkers. Thus, a gene-diet 
interaction involving the PPARA locus was also demonstrated within these populations.  
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Subjects with the V227A polymorphism are mostly heterozygous for the A227 
allele. Homozygotes of the A227 allele are rare (3-5%) in carriers of the polymorphism.  
Table 1.2 Association studies of the V227A polymorphism 
 
Study Subjects Results Comments 
 
Yamakawa-











Men: No significant difference in 
serum TG and total cholesterol. 
 
Women: Serum TG (27.5% reduction; 
p=0.038) and total cholesterol (8.3% 
reduction; p=0.046) were 
significantly lower in carriers of the 
A227 variant.  
 
- No significant 
difference in HDL-c, 
LDL-c and BMI 
between carriers and 
non-carriers of the 227A 
variant in men and 
women.  












Men: No significant difference in 
serum TG and total cholesterol. No 
serum HDL-c association with dietary 
PUFA. 
 
Women: Serum TG (8.4% reduction, 
p=0.048) and total cholesterol (3.2% 
reduction, p=0.047) were significantly 
lower in carriers of the A227 variant. 
Significant serum HDL-c association 
with dietary PUFA (p=0.049); where 
increasing PUFA intake lower HDL-
c.  
 
- No significant 
difference in HDL-c and 
LDL-c between carriers 
and non-carriers of the 
227A variant in men and 
women. 
 
- Allele frequency of 
227A was low in 
Singapore Malays 
(0.006) and Singapore 
Asian Indians (0.003). 





Not associated with changes in TG or 
total cholesterol.  
 
- No significant 
difference in LDL-c 
between carriers and 
non-carriers of the 227A 
variant. 
 










Unlike L162V, the effect of the A227 allele on cardiovascular risk in subjects with DM is 
unclear. However, the V227A polymorphism, together with other PPARα 
polymorphisms, were found at similar frequencies in Japanese subjects with maturity-
onset diabetes of the young (MODY) and in nondiabetic Japanese subjects (Hara et al. 
2001). This suggests that variation in the coding region of PPARA is unlikely to be a 
major cause of MODY, at least in Japanese.    
While L162V was functionally more active than the wild type (WT) on a PPRE, 
no such equivalent data has been reported for the V227A. Indeed, although the 
physiological impact of L162V and V227A is steadily emerging, detailed molecular 
mechanism of action by these polymorphisms, especially pertaining to the functionality 




1.7 Flavonoids  
Flavonoids are a family of phenolic compounds with strong bioactivity that are present in 
fruits, vegetables, and herbs. More than 5000 distinct flavonoids have been identified in 
plants, and several hundreds are known to occur in commonly consumed fruits, 
vegetables, grains, herbal products, and beverages. 
 
1.7.1 Structure 
Structurally, flavonoids have a common basic chemical structure that consist of 2 
aromatic rings (A and B rings) linked by a 3-carbon chain that forms an oxygenated 
heterocyclic ring (C ring) (Fig 1.8). Differences in the generic structure of the 
heterocyclic C ring, as well as the oxidation state and functional groups of the C ring, 
classify flavonoids as flavonols, flavan-3-ols (flavans), flavanones, flavones, isoflavones 
and among others (Erdman et al. 2007). Unlike flavones, the isoflavones are 
characterized by attachment of the B ring at the 3-position instead of the 2-position. The 
hydroxyl functional groups found on all 3 rings are potential sites for links to 
carbohydrates. Flavonoids that are bound to 1 or more sugar molecules are known as 
flavonoid glycosides, whereas those that are not bound to a sugar molecule are called 
aglycones. With the exception of flavan-3-ols, flavonoids occur in plants and most foods 
as glycosides. The structural complexity of flavonoids is further increased with the 
linking of acetyl and malonyl groups to the sugar conjugates. The combination of 
flavonoid structures, sugars, and acylation contribute to their complexity and the large 
number of individual molecules that have been identified (Beecher 2003; Erdman et al. 
2007).  
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Quercitin  A = OH  B = OH  C = H
Myricetin  A = OH  B = OH  C = OH
Kaempferol  A = H  B = OH  C = H








Naringenin  A = H  B = OH
Hesperetin  A = H  B = OCH3









Luteolin  A = OH  B = OH
Apigenin  A = H  B = OH












Daidzein  A = H  B = H  C = H  D = OH
Genistein  A = OH  B= H  C= H  D = OH
Biochanin A  A = OH  B = H  C = H  D = OCH3
2'-hydroxydaidzin  A = H  B = H  C = H  D = OH     
Formononetin  A = H  B = H  C = H  D = OCH3






















Flavonoid basic structure 
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1.7.2 Source 
Flavonols are the most widespread flavonoids in foods, and the most prominent flavonols 
in food are quercetin and kaempferol (Erdman et al. 2007). Red wine and tea can also 
contain a significant amount of flavonols. Flavan-3-ols are present in many fruits such as 
grape products, teas, cocoa, and chocolate. They are either monomers (epicatechin and 
catechin) or oligomers (e.g., proanthocyanidins). Catechin and epicatechin are the main 
flavan-3-ols in fruits and cocoa. Flavanones are present in high concentrations in citrus 
fruits. The main aglycones in citrus are naringenin, hesperetin, and eriodictyol.  
Flavones are much less common than flavonols in fruits and vegetables. The 
prominent flavones in food are luteolin and apigenin. Parsley and celery are the primary 
food sources. Isoflavones are flavonoids with structural similarities to estrogens. Soy and 
soybean-derived products are the main sources of isoflavones in the diet. The 3 soybean 
isoflavones are genistein, daidzein, and glycitein. Typically, more genistein exists in 
soybeans and soyfoods than daidzein, and glycitein comprises <10% of the total 
isoflavone content. Isoflavones are naturally present in the soybean primarily in their ß-
glycoside form (genistein, daidzein, and glycitein). Soy protein has gained considerable 
attention for its potential role in improving risk factors for cardiovascular disease and the 
FDA recommends that an intake of at least 25g of soy protein per day can lower total and 
LDL-c (Sacks et al. 2006). However, it remains controversial whether the favorable 





1.7.3.1 Consumption, absorption and metabolism 
In Western countries, isoflavone intake does not usually exceed 1-3 mg per day although 
it is somewhat higher in vegetarians consuming soy milk or yogurt and in women treated 
with isoflavone supplements (Erdman et al. 2007). The mean daily isoflavone intake 
among Japanese adults ranges from 25 to 50 mg (expressed as aglycone equivalents). 
Intake in Hong Kong and Singapore is lower than in Japan, although intake in Shanghai 
appears to be similar to that in Japan (Messina et al. 2006).  
Isoflavones exist primarily in plants in the inactive form as glycosides (Bhathena 
and Velasquez 2002). Once ingested, isoflavone glycosides (genistin and daidzin) are 
hydrolyzed in the intestines by bacterial ß-glucosidases and are converted to 
corresponding bioactive aglycones (genistein and daidzein). The aglycones are then 
absorbed from the intestinal tract and conjugated mainly in the liver to glucuronides, 
which are either re-excreted through the bile and re-absorbed by enterohepatic recycling 
or excreted unchanged in the urine. Daidzein may be further metabolized to equol or 
dihydrodaidzein in the colon. Daidzein, genistein, equol are the major isoflavones that 
have been detected in the blood and urine of humans. Dihydrodaidzein have also been 
detected in human plasma (Erdman et al. 2007).  
Concentrations of isoflavones and their metabolites in plasma and urine have been 
reported in several studies of humans and animals. In healthy humans consuming diets 
without soy, plasma concentrations of isoflavones are usually in the nanomolar range but 
are increase markedly in the micromolar range after ingestion of enriched isoflavones 
products (King and Bursill 1998). Plasma isoflavone concentrations of 1–4 µM have been 
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reported in various population groups consuming foods rich in isoflavones (Adlercreutz et 
al. 1993; Xu et al. 2000). 
 
1.7.3.2 Effects on lipid and glucose metabolism 
Obesity and diabetes mellitus are association with major cardiovascular risk factors 
(dyslipidemia, atherosclerosis, and coronary artery disease) responsible for excess 
morbidity and mortality (Bhathena and Velasquez 2002). Insulin resistance is a common 
feature of obesity and diabetes and is affected by the nature of dietary fat (Yamashita et al. 
1998). Thus, diet interventions to control insulin resistance may be one of the means for 
the management of obesity and diabetes.  
Although it remains unclear whether beneficial effects can be attributed to soy 
protein or isoflavones, a study on postmenopausal women, showed that the consumption 
of isoflavones, genistein, and daidzein was associated with lower body mass indexes, 
fasting insulin concentrations and higher HDL-c (Goodman-Gruen and Kritz-Silverstein 
2001). Genistein and daidzein also lowered the insulin response to an oral glucose load. 
Nonetheless, little information is available on the effects of soy in individuals with type 2 
diabetes, who are at higher risk due to hyperlipidemia, lower HDL levels, and 
abnormalities in LDL/lipoprotein composition (Hermansen et al. 2001; Jayagopal et al. 
2002). Indeed, in a recent study, soy isoflavones alone do not confer significant 
cardiovascular protection or positive effects on glycemic control in this group of patients 
(Gonzalez et al. 2007).   
Assessment of the effects on using either soy proteins differing in their isoflavone 
contents or with isoflavone extracted from red clover on lipidemia in several studies 
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(Manach et al. 2005) showed that only a small number of trials displayed an overall 
increase in HDL-c and a decrease LDL-c  (Wangen et al. 2001; Sanders et al. 2002; 
Nestel et al. 2004). In agreement, a recent scientific advisory by the American Heart 
Association based on the meta-analysis of 19 studies on the lipidemic effects of soy 
isoflavones reported that the average effect on LDL-c and other lipid risk factors was nil 
(Sacks et al. 2006). Hence, they attributed the beneficial effects of soy on cardiovascular 
and overall health was due to their high content of PUFA, fiber, vitamins and minerals 
and low content of saturated fat.  More studies with isolated isoflavones are needed to 
establish the hypolipemic effects of isoflavone.  
 
1.7.3.3 Molecular mechanism of isoflavones 
The mechanisms by which isoflavones exert their beneficial effects on diabetes and 
obesity are unclear (Bhathena and Velasquez 2002). As a result of their structural 
similarities to endogenous estrogens, isoflavones, especially genistein, act as weak 
estrogens and compete with estradiol for binding to ER to modulate gene transcription. 
Recently, biochanin A was shown to upregulate hepatic apoA-I mRNA expression 
through an ER dependent pathway (Chan et al. 2007). Isoflavones may also exert their 
biological effects via non-estrogen receptor-mediated mechanisms by inhibiting the 
activity of several enzymes, including protein tyrosine kinases, DNA topoisomerase I and 
DNA topoisomerase II, and ribosomal S6 kinase. Indeed, some of the cellular and 
metabolic effects of isoflavones may be through both ER and non-ER mediated 
mechanisms.  
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Several lines of evidence suggest that isoflavones may favorably affect glucose 
homeostasis, insulin secretion, and lipid metabolism (Erdman et al. 2007). A large part of 
these studies was carried out with genistein. In vitro studies suggest that genistein and 
daidzein inhibits glucose absorption in the intestines and also protects against glucose-
induced oxidation of LDL (Vedavanam et al. 1999). Genistein has also been shown to 
have a positive effect on lipid metabolism in the liver and adipose tissue which was 
accompanied by a decrease in triacylglycerol content, especially in hepatocytes 
(Nogowski et al. 1998). Genistein was also reported to decrease the number of high-
affinity insulin receptors in the livers of ovariectomized rats (Mackowiak et al. 1999). 
Thus, genistein appears to have direct effects on lipid metabolism in liver and adipose 
tissue by affecting both lipogenesis and lipolysis. In skeletal muscle cells, genistein was 
shown to inhibit glucose uptake  stimulated by uncoupling protein 3 (Huppertz et al. 
2001). Collectively, isoflavones, in particular genistein, may appear to have favorable 
biological actions on glucose and lipid metabolism that may explain their potential to 
benefit obesity and diabetes.  
 
1.7.4 Traditional Chinese medicine, a source of flavonoids 
Herbal formulations comprising more than one plant extract have been used in traditional 
Chinese medicine (TCM) for about three thousand years. Interest on their value and 
therapeutic efficacy has directed the increasing popularity of these natural remedies in 
recent years (Qiu 2007). TCM is rich in flavonoids and other phenolic compounds (Jung 
et al. 2006). While there are indications on the therapeutic potential of flavonoids, the 
rich source of flavonoids in TCM have yet to be fully exploited.  
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According to its clinical manifestations, diabetes mellitus is categorized as 
xiaokezheng or xiaodanzheng, both of which mean diabetes, in TCM. TCM has its own 
unique understanding in the etiology, diagnosis and therapeutics of a disease condition. 
However, some components of TCM have particular relevance to Western medicine. 
Xiaokezheng in TCM correlates closely with the western definition of diabetes mellitus in 
most but not all cases. Indeed, various symptoms associated with diabetes mellitus such 
as polyuria (excessive urination), polydipsia (excessive thirst), polyphagia (excessive 
hunger), weight loss are also seen in xiaokezheng. 
There are about 33 types of herbs most frequently used in Chinese traditional 
prescriptions for the clinical treatment of diabetes and its complications according to the 
Chinese pharmacopoeia (Li et al. 2004). However, regardless of the efficacy of their 
supposed anti-diabetic properties, the mechanisms of action of these herbs are rarely 
understood. Among these anti-diabetic herbs, the root of Astragalus membranaceus and 
its subspecies are present in the highest number of anti-diabetic herbal formulation. 
Another species of herbs purported to be anti-diabetic is the Pueraria spp. which belong 
to the same subfamily of Papilionaceae as Astragalus.  
 
1.7.4.1 The anti-diabetic herb, Pueraria Thomsonii 
The Pureraria species commonly associated with anti-diabetic properties are Pueraria 
lobata and Pueraria thomsonii. They are usually collected in the autumn or winter and 
are cut into cubes or sliced cross-sectionally. The antihyperglycemic actions of Pueraria 
extracts have been investigated in diabetic rats (Hsu et al. 2003). In addition some of the 
studies involved its use in conditions affecting menopausal women, such as osteoporosis, 
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coronary heart disease, and some hormone-dependent cancers (Wang et al. 2003a; Woo 
et al. 2003). The molecular basis for these may be due to the estrogenic affects of 
isoflavones isolated from the plant extract such as genistein, daidzein, formononetin and 
biochanin A (Ososki and Kennelly 2003). One Pueraria flavonoid, kakonein, was 
reported to be effective in lowering blood glucose level of alloxan or adrenalin-induced 
diabetic mice while another Pueraria flavonoid was useful in the treatment of diabetes 
complications and hyperlipidemia (Li et al. 2004). Nonetheless, detailed mechanistic 
studies of its bioactive compounds are few. Indeed, despite recommendations by the 
World Health Organization (WHO), few traditional antidiabetic plants have received 
scientific or medical scrutiny although this should be undertaken to ensure the safety and 






Drugs activating PPARα and PPARγ such as fibric acid derivatives and 
thiazolidinediones respectively, have beneficial effects on diabetes mellitus, 
dyslipidaemia and the associated metabolic syndrome. The search for compounds with 
dual PPARα and PPARγ activities is an area of intense pharmaceutical activity. 
Traditional Chinese herbal decoctions and formulations are extremely popular nutritional 
products consumed for their anti-diabetic properties, largely without any understanding 
of their mechanisms of action. We hypothesize that small phenolic molecules present in 
some ‘anti-diabetic’ botanical foods may activate the PPAR signaling system. Discovery 
and characterization of putative PPAR-activating compounds would be an important first 
step towards their possible application in the management of the metabolic syndrome.  
Recently, natural variants of PPAR have been shown to be functionally significant 
and to be important determinants of cardiovascular and metabolic health. V227A 
affecting the PPARα hinge region was associated with perturbations in plasma lipid 
levels in a relatively high proportion of selected Asian populations. However, the impact 
of this variant on the function of PPARα is not known. Furthermore, while the 
physiological relevance of V227A is slowly emerging, detailed molecular mechanism of 
action pertaining to its functionality, if any, remains elusive. Indeed, use of V227A as a 
molecular tool to functionally characterize the significance of PPARα and its interaction 
with corresponding proteins, such as coregulators, will aid in further understanding of 




To address the above issues, the objectives of this study were:  
1) To identify, isolate and structurally characterize PPAR-active 
compounds from an anti-diabetic botanical, Pueraria Thomsonii (PT), 
and to characterize their functional effects in relevant cell models.  
2) To examine the effects of the V227A variant on PPARα function and to 
elucidate the molecular mechanisms for any observed effects. 
To address our first objective, we isolate the bioactive compound(s) which are 
PPARα/PPARγ active from purported anti-diabetic herb, Pueraria Thomsonii (PT), using 
a specific chimeric PPAR screening assay. PT, a herb used in the traditional treatment of 
diabetes and its complications, was identified as the candidate herb after consultation 
from the Chinese pharmacopoeia. Following the identification of bioactive compounds 
from this botanical, we will characterize these PPARα/PPARγ-activating compound(s) 
together with closely related compounds and compared them with currently available 
reference drugs. A systematic characterization of their transcriptional properties, function 
in adipocyte differentiation, and the ability to induce endogenous PPAR regulated gene 
expressions will assess their potential use in managing metabolic diseases.  
To address our second objective, we first examine the functionality of V227A 
variant using various synthetic and endogenous PPARα ligands together with isoflavones 
characterized from the herb PT on the transactivation of PPARα regulated genes in lipid 
metabolism. Other than the nature of the ligand, PPARα activity is regulated through the 
action of AF-1 and/or AF-2, RXR dimerization, protein regulation and coregulator 
interaction. Thus, a methodical analysis of V227A PPARα activity, in regards to these 
mechanistic factors, will elucidate the major mechanism behind any observable effects. 
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Following identification of the major underlying mechanism, we will functionally 
characterize, in detail, the PPARα and protein interaction involved and the relevance of 
V227A on PPARα in such context. Finally, we will investigate whether the molecular 
mechanism elucidated is physiologically relevant at the chromatin level. 
Together, the detailed mechanistic study of PPARα V227A with the isolation and 
characterization of PPAR active compounds isolated from PT will both serve to further 
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2.1 DNA manipulation 
2.1.1 Full length PPAR expression plasmids 
Full length human PPARα (pSG5-FL-PPARα) and PPARγ (pPSG5-FL-PPARγ) 
expression vectors used for Sections 3.1 and 3.2 were obtained from Dr W Wahli 
(Universite de Lausanne, Switzerland).  
From Sections 3.3 to 3.5, full length PPARα expression was attained with 
pcDNA3.1-WT. These plasmids were obtained from Dr Tai E Shyong (Singapore 
General Hospital, Singapore). In brief, the full length human PPARα cDNA was cloned 
by RT-PCR from HepG2 cell RNA using primers with BamHI and ApaI sites into 
pcDNA3.1/ myc-His A (Invitrogen) to generate pcDNA3.1-PPARαWT. The valine at 
position 227 was mutated into alanine by PCR site-directed mutagenesis using 
Quikchange kit (Stratagene) according to the manufacturer’s instructions to generate 
pcDNA3.1-PPARαV227A. 
2.1.2 Gal-PPAR-LBD expression plasmids  
pGal-PPARαWT-LBD (residues 171-468) was constructed by excising pSG5FL-PPARα 
with BstUI and BamHI and ligating proximally to the DBD of Gal4 of the pM vector 
(Clontech). pGal-PPARαV227A-LBD was generated through the Quikchange kit using 
pGal-PPARαWT-LBD as a template. pGal-PPARγ-LBD was constructed by excising 
pSG5FL-PPARγ2 with RsaI and blunt-end ligating to Hind III site of pM.  
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2.1.3 UASG-Luc reporter plasmid  
The upstream activating sequence (UASG)-luciferase (Luc) reporter gene was 
constructed by cloning 5 copies of the upstream activating sequence of Gal4 in tandem to 
a luciferase gene in a pGL3-basic vector containing the basal thymidine kinase promoter..  
2.1.4 CYP4A6-PPRE-Luc reporter plasmid 
The pCYP4A6-PPRE-Luc was a gift of Dr W.Wahli, University of Lausanne, 
Switzerland (Krey et al. 1993).  
2.1.5 Full length RXRα expression plasmid 
pCMX-hRXRα was generated after excision of VP16 and re-ligation of the HindIII site 
of pCMX-VP16 hRXRα, a gift of Dr  Ronald M Evans, The Salk Institute, San Diego, 
CA (Forman et al. 1995).  
2.1.6 HMGCS2-Luc reporter plasmid 
The promoter of mitochondria HMG-CoA synthase (-1081 to + 22) was cloned by RT-
PCR of HepG2 cell genomic DNA using primers with NheI and HindIII sites into pGL3 
basic vector (Promega) to generate pHMGCS2-Luc.  
2.1.7 NCoR C-terminal expression plasmid 
pSG424-C-terminal NCoR (amino acid 1575- 2453) was a gift of Dr Tetsuya Tamagi, 
National Hospital Organization, Japan (Tagami et al. 1998). 
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2.1.8 Full length NCoR expression plasmid 
pSG5-NCoR (full length) was a gift of Dr RN Cohen, University of Chicago, Chicago, IL 
(Yu et al. 2005).  
2.1.9 VP16-PPARα expression plasmid  
The hinge and LBD (residues 167-468) of PPARα WT or V227A was cloned into the 
BamHI and HindIII site of pVP16 (Clontech) to give pVP16-WT and pVP16-V227A. 
The VP16 control plasmid, pVP16-ΔH1-H2, of helices 3 to 12 of PPARαLBD (residues 
245-468) was also cloned using the above strategy. 
2.1.10 Gal-p300 expression plasmid 
Residues 1-117 of E1A binding protein p300 from pCMVb-p300 HA (Addgene) were 
cloned into the EcoRI of pSG424 to generate pGal-p300. 
2.1.11 Gal-SRC-1 expression plasmid 
Residues 213-1061 of pCR3.1-hSRC-1A (Jenster et al. 1997) (a gift from Dr BW 
O’Malley, Baylor College of Medicine, Houston, TX) was cloned into the Sal1 and XbaI 
of pM vector to generate pGal-SRC-1 
2.1.12 Gal-SMRT expression plasmid 
pCMX-Gal-C-SMRT, encoding residues 2004-2517, was also gift of Dr RM Evans 
(Chen and Evans 1995). 
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2.1.13 Gal-PRIP expression plasmid 
The plasmid encoding PRIP (residues 819-1096) was pSG5-Gal4-hRAP250-del4, a gift 
of Dr JA Gustafsson, Karolinska Institutet, Sweden (Caira et al. 2000). 
2.1.14 Gal-TIF2 expression plasmid 
Residues 622-869 of TIF2 (Loy et al. 2003) were cloned into the BamHI and MluI site of 
pM vector. 
2.1.15 Gal-PGC1α expression plasmid 
Residues 120-284 of pSV- PGC1α (Addgene) was cloned into the BamHI and MluI site 
of pM vector. 
2.1.16 Gal-NCoR truncation expression plasmids 
Gal-NCoR truncated mutants in Fig. 3.5.4 were generated by cloning respective 
fragments into the EcoRI and SalI sites of the pM vector. GST-NCoR mutants (GST-G1 
to GST-G3 in Fig. 3.5.5) was generated by subcloning each NCoR truncated mutant into 
pGEX-4T-1 (Invitrogen).  
2.1.17 VP16-PPARα truncation expression plasmids 
VP16-PPARα truncated mutants in Fig. 3.5.6 were generated by cloning respective 
fragments into the BamHI and HindIII sites of the pVP16 vector.  
 
2.2 Materials and reagents 
WY14,643 was purchased from Tocris. [3H]-WY14,643 was purchased from American 
Radiolabeled Chemicals, Inc. Pioglitazone was a gift from Takeda Chemical Industries. 
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Biochanin A, genistein, formononetin, calycosin, daidzein, α-linolenic acid, linoleic acid, 
fenofibrate and trichostatin A (TSA)  from Sigma. Flavonoids were kind gifts from Dr. 
Andrew M. Jenner (Department Biochemistry, National University of Singapore). 
Additional diosmetin was purchased from Chromadex. Voucher specimens of Pueraria 
thomsonii (SBG-PT-040720) were deposited in the Singapore Herbarium, Botanical 
Gardens, National Parks Board.  
 
2.3 Cell culture 
Preadipocyte 3T3- L1 cells, HepG2 and HeLa cells were obtained from American Type 
Culture Collection. 3T3-L1 cells were cultured in DMEM. HepG2 and HeLa cells were 
cultured in minimum essential medium, Eagle modified (Sigma) with 2mM L-glutamine, 
1.5g/L sodium bicarbonate, 0.1mM non-essential amino acids, 1mM sodium pyruvate 
and charcoal-treated fetal bovine serum, 10%.  
 
2.4 Transient transfection and reporter gene assay 
Cells were transfected using Lipofectamine 2000 reagent (Invitrogen) or GenePORTER 2 
(GTS) according to manufacturer’s instructions. Briefly, cells were cultivated in charcoal 
treated medium for 3 days before seeding at 40,000 cells/well in 24 well microtiter plates 
and incubated for 24h before transfection. Transfected cells were then exposed to test 
samples in charcoal treated medium. In reporter gene bioassays, cells were lysed post 
treatment with 100μl of M-Per (Pierce) per well for 5 min. Luciferase activity was then 
measured using Glomax 96 Microplate Luminometer (Promega). Experiment results 
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obtained from reporter gene assays were re-confirmed with measurements of either 
renilla luciferase (Promega) or β-Gal (Promega) to ensure similar transfection efficiency.  
 
2.5 Ligand binding assay 
2.5.1 PPARγ  competitor binding assay  
A PPARγ competitor assay (PolarScreen, Invitrogen) was applied to evaluate the binding 
affinity of individual isoflavones to PPARγ -LBD. The assay was performed according to 
the manufacturer’s instructions. Briefly, recombinant PPARγ-LBD was added to a 
fluorescent PPARγ ligand (fluormone PPAR-Green) to form a PPARγ-LBD/fluormone 
complex with a high polarization index. This complex was added to individual test 
samples in 96-well plates, incubated at room temperature for 2 h and polarization values 
measured with Tecan Ultra 384 fluorescence polarization plate reader. PPARγ-specific 
ligands in test samples displaced the fluorescent fluormone from the PPARγ-LBD 
fluormone complex, resulting in lower polarization values. Assays were conducted in 
triplicate and data presented as means ± SEM. Curve fitting was performed using 
GraphPad Prism Software.  
2.5.2 Radiolabelled competitive binding assay 
Competitive PPARα ligand binding assay was performed as previously described (Lim et 
al. 2000). Briefly, HeLa cells in 24 well microtiter plates were transfected with 
pcDNA3.1-PPARαWT or PPARαV227A and incubated in 3 nM of [3H]-WY14,643 with 
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increasing doses of unlabeled WY14,643 at 37°C. The amount of radiolabelled 
WY14,643 specifically bound was measured after 24h incubation. 
 
2.6 Adipocyte differentiation assay 
Murine fibroblast or preadipocyte 3T3-L1 cells were seeded at a density of 40,000 
cells/well in 24-well plates and cultured to confluency for 2 days in DMEM. Post-
confluent preadipocytes were exposed to induction medium containing 10% charcoal 
dextran-stripped serum, insulin (5 mg/l), dexamethasone (1 μM), and 3-isobutyl-1-
methylxanthine (0.5 μM). Induction medium was removed after 2 days; cells were 
washed 3 times, and exposed to increasing doses of test compounds for 8 days. Medium 
was replenished with appropriate ligands every 2 days. After treatment, cells were 
washed with PBS, fixed with 4% paraformaldehyde, and lipid droplets were stained with 
0.5% oil-red O in 60% isopropanol. Stained cells were examined under phase-contrast 
photomicrography, and a minimum of 3 experiments were performed in duplicate.  
 
2.7 Western analysis 
Immunoblotting of samples obtained from co-immunoprecipitation assays or total cell 
lysates were performed according to standard western blotting protocol, using anti-
PPARα rabbit polyclonal antibody (Santa Cruz), anti-PPARγ mouse monoclonal 
antibody (Santa Cruz), anti-NCoR rabbit polyclonal antibody (Affinity Bioreagents) and 
anti-β-actin mouse monoclonal antibody (Sigma).   
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2.8 Reverse transcription polymerase chain reaction (RT-PCR) 
2.8.1 Real time RT-PCR 
Post-confluent 3T3-L1 cells or HepG2 cells were exposed to ligands before total RNA 
were isolated with Qiagen’s RNAeasy Kit. Reverse transcription of RNA was carried out 
with SuperScript III Reverse Transcriptase (Invitrogen) following manufacturer’s 
protocol with random primers. Quantitative PCR amplification and detection were 
performed with TaqMan Universal PCR MasterMix according to the manufacturer’s 
protocol on ABI Prism 7000 Sequence Detection System (Applied Biosystems) The gene 
expression assay kits for individual genes were as follow: PPARα (Hs00231882_m1), 
CPT1A (Hs001577079_m1), HMGCS1 (Hs00266810_m1), HMGCS2 
(Hs00266810_m1), PPARγ (Mm00440945_m1), aP2 (Mm00445880_m1), adiponectin 
(Mm00456425_m1) and 18S as internal control. Results are presented as the fold 
increase compared to vehicle. Values are the mean ± S.E. of two independent 
experiments. 
2.8.2 Duplex semi-quantitative RT-PCR 
HepG2 cells were transfected with pcDNA3.1-PPARαWT or –PPARαV227A and 
treated in the absence or presence of WY14,643. RNA was extracted from treated cells 
using RNeasy Mini Kit (Qiagen) post treatment. Two μl of cDNA was subjected to PCR 
with specific primer pairs that match bp 80-99 (PPARα forward, 5’-
TCCTGCAAGAAATGGGAAAC-3’) and bp 474-493 (PPARα reverse, 5’-
CGACAGAAAGGCACTTGTGA-3’) of the human PPARα sequence or; bp 143-162 
(HMGCS2 forward, 5’-ATACTTGGCCAAAGGACGTG-3’) and bp 604-623 (HMGCS2 
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reverse, 5’-GTGGGACGAGCATTACCACT-3’) of the human HMGCS2 sequence using 
the QuantumRNATM 18S internal standard kit (Ambion). The amplicons were resolved 
on 2% agarose electrophoresis and image was captured by Alpha DigiDoc. Bands were 
quantified using Scion Image and the expression levels of HMGCS2 gene transcript 
expressed as ratios against 18S rRNA internal control.  
 
2.9 Immunoflourescence 
HepG2 cells seeded on cover-slips in 24 well microtiter plates were transfected with 
pcDNA3.1-PPARαWT or V227A and treated in the absence or presence of WY14,643. 
At 24 h post treatment, the cells were fixed with cold absolute methanol for 10 min, 
followed by the incubation with anti-PPARα rabbit polyclonal antibody (Santa Cruz) 
(1:400) in a humidity chamber for 1 h at 37oC. After washing, the cell monolayer on the 
cover-slips was incubated with secondary antibodies conjugated with FITC (Amersham 
Pharmacia Biotech) (1:600). Optical immuno-fluorescence microscope (Olympus IX-81) 
was used to view the specimens at 100X magnification, excitation wavelengths of 480 
nm, for FITC using oil immersion objectives. The nucleus was stained with DAPI.  
 
2.10 siRNA knockdown 
BLOCK-iT™ Lentiviral RNAi Expression System (Invitrogen) was used according to the 
manufacturer’s instructions to produce lentiviruses for gene silencing of NCoR in HepG2 
cells. Double-stranded oligonucleotide encoding the shRNA of NCoR (siNCoR) (Top 
strand: 5' CACCGCTGAAGAGGGTTCTGTTTGTCGAAACAAACAGAACCCTCTTC 
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AGC 3’; Bottom strand: 5' AAAAGCTGAAGAGGGTTCTGTTTGTTTCGACAAACA 
GAACCCTCTTCAGC 3’) were synthesized and oligo-duplexes were cloned into a 
lentivirus expression vector (pLenti6/BLOCK-iTTM-DEST). The expression plasmid and 
other virus packaging plasmids were cotransfected into 293FT cells to generate 
replication-defective lentivirus. The resulting lentivirus was then used to infect HepG2 
for gene silencing of NCoR. Successful knockdown of NCoR was assessed using western 
blotting. A randomized sequence (siScram) (Forward: 5’ 
CACCAGGATGCAACACGTGGAATAGCGAACTATTCCACGTGTTGCATCCT 3’; 
Reverse: 5’ AAAAAGGATGCAACACGTGGAATAGTTCGCTATTCCACGTGTTGC 
ATCCT 3’) not targeting any known human transcript sequences was used as a control.  
 
2.11 Glutathione-S-transferase (GST) pull down 
GST fusion proteins were expressed in BL21-DE3 E. coli by induction with 0.4 mM 
isopropylthio-β-d-galactosidase at 37 °C. Proteins were isolated after disruption through 
sonication and affinity purified on glutathione-Sepharose 4B beads (Amersham 
Pharmacia) according to manufacturer’s protocol. WT and VA PPARα were in-vitro 
translated in reticulocyte lysate (Promega) using T7 polymerase, according to 
manufacturer’s protocol. 25μl of in vitro translated proteins was incubated with equal 
amounts of GST fusion proteins overnight at 4°C. Following this, GST fusion protein 
complexes were affinity purified with 50μl of glutathione-Sepharose 4B beads for 2h at 
4°C. After extensive washing, bound proteins were eluted by boiling in 2X loading buffer 
and analyzed by Western blotting for PPARα . 
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2.12 Immunoprecipitation (IP) 
HepG2 cells grown on 100 mm plates were transfected with pcDNA3.1-PPARαWT or 
V227A and treated in the absence or presence of WY14,643. At 24h post treatment, the 
cells were washed with cold PBS and lysed using RIPA buffer. Following centrifugation 
at 1500g for 15min, the supernatants were precleared with Protein A/G PLUS agarose 
beads (Santa Cruz) for 30min and incubated with 2μg/ml anti-PPARα rabbit polyclonal 
antibody at 4°C overnight. Following this, the antibody-protein complex was pulled 
down using A/G agarose beads and washed 5 times with RIPA buffer before elution of 
bound proteins by boiling in 2X loading buffer and analyzed by Western blotting for 
NCoR or PPARα . 
 
2.13 Chromatin immunoprecipitation (ChIP) 
HepG2 cells grown on 100 mm plates were transfected with pcDNA3.1-PPARαWT or 
V227A and treated in the absence or presence of WY14,643. At 24h post treatment, the 
cells were treated with formaldehyde to cross-link proteins to DNA and ChIP performed 
using the ChIP Assay Kit (Upstate) according to manufacturer’s instructions. ChIP was 
performed using the following antibodies at 2μg/ml: normal rabbit IgG, PPARα, SRC-1, 
NCoR and p300 (Santa Cruz). Primers used to amplify the PPRE region ( -198 to -34) of 
the mitochondria HMG-CoA synthase promoter are: Forward 5’ CAGCCATTCCCAC 
ACATGCTCA 3’; Reverse 5’ CAGACTTTATAAAGCCCCAAGACT 3’ ). In ChIP-re-
ChIP experiments, PPARα ChIP complexes were eluted by incubation for 30 min at 37 C 
in 50 μl 10mM dithiothreitol. After centrifugation, the supernatant was diluted 20 times 
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with re-ChIP buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, 
pH 8.1) and subjected again to the ChIP procedure using NCoR antibody.  
 
2.14 Isolation and structural characterization of bioactive compounds 
2.14.1 Solid-liquid chromatography separation  
Ten grams of the ethyl acetate Pueraria thomsonii (PT) extract was dry packed with 15g 
of silica gel (LiChroprep Si 60 40~63 μm, Merck) and applied onto the top of a Medium 
Pressure Liquid Chromatography (MPLC) (Buchi Chromatography B-680) glass column 
packed under pressure with 350g silica gel (LiChroprep Si 60 15~25 μm, Merck). The 
column was successively eluted using mixtures with increasing polarity as follows: 99:1, 
98:2, 97:3,...,90:10, 80:20,…,10:90, 0:100, and in the end washed with methanol.  
2.14.2 High Pressure Liquid Chromatography (HPLC), Mass Spectrometry (MS), 
Nuclear Magnetic Resonance (NMR) spectroscopy  
The HPLC chromatogram of compounds was by performed using a reverse-phase 
gradient run in Shimadzu LC2010A HPLC system. The column used was Waters Nova-
Pak C18 (3.9 x 150mm). The UV wavelength detector was set at 254nm. The MS and 
NMR spectroscopy was performed by the Chemical and Molecular Analysis Centre, 
Department of Chemistry, NUS.  
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2.15 Statistical analysis 
For Sections 3.1 to 3.2, all luciferase experiments were performed at least 3 times on 
separate occasions. Statistical analyses were conducted using SPSS 13.0 (SPSS Inc.). 
One-way ANOVA was used to determine dose-dependent activities of PPAR ligands, 
active herbal extracts, and differential effects of isoflavones on PPARα/PPARγ. For 
multiple comparisons with the vehicle group, Dunnett’s post-hoc test was used. For 
multiple pair-wise group comparisons, Bonferroni adjustments were applied. Repeated 
measurement analysis over concentration levels between AM and PT was also performed 
with Bonferroni correction.  
For Sections 3.3 to 3.5, all luciferase experiments were done in duplicates or 
triplicates at least three times on separate occasions. The difference between WT and 
V227A at each treatment was analyzed by 2 sample t-test. Adjustment for type 1 error 
due to multiple comparisons was done by Bonferroni procedure on groups with a 
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3.1 Discovery of PPAR bioactive flavonoids from the anti-diabetic herb, Pueraria 
thomsonii (PT) 
3.1.1 Evaluation of a chimera Gal-PPAR reporter gene bioassay 
To isolate PPAR active compounds from the anti-diabetic herb, Pueraria thomsonii (PT), 
a specific and sensitive screening assay was needed. One possible screening method is 
through cotransfection of the full length PPAR receptor with a PPRE driven reporter gene 
into human cell lines (Fig 3.1.1A, top panel). An agonist will induce the reporter gene 
signal in such an assay. However, transcription induced by PPAR and its obligate partner, 
RXR, on PPAR target genes can be due to the response of either PPAR or RXR agonists 
alone or in combination (Kliewer et al. 1992; Gearing et al. 1993; Keller et al. 1993). 
Thus, a full length PPAR reporter assay is not a specific tool for PPAR ligand screening.  
Alternatively, the chimeric receptor consisting of the PPAR LBD and the yeast 
Gal4 DBD will allow for specific screening of PPAR ligands only. This mammalian-one-
hybrid assay (Fig 3.1.1A, middle panel) is a variation of the mammalian-two-hybrid 
assay (Fig 3.1.1A, bottom panel). While the mammalian-two-hybrid assay characterizes 
protein-protein interactions, the mammalian-one-hybrid assay is used to characterize 
DNA-protein interactions. However, both hybrid assays work on the same principle that 
in most eukaryotic transcription factors, the activation domain and DBD are modular and 
can function in close proximity to each other without direct binding (Verschure et al. 
2006). The DBD is responsible for binding to DNA and the activating domain is 
responsible for activation of transcription.  In this study, the yeast Gal4 DBD was chosen 
because it binds strongly to its response element, the upstream activating sequence of 
galactosidase (UASG), and thereby giving rise to a sensitive assay. AF-2 on helix 12 of  
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PPAR (Nolte et al. 1998) provides the activation module in this mammalian-one-hybrid 
assay. Since activity of AF-2 is dependent on ligand binding, it allows transcription 
activation of the chimera only in the presence of a ligand, and thereby conferring low 
background and added sensitivity to the assay. The resulting chimera protein when 
activated by a PPAR ligand, will bind to UASG and activate the transcription of the 
luciferase reporter gene to indicate the presence of a specific PPAR ligand. Therefore, to 
differentiate the ligands of PPAR from that of its heterodimeric partner RXR, we 
employed the specific and sensitive chimera Gal-PPAR reporter gene bioassay.  
To determine the specificity and sensitivity of the chimera Gal-PPAR reporter 
gene bioassay, we cotransfected chimeric Gal-PPARα-LBD or Gal-PPARγ-LBD together 
with the UASG-Luc reporter gene in a human cell line expressing low levels of PPAR, 
HeLa cells. The PPARα specific ligand, WY14,643, dose-dependently activated the 
chimeric Gal-PPARα construct, with a 50% effective concentration (EC50) of 5μM and a 
maximal activity 14-fold of the vehicle (Fig. 3.1.1B). Similarly, the PPARγ specific 
ligand, pioglitazone, increased the activity of the Gal-PPARγ system at a maximum of 40 
fold of the vehicle with an EC50 of 3μM (Fig. 3.1.1C). There was minimal cross-reaction 
between pioglitazone and WY14,643 with PPARα and PPARγ, respectively, in this 
chimera Gal-PPAR reporter gene bioassay, indicating that this chimera bioassay could be 
used as a tool to detect PPAR activity of unknown compounds from botanicals.  
 
3.1.2 PPAR activity of PT extract   
Ethanolic extracts of botanicals with purported anti-diabetic properties were screened for 
PPAR activity using the evaluated chimeric Gal-PPAR reporter-gene bioassay in our 
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laboratory. PT, together with Astragalus membranaceus (AM) significantly stimulated 
both PPARα and PPARγ. PT was also more selective for PPARα. Thus, this project was 
focused on PT1.  
A dose response curve to quantify the PPAR activity of PT extract was carried out 
using the Gal-PPAR reporter gene bioassays. PPARα activity of PT was first observed at 
a concentration of 10μg/ml, rising to a peak at 300μg/ml (Fig 3.1.2). The PPARα activity 
of PT at its peak was 100% of the maximal activity of WY14,643, a PPARα agonist. The 
EC50 for PT was ~100μg/ml. PT extract also activated PPARγ. PPARγ activity of PT 
was first observed at a concentration of 30μg/ml, rising to a peak at 300μg/ml. However, 
the PPARγ activity of PT at its peak was only 30% of the maximal activity of 15dPGJ2, a 
natural PPARγ agonist.  
Therefore, PT extract from concentrations 30 to 300μg/ml was a dual 
PPARα/PPARγ activator and also a strong activator of PPARα. 
                                                 
1 PPAR activity of AM was characterized by other laboratory members.  
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Figure 3.1.1(B,C) Dose response curves of chimera Gal-PPAR reporter gene 
bioassays 
Using the mammalian-one-hybrid system (inset), HeLa cells were cotransfected with (B) 
Gal-PPARα  or (C) Gal-PPARγ (25ng) and the (UASG)5-Luc reporter gene (250ng) and 
exposed to WY14,643 or Pioglitazone for 48hr as indicated. Data points (mean±SEM, 
n=3) represented fold increase in luciferase activity over vehicle. Means without a 































































Figure 3.1.2 Effects of Pueraria thomsonii (PT) extract on chimera Gal-PPAR 
reporter gene bioassays 
 
HeLa cells cotransfected with Gal-PPARα  or Gal-PPARγ (25ng) and the (UASG)5-Luc 
reporter gene (250ng) were exposed to PT for 48hr as indicated. Data points (mean±SEM, 
n=3) represented percentage of the positive controls for PPARα (WY14,643, 30μM) and 















































3.1.3 Herbal extraction and bioassay guided fractionation 
To understand the molecular basis of the PPAR activity of PT, we performed bioassay-
guided fractionation of the crude extracts to isolate the PPAR active components.  
A strategy in which the crude extract was sequentially separated with organic 
solvents of decreasing polarity (Ethyl acetate < Hexane < DCM < Butanol) through 
solvent-solvent partition was employed (Figure 3.1.3). Solvent layers were assayed for 
PPARα and PPARγ activity. Active layers identified were then loaded onto a medium 
pressure liquid chromatography (MPLC) glass column packed with a silica gel matrix. 
The column was eluted using mixtures of non-polar (hexane) and polar (acetone) solvents. 
Fractions were collected and assayed for PPARα and PPARγ activity. After which, active 
fractions were combined and further separated using high pressure liquid chromatography 
(HPLC) with either Diol or C18 columns with solvents of varying polarity. Active 
fractions were identified through bioassays, and crystallized. Finally, the identities of the 
active compounds were confirmed through mass spectrometry (MS) and nuclear 
magnetic resonance (NMR).    
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Figure 3.1.3 Schematic representation of strategy for bioactive compounds 





























3.1.4 Solvent selection for PT extraction 
Using the above bioassay guided strategy, we first established the optimal solvent for 
extraction of PPAR active compounds from PT. Combinations of hexane/water, 
DCM/water, ethyl acetate/ water, butanol/water and water alone, were used. These 5 
different solvent extracted layers of PT were tested for PPAR activity using the chimeric 
Gal-PPAR reporter-gene bioassay. Extraction with 100% hexane, 100% ethyl acetate and 
100% butanol significantly stimulated both PPARα (Fig. 3.1.4A) and PPARγ (Fig. 
3.1.4B) at a dose of 100μg/ml. In contrast, extraction with 100% DCM and water alone 
exhibited minimal PPAR activity. For all three active solvent layers (hexane, ethyl 
acetate and butanol), PPARα activity was ~50-60% and PPARγ activity was ~20%. 
However, cell toxicity was observed to be ~80% and ~20% for the hexane and butanol 
layers respectively. Minimal cell toxicity was observed only in the ethyl acetate layer.  
Since extraction with 100% ethyl acetate resulted in one of the highest PPARα 
and PPARγ  activity and was at the same time, not toxic to cells, subsequent studies were 
focused on the ethyl acetate layer of PT.  
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Figure 3.1.4 PPAR activity of solvent extracted fractions of PT  
 
HeLa cells cotransfected with (A) Gal-PPARα  or (B) Gal-PPARγ (25ng) and the 
(UASG)5-Luc reporter gene (250ng) were exposed to each solvent fraction at a final 
concentration of 100μg/ml for 48hr. Data points (mean±SEM, n=3) represented 
percentage of the positive controls for PPARα (WY14,643, 30μM) and PPARγ (15-




















































































3.1.5 PPAR activity of PT ethyl acetate layer 
PT was identified as a PPAR active herb from screening experiments performed 
previously. A dose response curve to validate its activity after 100% ethyl acetate 
extraction was carried out using the Gal-PPAR reporter gene bioassays. PPARα activity 
of PT was first observed at a concentration of 10μg/ml, rising to a peak at 100μg/ml (Fig 
3.1.5). The PPARα activity of PT at its peak was 60% of the maximal activity of 
WY14,643. The EC50
 
for PT was ~50μg/ml. Ethyl acetate PT layer also activated PPARγ. 
PPARγ activity of PT was first observed at a concentration of 10μg/ml, rising to a peak at 
100μg/ml. However, the PPARγ activity of PT at its peak was only 20% of the maximal 
activity of pioglitazone.  
Therefore, from concentrations 10 to 100μg/ml, the ethyl acetate extracted layer 
of PT was a dual PPARα and PPARγ activator and was a strong activator of PPARα.  
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Figure 3.1.5 Dose response of ethyl acetate PT layer on chimera Gal-PPAR reporter 
gene bioassays 
 
HeLa cells cotransfected with Gal-PPARα  or Gal-PPARγ (25ng) and the (UASG)5-Luc 
reporter gene (250ng) were exposed to PT ethyl acetate fraction for 48hr as indicated. 
Data points (mean±SEM, n=3) represented percentage of the positive controls for 
PPARα (WY14,643, 30μM) and PPARγ (Pioglitazone, 30μM). Means without a 







































3.1.6 PPAR activity of MPLC separated fractions from PT  
To identify the bioactive compound responsible for PPAR activation in the ethyl acetate 
layer of PT, bioassay guided fractionation was employed. Preliminary fractionation was 
first performed on 10g of the ethyl acetate PT layer which was dry packed with 15g of 
silica gel and loaded onto the MPLC. The column was eluted using mixtures of hexane 
and acetone with increasing polarity and in the end washed with methanol. 47 fractions 
were collected and assayed for PPARα activity. Majority of the PPARα active 
compounds were eluted in Fractions 10-27 and 30-47 (Fig 3.1.6A). Among these 
fractions, major peaks of PPARα activity were observed in Fractions 13, 18 and between 
Fractions 32 to 34. A majority of PPARγ bioactive compounds were also eluted in 
Fractions 10-27 and 30-47 (Fig 3.1.6B). Since the final aim was to identify 
PPARα/PPARγ dual agonists, Fractions 1 to 10 were not tested for PPARγ bioactivity as 
they showed minimal PPARα activity previously (Fig 3.1.6A). Among these fractions, 
major peaks of PPARγ activity were observed in Fractions 17, 23, 41 and, again, between 
Fractions 32 to 34.  
To identify PPAR active compounds from PT which are also dual PPARα/PPARγ 
agonists in nature, active Fraction 32 was chosen for further separation using HPLC.  
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Figure 3.1.6 MPLC separation of PT ethyl acetate extract using silica as the solid 
phase matrix  
 
Ten grams of PT ethyl acetate extract was dry packed onto a MPLC glass column 
containing silica gel. The column was successively eluted using mixtures of Hexane and 
Acetone. Fractions collected were dried, reconstituted to 20mg/mL and tested for (A) 
PPARα and (B) PPARγ activity using the chimera Gal-PPAR reporter gene bioassay 
system at a final concentration of 20μg/mL for 48hr. Data points (means±SEM, n=3) 
represented percentage of the positive controls for PPARα (WY14,643, 30μM) and 




























































































































































































































3.1.7 PPAR activity of fractions further separated by HPLC  
The dual PPARα/PPARγ active, MPLC separated Fraction 32 of PT was further 
fractionated by HPLC, using a normal phase Diol column, with DCM (100%-50%) and 
ethyl acetate (0%-50) as the mobile phase. Fractions A to S were collected, dried, and 
reconstituted to 20mg/mL. Among these fractions, Fraction Q exhibited strong dual 
PPARα/PPARγ and was present in sufficient quantities to be isolated at 97% purity. 
Structural characterization with mass spectrometry and NMR indicated that it is daidzin.  
 
3.1.8 Bioactive compounds from PT  
Besides daidzin, the dual PPARα/PPARγ active Fraction 32 was also fractionated by 
another HPLC method, using a reverse phase C18 column, with methanol (100%-50%) 
and water (0%-50) as the mobile phase (Table 3.1). Of the 11 fractions obtained, 
sufficient quantities were present in the third fraction to be isolated at 96% purity. 
Structural characterization with mass spectrometry and NMR indicated that it was 
genistin.  
Two types of HPLC columns were utilized because C18 is able to separate 
compounds of higher polarity, while diol separates compounds of mid range polarity. 
Together, both C18 and diol can reversibly bind to a broad range of organic compounds 
which elute with a range of solvents according to their polarity. Such separation enables 
selective removal and concentration of organic compounds from complex mixtures. By 
controlling the elution sequence of the compounds retained on a matrix, biologically 
active components can be isolated from the fractions collected. From Fraction 32, daidzin 
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and genistin were isolated from PT through such strategy. Furthermore, because daidzin 
and genistin was isolated form diol and C18 respectively, this suggests that genistin is 
more polar than daidzin. 
Similar strategies were employed for Fraction 13, 18 and 34 and daidzein, 
2’hydroxy-daidzein and puerarin were identified from these fractions respectively.   
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Figure 3.1.7 PPAR activity of fractions from HPLC separation of PPARα active 
Fraction 32 with a Diol column 
 
PPAR active fraction 32 of MPLC separated ethyl acetate extracts of Pueraria thomsonii 
(PT) were combined and further separated by HPLC using DCM and ethyl acetate as the 
mobile phase. Fractions A to S were collected, dried, reconstituted to 20mg/mL and 
tested for (A) PPARα and (B) PPARγ activity using the chimera Gal-PPAR reporter gene 
bioassay system at a final concentration of 20μg/mL for 48hr. Data points (means±SEM, 
n=3) represented percentage of the positive controls for PPARα (WY14,643, 30μM) and 
PPARγ (Pioglitazone, 30μM). Grey arrows indicate fraction chosen for further 
characterization. 
 







































Table 3.1 Compounds isolated from various fractions of MPLC separation of PT 




Fractions Column Solvent conditions Compound
32 Diol DCM: Ethyl Acetate Daidzin
32 C18 Methanol: Water Genistin
34 C18 Methanol: Water Puerarin
13 Diol Hexane: Acetone Daidzein





3.2 Characterization of flavonoids on PPARα and PPARγ activity 
3.2.1 Effects of isoflavones on PPAR using the chimera Gal-PPAR reporter gene 
bioassay 
Among the compounds isolated from the PPAR active herb, PT, daidzein is an isoflavone. 
From another PPAR active herb, AM, others in our laboratory have also identified the 
isoflavones, formononetin and calycosin, to be PPAR activating. Together with the 
commonly studied isoflavones, genistein and its precursor biochanin A, we compared the 
PPAR actions of these 5 isoflavones concurrently to evaluate their potential as dual 
PPARα/PPARγ activators.  
With the chimeric Gal-PPARα assay, biochanin A, formononetin, and genistein 
were the most potent activators of PPARα with EC50 of 1.3μM, 1.0μM, and 16μM, 
respectively, comparing favorably with WY14,643 (EC50 of 5μM) (Fig 3.2.1A, Table 
3.2). In terms of maximal PPARα activity, biochanin A and genistein were the most 
efficacious, exhibiting up to 65–71% of that observed with WY14,643. However, peak 
activity of genistein for PPARα was observed only at high doses ~30μM, unlike 
biochanin A, whose peak was 10-fold lower at 3μM (Fig 3.2.1A). For PPARγ, biochanin 
A, formononetin, and genistein were the most potent activators (EC50 of 3.7μM, 2.6μM, 
and 23μM vs. pioglitazone; 3 μM) (Fig 3.2.1B, Table 3.2). The 5 isoflavones did not 




Thus, with the chimera Gal-PPAR reporter gene bioassay, the isoflavones, 
genistein, biochanin A and formononetin, were identified as strong activators of PPARα 
and PPARγ. However, biochanin A was most potent as maximal PPARα/PPARγ activity 
occurred at a physiologically relevant level of 3μM. 
 
3.2.2 Evaluation of a full length PPAR reporter gene bioassay 
While the chimera Gal-PPAR reporter gene assay was an efficient tool for PPAR ligand 
screening, the chimera consisted of the yeast Gal4 DBD and only the LBD of PPAR. This 
artificial construct provides limited insights to identified PPAR ligands in a 
physiologically relevant context because full transcription of PPAR in the presence of 
ligands involves an interplay with its heterodimeric partner, RXR, and the other domains 
of the receptor.  
Thus, to determine whether dual PPAR bioactivity of these isoflavones could be 
observed in a more natural context, a full length reporter gene bioassay was first 
evaluated. We cotransfected full length PPARα or PPARγ together with a reporter gene 
CYP4A6-PPRE-Luc containing two copies of the consensus PPRE driven by the 
CYP4A6 promoter in a functionally relevant hepatic cell line expressing endogenous 
RXR (HepG2). The PPARα specific ligand, WY14,643, dose-dependently activated 
PPARα with a maximal activity 2 fold of the vehicle at 90μM (Fig. 3.2.2A). Similarly, 
the PPARγ specific ligand, pioglitazone, increased the activity of the PPARγ at a 
maximum of 5 fold of the vehicle between 5-30μM (Fig. 3.2.2B).  
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HepG2 cells were also transfected with CYP4A6-PPRE-Luc alone to investigate 
the effects of endogenous PPAR on the reporter gene. In the presence of WY14,643, 
there was minimal activation by endogenous PPARα. However, in the presence of 
pioglitazone, endogenous PPARγ  activated the reporter gene up to 3 folds between 30-
90μM.  
In comparison to the chimera Gal-PPAR bioassay, this bioassay exhibited a lower 
specificity activity perhaps, reflecting the actions of endogenous receptors and effects of 
the heterodimeric partner RXR. 
 
3.2.3 Effects of isoflavones on PPAR using the full length reporter gene bioassay 
Using the evaluated full length PPAR assay, biochanin A, formononetin and genistein 
exhibited the highest PPARα (EC50 of 1μM, 3.7μM, and 9.5μM, respectively) and 
PPARγ (EC50 of 1μM, 4.3μM, 12μM) stimulating activities (Fig 3.2.3, Table 3.2). In 
particular, biochanin A was an order of magnitude more potent than calycosin and 
daidzein and comparable to values observed for WY14,643 and pioglitazone for both 
PPARα and PPARγ. Maximal activities for biochanin A reached 188% and 102% of 
reference drugs for PPARα and PPARγ, respectively.  
Consistent with the chimera Gal-PPAR reporter gene assay, formononetin, 
genistein and in particular, biochanin A were strong PPARα/PPARγ activators in the full 
length reporter gene bioassay. Furthermore, in both assays, biochanin A, formononetin 
and genistein were, in general, more PPAR active than calycosin and daidzein. 
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Figure 3.2.1 Effect of isoflavones on chimera Gal-PPAR reporter gene bioassays 
 
HeLa cells cotransfected with (A) Gal-PPARα or (B) Gal-PPARγ (25ng) and the 
(UASG)5-Luc reporter gene (250ng) were exposed to increasing amounts of isoflavones. 
genistein (Gen), formononetin (For), biochanin A (Bio), calycosin (Cal), and daidzein 
(Dai) for 48hr. Doses used were 0, 1, 3, 10, 30, 60 and 100μM for all isoflavones, except 
genistein and biochanin A, where the highest dose was 90μM. Data points (means±SEM, 
n=3) represented percentage of the positive controls for PPARα (WY14,643, 30μM) and 
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μM % μM % μM % μM %
Calycosin 22 12 45 18 22 157 36 93
Formononetin3 <1 22 2.6 17 3.7 246 4.3 96
Daidzein NSA4 NSA 73 25 NSA NSA NSA NSA
Genistein 16 65 23 35 9.5 266 12 104
Biochanin A3 1.3 71 3.7 20 <1 188 <1 102
WY14,643 5.9 100 NSA5 NSA5 2.2 100 NSA NSA
Pioglitazone NSA NSA 3.6 100 NSA NSA 0.5 100
1 Maximal activity expressed as percentage of a saturating dose (30μM) of the PPARα selective ligand, WY14,643
2 Maximal activity expressed as percentage of a saturating dose (30μM) of the PPARγ selective ligand, Pioglitazone
3 Most potent PPARα and PPARγ activators
4 NSA, no significant activity
5 No significant activity up to 30μM
α γ
Gal-PPAR in HeLa PPAR in HepG2
α γ
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3.2.2 Dose response curves of full length PPAR reporter gene bioassays 
 
HepG2 cells cotransfected with full length (A) PPARα  or (B) PPARγ (50ng) and the 
CYP4A6-PPRE-Luc reporter gene (100ng) (inset) were exposed to WY14,643 or 
Pioglitazone as indicated for 48hr. Cells transfected with CYP4A6-Luc reporter vector 
only reflects endogenous PPAR activity. Data points (means±SEM, n=3) represented fold 
increase in luciferase activity over vehicle. Means without a common letter differ, p<0.05.  
 



























































Figure 3.2.3 Effects of isoflavones on full length PPAR activity  
 
HepG2 cells cotransfected with full length (A) PPARα or (B) PPARγ (50ng) and the 
CYP4A6-PPRE-Luc reporter gene (100ng) were exposed to increasing amounts of 
isoflavones for 48hr. Genistein (Gen), formononetin (For), biochanin A (Bio), calycosin 
(Cal), and daidzein (Dai). Doses used were 0, 1, 3, 10, 30, 60 and 100μM for all 
isoflavones, except genistein and biochanin A, where the highest dose was 90μM. Data 
points (means±SEM, n=3) represented percentage of the positive controls for PPARα 
(WY14,643, 30μM) and PPARγ (Pioglitazone, 30μM) respectively. Values without a 
common letter differ, p<0.05. 
 


























































































3.2.4 Effects of isoflavones on selected PPARα regulated genes  
 
To further evaluate the effects of isoflavones on PPARα regulated endogenous genes, full 
length PPARα was overexpressed in HepG2 cells and treated with isoflavones. PPARα 
regulated expression of selected genes (PPARα (Pineda Torra et al. 2002), CPT1A 
(Mascaro et al. 1998) and HMGCS2 (Rodriguez et al. 1994)) were measured by real time 
RT-PCR. CPT1A is the rate limiting enzyme that controls fatty acid import in 
mitochondria while HMGCS2 is the key enzyme in ketone bodies conversion during 
fasting. The HMGCS1 gene, lacking a PPRE on its promoter (Hegardt 1999), was used as 
a negative control.  
As expected, an increase in gene expression for CPT1A (Fig 3.2.4B) and 
HMGCS2 (Fig 3.2.4D) was observed with WY14,643. However, upregulation of PPARα 
gene expression was not observed (Fig 3.2.4A). The effects of isoflavones on the 
expression profile of these three genes were, in general, similar to that of WY14,643. In 
particular, biochanin A induced the highest increase (2-fold vs. vehicle) in HMGCS2 
gene expression among the isoflavones and this increase was comparable to the effects of 
WY14,643 (Fig 3.2.4D). Gene expression of the negative control, cytosol HMGCS1, was 
not affected by WY14,643 or isoflavones (Fig 3.2.4C). 
Thus, consistent with the chimera Gal-PPAR and full length reporter gene assays, 
biochanin A, and other isoflavones, upregulates PPARα endogenous genes. Furthermore, 
the upregulation of PPARα controlled genes, like the HMGCS2 gene, was not due to 
indirect activation from an upregulation of PPARα itself as treatments with isoflavones 
did not affect the expression of PPARα.  
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3.2.5 PPARγ binding properties of isoflavones  
Since activation of PPARα activity by isoflavones was not due to indirect mechanism 
such as PPARα gene upregulation, we investigated whether the different transactivation 
activity were caused by differential binding affinities. Due the availability of a non-
radioactive PPARγ polarization competitor assay, the ability of isoflavones to displace 
PPARγ-LBD fluorescent-ligand complexes was measured. As expected, doses of 
pioglitazone (at least 1μM) significantly displaced the fluormone, whereas estradiol did 
not (Fig 3.2.5). All 5 isoflavones significantly displaced fluormone at doses of at least 
1μM, indicating that they bind PPARγ at its LBD pocket. In this assay, calycosin and 
formononetin exhibited poor solubility and precipitated at doses ~30μM.  
Excluding formononetin and calycosin, the 50% inhibitory concentration (IC50) 
of the other 3 compounds were in the order biochanin A, genistein, daidzein, 
corresponding to trends in EC50 observed with the Gal-PPARγ and full length PPARγ 
transactivation assays. 
 112
Figure 3.2.4 Effects of isoflavones on selected PPARα regulated genes in HepG2 
 
HepG2 cells cotransfected with full length PPARα (50ng) and exposed to 3μM of 
isoflavones. Genistein (Gen), formononetin (For), biochanin A (Bio), calycosin (Cal), 
and daidzein (Dai). At 24h post ligand treatment, total RNA was extracted, and RNA 
expression for PPARα (A), CPT1A (B), HMGCS1 (C) and HMGCS2 (D) or 18s was 
evaluated by real-time RT-PCR. Data represents means±SEM of 2 separate experiments 












































































Figure 3.2.5 PPARγ competitive ligand binding assay 
 
Increasing doses (0.1, 0.3, 1, 3, 10, 30 and 100μM) of isoflavones were added to a 
liganded PPARγ fluorome complex. Changes in polarization values (mP) caused by 
displacement of fluorescent PPARγ ligand (fluorome) by isoflavones were measured. 
Values are mean ± SEM, n=3.   
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3.2.6 Effects of isoflavones on endogenous PPARγ function  
Activation of PPARγ by isoflavones had been demonstrated through the overexpression 
of PPARγ in the full length reporter assay using various cell lines previously. To 
investigate the relevance of isoflavones on lipid metabolism in a process of which PPARγ 
plays a major role, the PPAR-driven reporter-gene CYP4A6-PPRE-Luc was transfected 
into differentiated 3T3-L1 preadipocytes, to measure endogenous PPARγ-driven 
responses. 3T3-L1 cells endogenously express high levels of PPARγ after adipocyte 
differentiation (Chawla et al. 1994). As expected, pioglitazone induced a significant rise 
in PPARγ activity (4-fold vs. vehicle) (Fig 3.2.6A). At a low dose of 3μM, only 
biochanin A increased activity of the CYP4A6-PPRE-Luc reporter (7.6-fold vs. vehicle). 
At a higher dose of 10μM, formononetin was also active (5.5-fold vs. vehicle). Being 
more potent than the other isoflavones, biochanin A displayed a reversed dose response 
compared with the other isoflavones. It is likely that the biphasic response of isoflavones 
may be due to the limitations in coregulator content or differences in protein expression 
levels at different isoflavone concentrations (eg. 10μM). Western blot analysis with 
specific PPARγ antibody indicated that these 3T3-L1 adipocytes endogenously expressed 
PPARγ (Fig 3.2.6B).  
These results suggested that both biochanin A and formononetin at low doses 
could activate endogenous PPARγ in differentiated preadipocytes.  
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Figure 3.2.6 Effects of isoflavones on endogenous PPARγ  function in adipocytes 
  
Differentiated 3T3-L1 cells (A) were transfected with CYP4A6-PPRE-Luc reporter gene 
only and exposed to genistein (Gen), formononetin (For), biochanin A (Bio), calycosin 
(Cal), and daidzein (Dai) at 3 and 10μM for 48hr. Positive control (Pos) was Pioglitazone 
(30 μM). Data (mean ± SEM, n=3) are fold increases in luciferase activity over vehicle. 
*p<0.05; **p<0.01, compared to vehicle. (B) PPARγ protein expression of differentiated 
adipocytes. 3T3-L1 cells were exposed to isoflavones (3 μM) and PPARγ protein 
detected with an anti-PPARγ mouse monoclonal antibody. Protein loading control, actin, 
































3.2.7 Effects of isoflavones on 3T3-L1 cells differentiation  
To determine if activation of PPARγ by biochanin A, genistein, and formononetin was 
associated with adipose differentiation, we visualized accumulation of lipid droplets with 
oil-red O staining. Adipocyte differentiation is used as an indication of the functional 
consequences of PPARγ ligand activation since PPARγ is the master regulator of 
adipocyte differentiation (Forman et al. 1995). Pioglitazone, but not the vehicle or 
WY14,643, strongly stimulated preadipocyte differentiation, indicating the PPARγ 
specificity of the assay (Fig 3.2.7). At a dose of 1μM, only biochanin A stimulated lipid 
droplet accumulation in preadipocytes above vehicle. Formononetin and genistein 
stimulated lipid accumulation at higher doses of at least 3μM and 15μM, respectively.  
Thus, among the isoflavones tested, biochanin A was the most potent stimulator 
of PPARγ activity and could lead to adipocyte differentiation a dose of 1μM. 
Furthermore, together with the characterization of isoflavone’s PPARα activity 
performed previously, we established that isoflavones were dual PPARα/PPARγ active 
and certain members, in particular, biochanin A, was more potent than the others.  
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Figure 3.2.7 Effects of isoflavones on 3T3-L1 preadipocyte differentiation  
 
3T3-L1 cells were exposed to induction media and exposed to genistein (Gen), 
formononetin (For), biochanin A (Bio) at the doses indicated. After 8 days of exposure to 
isoflavones, differentiated cells were stained with Oil-Red O. Photomicrographs were at 
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 3.2.8 Screening of various flavonoid groups for PPAR activity 
Since isoflavones displayed dual PPARα/PPARγ activity, we investigated whether other 
structurally similar flavonoids have potential dual PPARα/PPARγ activity using the 
chimeric Gal-PPAR assays.  
The 19 flavonoids2 screened were grouped according to anthocyanins (catechin 
and epicatechin), flavonols (quercitin, myricetin, kaempferol, isorhamnetin and taxifolin), 
flavanones (naringenin, hesperetin and eriodictyol), flavones (luteolin, apigenin and 
diosmetin), isoflavones (daidzein, genistein, biochanin A, formononetin and calycosin), 
and chalcone (phloretin). As shown previously, isoflavones were PPAR active (Fig 3.2.8). 
Surprisingly, the flavone group was the only other flavonoid group that was PPAR active. 
One of these flavones, diosmetin, showed PPARγ selective activity. At a dose of 3 μM, 
diosmetin increased PPARγ activity up to 3 fold vs. vehicle, and had the highest PPARγ 
activity among the flavonoids tested (Fig 3.2.8B). In contrast, its PPARα activation was 
relatively weak (1.3 fold vs. vehicle) (Fig 3.2.8A). In the same flavone group, apigenin 
also showed moderate PPARγ activity (1.9 fold vs. vehicle).  
This suggested that other than isoflavones, which were dual PPARα/PPARγ 
agonists, flavones in the flavonoids group were also PPAR active. In particular, 
diosmetin was PPARγ selective.  
                                                 
2 Structures of flavonoids in Fig 1.8 
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Figure 3.2.8 Screening of different groups of flavonoids for PPAR activity  
 
HeLa cells cotransfected with (A) Gal-PPARα or (B) Gal-PPARγ (25ng) and the 
(UASG)5-Luc reporter gene (250ng) were exposed to 3μM of selected flavonoids for 
48hr. Data points (means±SEM, n=3) are fold increases in luciferase activity over vehicle. 
Positive controls were WY14,643 (30μM) and Pioglitazone (30μM) for PPARα and 






























































































































































 3.2.9 Effects of diosmetin, from the flavone group of flavonoids, on PPAR  
To characterize the unexpected PPARγ selective activation of diosmetin, cells were co-
transfected with full length PPARα, PPARβ or PPARγ expression vector and the reporter 
vector CYP4A6-PPRE-Luc, and exposed to diosmetin. Diosmetin activated full length 
PPARγ in a dose dependant manner, and the maximal activity (2.7 fold) at 10μM was 
~50% of the positive control (pioglitazone, 5.7 fold induction vs. vehicle) (Fig 3.2.9A). 
In contrast, diosmetin did not activate PPARα or PPARβ. 
In PPARγ competitor binding assays, diosmetin replaced fluormone at 1μM and 
displayed an IC50 of 8.4μM, indicating that it transactivates PPARγ by binding to its 
ligand-binding pocket (Fig 3.2.9B). In 3T3-L1 differentiated cells, diosmetin induced 
transcriptional activity dose-dependently (up to 5.1 fold) and was comparable to 
pioglitazone even at a low dose of 10μM (Fig 3.2.9C). Similarly, diosmetin moderately 
stimulate preadipocyte differentiation (Fig 3.2.9D). 
In all, diosmetin showed selective PPARγ activation, through binding of its ligand 
binding pocket, in PPAR reporter gene and PPARγ functional studies.  
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Figure 3.2.9 Identification of the non-isoflavonoid, Diosmetin, as a PPARγ  selective 
agonist 
 
(A) HeLa cells cotransfected with full length PPARα, PPARγ or PPARβ (50ng) and the 
CYP4A6-PPRE-Luc reporter gene (100ng) were exposed to increasing amounts of 
diosmetin (μM) as indicated for 48hr. Positive controls were WY14,643, Pioglitazone 
and GW0742, in μM,  for PPARα, PPARγ and PPARβ respectively. Data points 
(means±SEM, n=3) are fold increases in luciferase activity over vehicle. *p<0.05; 
**p<0.01, compared to vehicle. 
 
(B) Increasing doses (0.1, 0.3, 1, 3, 10, 30 and 100μM) of diosmetin were added to a 
liganded PPARγ fluorome complex. Changes in polarization values (mP) caused by 
displacement of fluorescent PPARγ ligand (fluorome) by isoflavones were measured. 
Values are mean ± SEM, n=3.   
 
(C) Differentiated 3T3-L1 cells were transfected with CYP4A6-PPRE-Luc reporter gene 
only and exposed to Diosmetin as indicated for 48hr. Positive control (Pos) was 
Pioglitazone (30 μM). Data (mean ± SEM, n=3) are fold increases in luciferase activity 
over vehicle. *p<0.05; compared to vehicle.  
 
(D) 3T3-L1 cells were exposed to induction media and exposed to diosmetin (1μM) or 
Pioglitazone (1μM). After 8 days of exposure to ligands, differentiated cells were stained 
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3.2.10 Effects of isoflavones and diosmetin on selected PPARγ regulated genes 
Together with diosmetin and isoflavones, we studied the effects of these flavonoids on 
PPARγ regulated endogenous genes. 3T3-L1 cells were exposed to these flavonoids and 
the effects on selected PPARγ regulated genes (aP2 (Tontonoz et al. 1994) and 
adiponectin (Iwaki et al. 2003)) measured by real-time RT-PCR. aP2 is involved in the 
regulation of lipid and glucose metabolism while adiponectin, an adipokine, is an insulin 
sensitizer. PPARγ has not been reported to be self-regulatory but was measured to 
exclude the possibility that activation of PPARγ regulated genes by flavonoids is due to 
an upregulation of PPARγ gene expression through a PPARγ independent pathway. 
As expected, pioglitazone increased the gene expression of aP2 and adiponectin 
up to 48 and 18 folds respectively (Fig. 3.2.10B and C). Surprisingly, pioglitazone also 
increased the gene expression of PPARγ up to 3 folds. Diosmetin showed relatively weak 
upregulation of adiponectin (1.6 fold vs. vehicle) and had no effect on the aP2 gene. For 
isoflavones, only genistein and biochanin A increased the gene expression of both aP2 (~ 
3 fold) and adiponectin (~4 fold). However, these increases were relatively weak 
compared to pioglitazone. In addition, increase in PPARγ gene expression with genistein 
was comparable to that of pioglitazone.  
Altogether, we show previously and herein that isoflavones, especially genistein 
and biochanin A, are dual PPARα/PPARγ agonists which affected PPAR reporter gene, 
PPARγ function and PPAR endogenous genes. Furthermore, our work also suggests that 
parent botanicals of isoflavones, such as PT, are potential anti-diabetic agents useful for 
lipid profile management. 
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Figure 3.2.10 Effects of flavonoids on selected PPAR regulated genes in 
differentiated 3T3-L1 cells 
 
3T3-L1 cells were exposed to induction media and exposed to 3μM of isoflavones for 8 
days. Genistein (Gen), formononetin (For), biochanin A (Bio), calycosin (Cal), and 
daidzein (Dai). Total RNA was extracted, and RNA expression for PPARγ (A), aP2 (B) 
and adiponectin (C) or 18s was evaluated by real-time RT-PCR. Data represents 
means±SEM, n=2. Positive control was Pioglitazone at 30μM.  
 
























































 3.3 Characterization of flavonoids and PPARα ligands on a natural PPARα V227A 
variant 
Meta-analysis of soy isoflavones intake in human subjects indicates their beneficial role 
on lipid profiles in the body (Zhan and Ho 2005). However, the overall efficacy of soy 
isoflavones still remains debatable (Erdman et al. 2007).  Adding to this debate is a recent 
study which reported no overall improvements in lipid plasma concentration except in a 
subset of the participants who are carriers of an estrogen receptor β polymorphism. 
Carriers of this polymorphism, ERβ(cx), experienced a significant increase in HDL-c in 
response to isoflavone intake (Hall et al. 2006). Isoflavones are also reported ligands of 
the NRs, ERβ and ERα.  
Similar gene-diet interactions have also been reported for PPARα, an important 
NR involved in the regulation of lipid metabolism (Lefebvre et al. 2006).   In women 
carriers of the PPARα V227A polymorphism, an increase in dietary PUFA intake was 
associated with lower HDL-c concentration (Chan et al. 2006). Similar to isoflavones, 
PUFA are ligands of PPARα. While the gene-diet interaction between PPARα and 
PUFA was reported, the dietary effect of isoflavones on lipid profiles in relation to 
PPARα polymorphisms is still unknown.   
Unlike ERβ(cx) which is a splice variant (Ogawa et al. 1998),  V227A is a point 
mutation which occurs on helix 2 of  the PPARα LBD.  This mutation lies within the 
region where point mutations A234T, R243Q, and R243W on the thyroid receptor β 
(T3Rβ) has been reported and functionally characterized in thyroid hormone resistant 
patients (Behr and Loos 1992; Onigata et al. 1995; Yagi et al. 1997; Safer et al. 1998) 
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(Fig 3.3.1A). Another reported point mutation on the PPARα is the L162V 
polymorphism (Vohl et al. 2000). While L162V occurs on the DNA binding domain of 
PPARα and is functionally active in vitro (Flavell et al. 2000; Sapone et al. 2000), 
function of V227A at the LBD is unknown. Furthermore, effects of isoflavones on 
V227A activity are also unclear.  
 
3.3.1 Transcriptional activity of V227A with genistein and biochanin A on the CYP4A6 
PPRE 
To investigate the transcription function of the variant in the presence of isoflavones 
(genistein and biochanin A) characterized previously, HepG2 cells were co-transfected 
with plasmids encoding either full length wild type (WT) or V227A PPARα, and a 
reporter gene CYP4A6-PPRE-Luc containing two copies of the consensus PPRE derived 
from the CYP4A6 promoter (Krey et al. 1993). In the presence of genistein (Fig 3.3.1B) 
or biochanin A (Fig 3.3.1C), both WT and V227A displayed similar transactivation 
activity from 1 to 10μM. Only at a high dose of 30μM genistein was V227A 27% weaker.  
Thus, in the presence of physiologically relevant levels of the isoflavones, there 
was no difference in PPARα activity between WT and V227A. 
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Figure 3.3.1(A) Amino acid sequence comparison of Helices 1 and Helix 2 of T3Rβ 
and PPARα  
 
The V227A PPARα variants and T3Rβ (A234, R243) mutants associated with resistance 
to thyroid hormones are marked with asterisks. 
Helix 1 Helix 2
*
 
hT3Rβ 211 KPEPTDEEWELIKTVTEAHVATNAQGSHWKQKRKFLPEDIGQA 253
    
hPPARα 196 EDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPP 238
**
. . . .
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Figure 3.3.1(B,C) The PPARα V227A variant exhibits similar transactivation 
activity on the consensus CYP4A6-PPRE with genistein and biochanin A 
 
HepG2 cells were co-transfected with reporter vector CYP4A6-PPRE-Luc (100ng) and 
full length WT or V227A PPARα (50ng) before treatment with genistein (B) or 
biochanin A (C) for 48 h. Values are mean ± SE of three replicates, and expressed as 
percentage of maximal WT activity (WY14,643, 100μM). * p<0.05.  
 














































3.3.2 Transcriptional activity of V227A with WY14,643 and α-linolenic acid on the 
CYP4A6 PPRE 
Although there was no difference in transcription activity between WT and V227A with 
isoflavones, we investigated the transcription function of the variant in the presence of 
the potent PPARα synthetic ligand, WY14,643 and the endogenous PPARα ligand, α-
linolenic acid. HeLa and HepG2 cells were co-transfected with plasmids encoding either 
WT or V227A PPARα, and the reporter gene CYP4A6-PPRE-Luc. In HeLa cells, 
V227A was 35%-49% weaker than WT on exposure to the potent fibrate WY14,643 (Fig. 
3.3.2A); and about ~25% weaker than WT at high doses of the less potent, α-linolenic 
acid (Fig. 3.3.2B). In HepG2 cells, V227A was ~23% weaker with WY14,643 (Fig 
3.3.2C); and in the presence of the α-linolenic acid, V227A was 22% weaker than WT at 
the highest dose (Fig 3.3.2D). Lesser differences between WT and V227A observed in 
HepG2 cells may be due to interference from endogenously expressed WT PPARα.  
Thus with the CYP4A6 PPRE, we demonstrate that V227A is a functional 
PPARα variant in the presence of isoflavones, the fibrate drug WY14,643 and the 
endogenous ligand α-linolenic acid. Interestingly, V227A exhibited subtle, yet 
significantly weaker transactivation activity compared to WT with WY14,643 and α-
linolenic acid. 
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Figure 3.3.2 The PPARα V227A variant exhibits lower transactivation activity on 
the CYP4A6-PPRE in the presence of WY14,643 and α-linolenic acid 
 
HeLa (A, B) and HepG2 (C, D) cells were co-transfected with reporter vector CYP4A6-
PPRE-Luc (100ng) and full length WT or V227A PPARα (50ng) before treatment with 
WY14,643 or α-Linolenic acid for 48 h. Values are mean ± SE of three replicates, and 




































































































3.3.3 Transcriptional activity of V227A with fenofibrate and linoleic acid on the 
CYP4A6 PPRE 
Fenofibrate is a PPARα agonist and belongs to the same class of lipid lowering drug as 
WY14,643. Linoleic acid, an ω-6 fatty acid, and α-linolenic acid, a ω-3 fatty acid, are 
PUFA commonly found in the diet. Since V227A exhibited lower transactivation activity 
with WY14,643 and α-linolenic acid, we also investigated the effects of related ligands, 
fenofibrate and linoleic acid, from each respective group on the transactivation of V227A. 
In contrast to WY14,643 and α-linolenic acid, transactivation activity of V227A in the 
presence of fenofibrate or linoleic acid was similar to WT at all doses of ligands tested 
(Fig 3.3.3).  
 
3.3.4 Transcriptional activity of V227A with GW9662 on the CYP4A6 PPRE 
Besides the fibrates and PUFA groups of PPARα agonists, we also investigated V227A 
transcriptional activity in the presence of GW9662, a PPARγ antagonist but also a partial 
PPARα agonist (Leesnitzer et al. 2002; Seimandi et al. 2005). In HeLa cells, activation of 
WT by GW9662 was highest at 50μM. However, maximal activation of WT by GW9662 
was only ~40% of the positive control (WY14,643) and was consistent with its partial 
agonist activity. In comparison, V227A was 30% and 38% weaker on exposure to 
GW9662 at 20 and 50μM respectively (Fig 3.3.4). 
Among the PPARα ligands tested, we demonstrate that weaker transcriptional 
activity of V227A was only observed on selected ligands and was most marked with 
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WY14,643. Therefore, to study the molecular mechanism behind the lower 
transactivation of V227A in subsequent work, WY14,643 was the primary ligand used.   
 
3.3.5 Lower transactivation of V227A is independent of PPARα amount transfected 
Before the molecular mechanism behind the weaker activity of V227A was 
elucidated, we investigated whether lower transcription function of V227A with 
WY14,643 was due to varying amounts of V227A transfected. HeLa cells were co-
transfected with plasmids encoding either WT or V227A PPARα, at varying amounts, 
and the reporter gene CYP4A6-PPRE-Luc. Varying the amounts of V227A (25-75ng) 
transfected, V227A transactivation activity remained lower (~76%-44%) than WT in the 
presence of WY14,643 (Fig. 3.3.5A). Conversely, at varying amounts of WT (25-75ng), 
WT transactivation activity remained higher than V227A with WY14,643 (Fig. 3.3.5B).  
These data suggest that the lower transactivation activity observed for V227A was not 
due to unequal transfection efficiency. 
 In addition, to improve the expression efficiency of PPARα variant in HepG2 
cells, an adenovirus-mediated expression system was employed to allow for a 
consistently high expression of mutant and WT PPARα (see Appendix, Pg 244). In this 
setting, the V227A variant consistently induced about half the transactivation activity 
observed with the WT PPARα. Hence, this suggests that the overexpression experiments 
are valid methods to explore the physiological relevance of gene variants and allows for 
further pathogenic mechanisms to be deduced. 
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Figure 3.3.3 The PPARα V227A variant exhibits similar transactivation activity on 
the CYP4A6-PPRE with linoleic acid and fenofibrate 
 
HepG2 cells were co-transfected with reporter vector CYP4A6-PPRE-Luc (100ng) and 
full length WT or V227A PPARα (50ng) before treatment with linoleic acid or 
fenofibrate for 48 h. Values are mean ± SE of three replicates, and expressed as 





























 Figure 3.3.4 The PPARα V227A variant exhibits lower transactivation activity on 
the CYP4A6-PPRE with GW9662 
 
HeLa cells were co-transfected with reporter vector CYP4A6-PPRE-Luc (100ng) and full 
length WT or V227A PPARα (50ng) before treatment with GW9662 for 48 h. Values are 
mean ± SE of three replicates, and expressed as percentage of maximal WT activity (+; 
































Figure 3.3.5 Lower PPARα V227A variant transactivation activity on the consensus 
CYP4A6-PPRE in the presence of WY14,643 is independent of PPARα amount 
 
HeLa cells were co-transfected with reporter vector CYP4A6-PPRE-Luc (100ng) and 
varying amounts of full length V227A (A) or WT (B) PPARα before treatment with 
WY14,643 (μM) for 48 h. Values are mean ± SE of three replicates, and expressed as 
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3.3.6 Lower transactivation activity of V227A on the natural HMGCS2 promoter and its 
gene expression 
While we had shown previously that V227A was weaker on the PPRE, the effects of this 
variant was further evaluate in the process whereby PPARα plays a key role, lipid 
metabolism. The PPRE on the HMGCS2 promoter is the most PPAR responsive among 
16 known PPREs compared (Juge-Aubry et al. 1997) and is also a well characterized 
PPARα responsive gene (Rodriguez et al. 1994). The HMGCS2 enzyme is involved in 
ketone bodies formation during fasting and has a partial role in cholesterol metabolism 
(Hegardt 1999) (Fig 1.3). Thus, examination of V227A on such a PPARα regulated 
endogenous gene would enable a clearer understanding towards the role of V227A in a 
physiologically relevant context.  
Cells were co-transfected with WT and V227A PPARα, and a luciferase-reporter 
driven by residues -1081 to +22 of HMGCS2 promoter (HMGCS2- Luc) (Rodriguez et al. 
1994). In this system, V227A was 22-25% weaker than WT with WY14,643 (Fig. 
3.3.6A), and ~27% weaker than WT with high doses of α-linolenic acid in HeLa cells 
(Fig. 3.3.6B). In HepG2 cells, V227A was 17%-14% weaker than WT with 50μM and 
100μM of WY14,643 respectively (Fig 3.3.6C); and in the presence of α-linolenic acid 
(100μM), V227A was 25% weaker compared to WT (Fig 3.3.6D).  
Next, to evaluate the effects of V227A in its functional context, we measured 
expression of HMGCS2 mRNA by duplex semi-quantitative RT-PCR (Walter et al. 
2004). WT or V227A were expressed in HepG2 cells and exposed to WY14,643. Ligand 
treatment did not affect WT or V227A PPARα gene expression (Fig. 3.3.6E, upper 
panels). In cells transfected with empty vector, WY14,643 dose-dependently induced 
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HMGCS2 mRNA expression consistent with endogenous PPARα effect (Fig. 3.3.6E). As 
expected, transfection of PPARα plasmids increased expression of PPARα mRNA, and 
no differences were detected in the expression of the WT and V227A variant (Fig. 3.3.6E, 
upper panels). The presence of ligand dose-dependently increased HMGCS2 mRNA, 
such that mRNA content was about 75% higher compared to baseline at maximal dose, 
consistent with HMGCS2 being a PPARα-regulated gene (Fig. 3.3.6E, lower panels). 
With the V227A plasmid, HMGCS2 mRNA expression was consistently lower compared 
to WT. Transactivation was ~36% lower in the absence of ligand and was ~20%-10% 
lower with WY14,643 (10μM, 100μM) in three independent experiments.  
In agreement with V227A’s transactivation activity on the CYP4A6 PPRE (Fig 
3.3.2), V227A induced lower promoter activity in the HMGCS2 gene.   
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Figure 3.3.6 The PPARα V227A variant exhibits lower transactivation activity on 
the mitochondria HMG-CoA synthase (HMGCS2) promoter activity 
 
HeLa cells (A,B) and HepG2 cells (C,D), were co-transfected with either full length WT 
or V227A PPARα (50ng), and a reporter construct driven by residues -1081 to +22 of the 
HMGCS2 promoter (100ng). Cells were exposed to indicated doses of WY14,643 or α-
linolenic acid for 48 h and luciferase activity are expressed as percentage of maximal WT 
activity (mean ± SE of three replicates). * p<0.05; **p<0.01. (E) HMGCS2 mRNA 
expression. HepG2 cells were transfected with full length WT or V227A PPARα (50ng) 
and treated WY14,643 (10, 100μM) for 24 h. RNA was extracted and subjected to duplex 
semi-quantitative RT-PCR. Quantification of mRNA encoding PPARα and HMGCS2 
were performed using specific primers with 18s rRNA as endogenous standard. Upper 
and lower panels were amplified with primers specific for PPARα and HMGCS2 
respectively. A representative data set from three independent experiments is shown 
 
 







































































































3.3.7 V227A inhibits transactivation by WT PPARα in a dominant negative manner 
Lower transactivation activity of a PPARα splice variant (Gervois et al. 1999) and 
several artificial PPARα mutants (Michalik et al. 2005; Seimandi et al. 2005) have been 
reported to occur in a dominant negative way. Therefore, to evaluate the effects of mutant 
on WT activity, WT or V227A PPARα were co-expressed in HepG2 cells (Fig. 3.3.7). 
WT PPARα transactivity was attenuated by 36% and 20% for the HMGCS2 and 
CYP4A6-PPRE promoters respectively, in the presence of V227A plasmid (Fig 3.3.7). 
This dominant negative effect was most marked for the CYP4A6 promoter where a 43% 
reduction in WT activity was observed with 10-fold excess of V227A.  
In all, the V227A variant exhibited weaker transactivation activity in both 
CYP4A6-PPRE and HMGCS2 promoters in HeLa and HepG2 cells in a dominant-
negative manner.  
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Figure 3.3.7 The PPARα V227A variant exhibits dominant negative activity  
 
HepG2 cells were co-transfected with both full length WT (100ng) and V227A PPARα 
(100ng or 1000ng); with either the HMGCS2-Luc (200ng) or CYP4A6-PPRE-Luc 
(200ng) reporter genes, in the absence or presence of WY14,643 (100μM) for 48 h. 
Values are mean ± SE of three replicates, and expressed as percentage of maximal WT 
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 3.4 Mechanism(s) elucidation for attenuated PPARα V227A activity 
3.4.1 Role of V227A on the LBD 
To dissect the molecular basis of reduced transactivation, we systematically studied the 
effects of the V227A polymorphism on PPARα-mediated signaling pathways. Since the 
mutation occurs at the ligand binding domain of PPARα, we first investigated the effects 
of V227A on the properties of the LBD.  
Using the mammalian-one-hybrid system as described in Section 3.1.1, chimeric 
receptors consisting of the PPARα LBD (residues 171-468) of the WT or V227A variants, 
and the yeast Gal4DBD were cotransfected with the UASG-luc reporter gene into HeLa 
cells to examine the effects of the V227A polymorphism in the LBD on transcriptional 
activation. In the presence of WY14,643, V227A LBD exhibited 62%-66% lower 
transactivation activity compared to the WT (Fig. 3.4.1A). Similarly, Gal-V227A was 
28% weaker than Gal-WT with high doses of α-linolenic acid, suggesting that the 
mechanism for defective transactivation resides in reduced LBD activation function.  
To determine if the V227A substitution affected ligand affinity, the ligand binding 
properties of the mutant receptor was examined in a competition assay. In this assay, 
[3H]-WY14,643 binding to WT PPARα was largely replaced by unlabeled WY14,643 at 
doses ≥5nM, whereas the non-PPAR ligand, dihydrotestosterone (DHT), did not affect 
[3H]-WY14,643 binding (Fig. 3.4.1B). No significant differences in the relative binding 
affinity of WY14,643 to WT or V227A PPARα were observed, indicating the differences 
in V227A transactivation function were unlikely to be due to defective ligand binding at 
≥5nM.  
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Here, we demonstrated that while lower transactivation in V227A was a result of 
reduced LBD function, a difference in ligand binding was not likely to be the cause.  
 
3.4.2 Effects of RXR content on V227A 
The mammalian-one-hybrid assay was used as a tool in the identification and 
characterization of specific PPAR ligands in Section 3.1 and 3.2 previously. This is 
useful because activation by PPAR ligand in this system is independent of the obligate 
heterodimerization partner, RXR. Thus, the results in Fig 3.4.1A suggested that the 
weaker transcriptional activity was independent of RXR.  
To confirm this and to examine whether endogenous RXR was limiting due to 
overexpression of the PPARα receptor, cells were co-transfected with plasmids encoding 
this obligate heterodimer, PPARα WT or V227A and the CYP4A6 PPRE reporter gene. 
Differences between WT and V227A were still observed, suggesting that weaker activity 
of V227A was not stoichiometrically limited by RXR (Fig 3.5.2).  
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Figure 3.4.1 Effects of V227A on the ligand binding domain 
 
HeLa (A) cells were co-transfected with chimeric Gal-PPARαWT-LBD or Gal-
PPARαV227A-LBD (50ng) together with 100ng of (UASG)5-Luc reporter before 
treatment with ligands for 48 h in the mammalian one-hybrid assay. Values are mean ± 
SE of three replicates, and expressed as percentage of maximal WT activity. * p<0.05; 
**p<0.01. (B) Ligand binding affinity. WT or V227A PPARα in HeLa cells were 
exposed to 3nM [3H]-WY14,643 alone or with increasing concentrations of unlabeled 
WY14,643. The amount of [3H]-WY14,643 specifically bound after 24hours incubation 
was measured and expressed as a percentage of relative to controls not exposed to cold 



















































Figure 3.4.2 Weaker transactivation of V227A is independent of RXR content  
 
WT or V227A PPARα (50ng) plasmids were co-transfected in HepG2 cells with 50ng of 
RXRα and 100ng of CYP4A6-PPRE-Luc reporter plasmids prior to the treatment with 
WY14,643 in HepG2 for 48 h. Values are mean ± SE of three replicates, and expressed 

































3.4.3 Role of V227A on PPARα expression and localization  
Since lower transactivation of V227A was not dependent on ligand binding and RXR, we 
next examined whether weaker activity was due to differences in protein expression. 
Immunoblot studies revealed that WT and V227A protein content in HepG2 cells were 
comparable in the absence and presence of ligand (Fig. 3.4.3A and B), indicating the 
substitution did not affect PPARα protein stability.  
A natural PPARα splice variant has been reported to affect nuclear location 
(Gervois et al. 1999), thus, we investigated whether the variant affected sub-cellular 
localization. Immunofluorescence studies showed that overexpressed WT and V227A 
PPARα resided in the nucleus, in the presence and absence of ligand, and no differences 
in sub-cellular localization patterns were observed (Fig. 3.4.3C).  
Taken together, weaker V227A activity was not due to differences in protein 
expression and nuclear localization. 
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Figure 3.4.3 Weaker transactivation of V227A is independent of protein expression 
and nuclear localization 
 
HepG2 cells (A) were transfected with 50ng of WT or V227A PPARα and treated with 
increasing doses of WY14,643 and harvested 48 h post-treatment. PPARα protein was 
detected with specific antibody and quantified using ScionImage analyzer. (B) Ratio of 
PPARα and Actin using Scion Image. (C) Sub-cellular localization of PPARα proteins. 
Full length WT or V227A PPARα (50ng) were transfected into HepG2 before treatment 
with WY14,643 for 48 h. The resulting cells were stained with PPARα polyclonal 
antibody and goat anti-rabbit antibody conjugated with FITC. Nucleus was stained with 



























WT 0μM V227A 0μM WT 100μM VA 100μM
 
 146
3.4.4 Role of V227A on coregulator interaction 
To further elucidate the mechanism(s) for the decrease in transcriptional activity of the 
variant, we compared interactions of WT and V227A with major coregulator proteins 
known to interact with PPARα (Yu and Reddy 2007).  Interactions between PPARα LBD 
(residues 167-468) linked to VP16 activation domain, and Gal-NR interacting domains of 
major coregulators (Dowell et al. 1997; Voegel et al. 1998; Dowell et al. 1999; Caira et al. 
2000; Vega et al. 2000; Xu et al. 2002) known to interact with PPARα (Table 3.3), in the 
mammalian-two-hybrid assay, a sensitive method for the measurement of protein-protein 
interaction.  
No obvious differences between WT and V227A were observed in the 
recruitment of the coactivators SRC-1, TIF2, PGC-1, p300 and PRIP, in the absence or 
presence of ligand (Table 3.3). Strikingly, marked differences (about 2-fold higher for 
V227A) were observed in the relative binding of the corepressors, NCoR and SMRT, in 
the absence of ligand (Table 3.3). Lesser but still significantly increased interactions with 
V227A were still observed with low dose of ligand, suggesting that increased corepressor 
recruitment contributed to reduced transactivation function of V227A. 
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Ligand - + - + 
Gal- Coactivator2   
SRC-1 (213-1061) 3.1 ± 0.3 5.5 ± 0.8 4.9 ± 0.5 6.0 ± 0.4 
TIF2 (622-869) 1.6 ± 0.0 2.2 ± 0.1 1.8 ± 0.1 2.4 ± 0.1 
PGC1α (120-284) 1.1 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 2.3 ± 0.1 
p300 (1-117) 26.5 ± 1.0 27.6 ± 3.0 22.7 ± 0.1 24.3 ± 0.1 
PRIP (819-1096) 4.8 ± 0.5 7.4 ± 0.6 6.9 ± 1.1 8.2 ± 0.8 
Gal-Corepressor2   
SMRT (2004-2517) 1.9 ± 0.1 1.9 ± 0.2 4.0 ± 0.3 2.8 ± 0.3 
NCoR (1575-2453) 5.3 ± 0.8 4.3 ± 0.7 10.4 ± 0.4 6.7 ± 0.5 
 
 
1 HeLa cells were co-transfected with chimeric VP16-WT, VP16-V227A 
(100ng) and Gal-coregulator (100ng) together with (UASG)5-Luc reporter 
(500ng). Cells were exposed to the absence or presence of  WY14,643 
(10μM) for 48 h. Interaction was expressed as fold (mean±SE of three 
replicates) of VP16 alone. 
  
2 The coregulator regions, cloned downstream of GAL4DBD, were based on 
residues reported to interact with PPARα: SRC-1 (residues 579-932) 
(Dowell et al. 1997); TIF2 (residues 624-869) (Caira et al. 2000); PGC1α 
(residues 120-284) (Vega et al. 2000), p300 (residues 39-117)(Dowell et al. 
1997); PRIP (residues 887-891) (Voegel et al. 1998); SMRT (residues 2124-
2149, 2329-2358) (Xu et al. 2002); and NCoR (residues 2110-2453) (Dowell 
et al. 1999).  
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3.4.5 Role of V227A on nuclear corepressor (NCoR) interaction 
To confirm that V227A had increase interaction with corepressors and this effect was due 
to the function of helices 1 and 2 where V227A resides, a LBD mutant (residues 245- 468) 
(ΔH1-H2) lacking helices 1 and 2  was compared with WT and V227A. In the absence of 
ligand, WT PPARα bound strongly to NCoR, while ΔH1-H2 exhibited minimal binding 
(Fig. 3.4.4A). The presence of ligand induced release of NCoR from WT PPAR-LBD in a 
dose-dependent manner; and at maximal ligand dose, no NCoR binding was observed. 
Strikingly V227A bound with 100% higher avidity to NCoR compared to WT. The 
presence of ligand dose-dependently caused release of corepressor, but to a lesser degree 
compared to WT (Fig. 3.4.4A). Similar differences were observed with α-linolenic acid, 
wherein V227A bound NCoR with greater avidity versus WT (Fig. 3.4.4B).  
Together, the data suggested that increase NCoR recruitment likely contributed to 
the reduction in transactivation function of V227A. Interestingly, the role of NCoR in 
PPARα has been controversial (Semple et al. 2005). In order to understand the 
mechanistic basis of this increased corepressor recruitment and the significance of NCoR 
in PPARα function, we undertook detailed experiments to examine NCoR/PPARα 
interactions.  
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Figure 3.4.4. Interaction of NCoR in the mammalian-two-hybrid assay 
 
HeLa (A) and HepG2 (B) cells were co-transfected with chimeric VP16-WT, VP16-
V227A or VP16-ΔH1-H2 (100ng) and Gal-NCoR (100ng) together with (UASG)5-Luc 
reporter (500ng). Cells were exposed to indicated doses of WY14,643 (A) or α-linolenic 
acid (B) for 48 h. Interaction was expressed as fold (mean±SE of three replicates) of 


















































3.5 Molecular mechanism of attenuated PPARα V227A activity by NCoR 
3.5.1 Effects of NCoR overexpression 
NCoR is a modular protein that contains N-terminal repression domains and C-terminal 
nuclear receptor interaction domain (ID) (Horlein et al. 1995; Seol et al. 1996; Zamir et al. 
1996; Cohen et al. 1998; Webb et al. 2000). Using the mammalian-two-hybrid system, 
we previously established an increased in V227A interaction with the C-terminal of 
NCoR (residues 1575-2453). As the mammalian-two-hybrid system only measures 
protein-protein interaction, we next evaluated the relevance of this interaction on the 
PPRE with cotransfected full length NCoR. In the absence of ligand, overexpressing 
NCoR increased the difference in transcription activity between full-length WT and 
V227A from 23% to 69% in HeLa cells (Fig 3.5.1A). Increased suppression of V227A 
versus WT transactivity by NCoR was also observed in the presence of ligand. Similarly, 
differences between WT and V227A were more evident in the presence of NCoR in 
HepG2 cells (Fig 3.5.1B). Interestingly, comparing rows 1 and 2 of Fig 3.5.1A, the 
presence of NCoR did not affect the activity of WT. In contrast, overexpression of NCoR 
caused a further decrease in V227A activity and was observed with or without ligands in 
both cell lines tested.   
Taken together, the data suggested that the activity of V227A was more sensitive 
to NCoR content on the PPRE than WT. Consequently, the difference in activity between 
V227A and WT increased. 
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Figure 3.5.1. Transcriptional activity of PPARαV227A is sensitive to NCoR 
overexpression  
 
HeLa (A) or HepG2 cells (B) were co-transfected with either full length WT or V227A 
PPARα (50ng) and reporter vector CYP4A6-PPRE-Luc (100ng) in the absence or 
presence of full length NCoR (10ng). Transfected cells were exposed to increasing doses 
of WY14,643 (10, 100 μM) for 48 h. Values are mean ± SE of three replicates, and 















- - + + ++ ++





























- - + + ++ ++
















3.5.2 Effects of NCoR silencing 
While overexpression of NCoR further augmented the difference between WT and 
V227A, we also investigated the effects of silencing endogenous NCoR expression on 
transcriptional activity of V227A. HepG2 cells were transiently infected with lentiviral 
constructs encoding short hairpin sequences complementary to NCoR (siNCoR) or a 
randomized sequence (siScram). Cell extracts immunoblotted with anti-NCoR confirmed 
that expression of the corepressor protein was reduced in cells expressing siNCoR 
compared to siScram (Fig. 3.5.2). Reduction of NCoR was associated with a relative 
increase in V227A activity, such that differences between WT and variant PPARα 
became less evident (36% versus 23% attenuation) (Fig. 3.5.2). 
Thus, while additional amounts of NCoR increased the difference between WT 
and VA, silencing of NCoR decreased this difference.  
 
3.5.3 Effects of histone deacetylase (HDAC) inhibition 
As repression of transactivation activity by NCoR was dependent on its HDAC properties, 
we investigated the effects of the HDAC inhibitor, TSA. The presence of TSA dose-
dependently restored V227A activity (Fig 3.5.3). Functional differences between WT and 
V227A decreased from 46.4% in the absence of TSA to 17.6% and 7.6% with the 
addition of 100 and 200 nM of TSA respectively.  
In all, we demonstrated that transcriptional activity of V227A was further 
decreased with NCoR overexpression and the weaker transcriptional activity of V227A 
can be partially recovered after NCoR knockdown and in the presence of HDAC inhibitor. 
These results suggested that NCoR is a bona-fide repressor of PPARα activity and that 
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reduced transactivation activity of the V227A variant can be explained, at least partially, 
by its increased affinity for this corepressor.  
 
3.5.4 Identification of receptor-interacting domain (ID) on NCoR for PPARα interaction 
While the nuclear receptor interaction domains on the C-terminal of NCoR have been 
described for TR and RAR, RXR and PPARγ (Horlein et al. 1995; Seol et al. 1996; Hu 
and Lazar 1999; Cohen et al. 2000; Webb et al. 2000; Cohen et al. 2001; Hu et al. 2001; 
Makowski et al. 2003), it remains unclear whether any, or specific combinations, of the 
three identified domains interacts with PPARα.  
In order to characterize domains mediating NCoR/PPARα interactions, we 
constructed Gal-NCoR expression plasmids containing one, two, or all three receptor 
interaction domains (ID) (Fig. 3.5.4A). The ID contained a core consensus nonapeptide 
motif (LXXI/HIXXXI/L) termed CoRNR box which mediates corepressor assembly on 
nuclear receptors (Hu and Lazar 1999; Hu et al. 2001).  Chimeric Gal-NCoR proteins 
were co-expressed with VP16-PPARα-LBD, in the mammalian two-hybrid interaction 
assay. The absence of interactions with NCoR fragments G5 and G6 (containing ID2 and 
ID3), and G7 (containing ID3), indicated that ID2 and ID3 did not interact with PPARα 
(Fig 3.5.4B). On the other hand PPARα exhibited strongest interactions with the N-
terminal NCoR truncation fragments G3 and G4 (containing ID1), both in the absence 
and presence of ligand, suggesting that ID1 was the most critical interaction domain (Fig. 
3.5.4B). Fragment G2 (containing the CoRNR box and C-terminal flanking sequences of 
ID1) exhibited >9-fold stronger binding compared to G1 (without an intact CoRNR box), 
indicating the critical important of the CoRNR box to PPARα interactions.  Fragment G3 
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(containing the CoRNR box and both C- and N-terminal flanking sequences of ID1) 
induced 2.7-fold higher interactions than Fragment G2, indicating a role of the first 24 
amino acids (2251-2274) immediately N-terminal of the ID1 CoRNR box for 
PPARα/NCoR interactions. Intriguingly Fragment G4 (containing ID1 and ID2) 
exhibited stronger interactions compared to Fragment G8 (containing all 3 ID and N-
terminal sequences) suggesting a potential suppressive function in NCoR residues 1575-
2039.  
The aggregate data indicate that ID 1, but not ID2 and ID3, was the PPARα ID. In 
particular, NCoR residues (residues 2251 to 2280) were necessary and sufficient for 
optimal interactions with PPARα. Compared to WT, the V227A variant showed stronger 
interaction with NCoR fragments, both in the absence and presence of ligand (Fig.3.5.4B), 
consistent with previous experiments and its lower transactivation activity.  
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Figure 3.5.2 NCoR silencing decreases the transcriptional difference between 
PPARα WT and V227A 
 
HepG2 cells were transiently infected by pLenti6-GW/U6-scrambleshRNA (siScram) or 
pLenti6-GW/U6-NCoRshRNA (siNCoR) and co-transfected with either full length WT or 
V227A PPARα (50ng) and reporter vector CYP4A6-PPRE-Luc (100ng) before exposure 
to WY14,643 (100μM) for 48 h. Values are mean ± SE of two replicates, and expressed 
as percentage of maximal WT activity of siNCoR. * p<0.05. Cell lysates were 
immunoblotted with anti-NCoR to evaluate effects of NCoR knockdown. Cell lysates 




























Figure 3.5.3 Transcriptional activity of PPARαV227A is sensitive to HDAC 
inhibitor 
 
HeLa cells overexpressing WT or V227A PPARα (50ng) together with CYP4A6-PPRE-
Luc (100ng) were exposed to an increasing dose of trichostatin A (TSA) (100nM, 200nM) 
in the absence or presence of WY14,643 (100 μM ) for 48 h. Values are mean ± SE of 
three replicates, and expressed as percentage of maximal WT activity (WY14,643, 
100μM) **p<0.01. Cell lysates immunoblotted with anti-PPARα indicated that PPARα 
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Figure 3.5.4. Interactions between PPARα with receptor interaction domains of 
NCoR  
 
(A) Schematic diagram of Gal-NCoR truncation fragments and the mammalian-two-
hybrid system. Grey boxes represent unique CoRNR box sequences within each receptor 
interaction domain (ID), residues 2277-2285, 2073-2081, 1949-1953 for ID1, ID2 and 
ID3 respectively. Black boxes represents the first 24 amino acids immediately N-terminal 
of the ID1 CoRNR box. (B) HeLa cells were co-transfected with 100ng of PPARα LBD 
chimeras, VP16-WT- or VP-V227A (100ng), and indicated C-terminal Gal-NCoR 
truncated fragments (100ng) with the (UASG)5-Luc reporter gene (500ng), in the absence 
or presence of WY14,643 (10μM) for 48 h. Fold interaction (mean ± SE of three 
replicates) was expressed as folds of G1 at 0μM. * p<0.05; **p<0.01. 
 
 








































3.5.5 Role of V227A on NCoR-PPARα interaction in-vitro 
To further confirm residues 2251 to 2280 of ID1 is the PPARα ID, we constructed GST-
NCoR fragments in the GST-pull down assay. Chimeric NCoR fragments were incubated 
with in vitro translated full length PPARα WT or V227A and bound proteins were 
evaluated by western blot analysis using anti-PPARα rabbit polyclonal antibody. 
Consistent with previous results, interaction of the NCoR truncated mutants with WT and 
V227A was strongest with NCoR fragment G3, containing the entire ID1. Strikingly, 
interactions of PPARα V227A with G3 were stronger than WT, confirming the critical 
importance of this residue to PPAR/corepressor binding (Fig. 3.5.5).  
Our results showed for the first time that PPARα/NCoR interactions are mediated 
predominantly by ID1 on the NCoR, and that the V227A substitution significantly 
increases this interaction.  
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Figure 3.5.5 Interactions of PPARα and NCoR using GST pull down assay 
 
GST-NCoR truncated fragments (G1: 2282-2453; G2: 2276-2453; G3: 2251-2453) were 
incubated with equal amounts of in-vitro translated full length PPARα WT or V227A and 
GST pulldown performed using Sepharose 4B beads. Bound proteins were identified 
using anti-PPARα rabbit polyclonal antibody. Input shows the immunoblot for in-vitro 






























3.5.6 Role of residue 227A on NCoR ID1 interaction 
To further define the role of residue 227 for NCoR interactions, several VP16-PPARα 
truncation fragments, centered on the hinge region (residues 167-244) (Desvergne and 
Wahli 1999) that begins at the termination of DBD and extending to helix 2 were 
constructed for the mammalian two-hybrid assay (Fig. 3.5.6A).  
The Gal4-NCoR truncated fragment G3 (N∆2250) was used for the interaction 
study since this fragment exhibited highest binding to PPARα (Fig. 3.5.4). Fragments 
containing PPARα-DBD and the pre-helix 1 region (residues 94-198) by themselves did 
not interact with NCoR (Fig. 3.5.6B). Interactions were strongest with the PPARα 
fragment containing the entire helices 1-12 (residues 196-468) but excluding the pre-
helix 1 region (Fig. 3.5.6B). Unexpectedly inclusion of the pre-helix 1 region 167-198 to 
the LBD, reduced interaction with NCoR. Mutant LBD fragments missing portions of 
helix 1 or helix 2 resulted in drastic reduction of interactions, suggesting a critical role for 
these 2 helices in PPARα/NCoR interactions. Most strikingly, the V227AN∆195 variant 
bound NCoR with >4-fold stronger avidity than the corresponding WTN∆195 fragment 
(Fig. 3.5.6B), indicating that the V227A substitution introduces a residue that greatly 
stabilizes PPARα-NCoR ID1 interactions.  
 161
Figure 3.5.6 Interactions of NCoR with deletion fragments of PPARα hinge 
 
(A) Schematic diagram of VP16-PPARα truncation fragments. Black boxes represent 
DBD (residues 94-166), gray boxes represent residues 167-195 before helix 1. White 
boxes represent residues 196-468 of helix 1 to helix 12. (B) WT or V227A PPARα VP16 
truncated fragments (100ng) were co-expressed with G3 (NΔ2250) (Fig. 3.5.4) (100ng) 
and the (UASG)5-Luc reporter gene (500ng) in the mammalian two-hybrid assay. Fold 







































3.5.7 Role of V227A on ternary interactions with coregulators 
Our previous data have established that V227A provides additional contacts for PPARα-
NCoR interaction. Since NCoR and SRC-1 have been shown to compete for the same 
binding site on PPARα (Xu et al. 2002), we next investigated the dynamics of 
corepressor and coactivator interactions with PPAR and the role that V227A played in 
such context.  
We first observed the effects of SRC-1 on PPARα-regulated transactivation on the 
HMGCS2 promoter (Fig. 3.5.7A). Interestingly, exogenous SRC-1 could dose-
dependently restore transactivation defect of V227A, indicating a competitive role 
between NCoR and SRC-1.   
In order to measure the effects of SRC-1 on NCoR/PPARα interactions, we 
performed the mammalian-two-hybrid assay in the presence of increasing doses of full 
length SRC-1.  Low doses of exogenous coactivator increased transactivity of the Gal-
NCoR/VP16-PPARα complex as expected (Fig. 3.5.7B). However increasing doses of 
SRC-1 reduced WT PPARα/NCoR interactions to below baseline, consistent with a 
model in which NCoR and SRC-1 competed for the same PPARα binding site. The 
pattern of binding of NCoR to V227A was similar to WT except that it was higher at all 
doses of SRC-1, indicating that the substitution interfered with the dynamics of 
corepressor/coactivator exchange. 
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Figure 3.5.7 Ternary interactions between SRC-1, NCoR and PPARα  
 
(A) SRC-1 overexpression. HeLa cells were co-transfected with either full length WT or 
V227A PPARα (50ng), a reporter construct driven by residues -1081 to +22 of the 
HMGCS2 promoter (100ng) and increasing  amounts of full length SRC-1 (50, 100ng) 
with 100 μM WY 14,643 for 48 h. Values (mean ± SE of three replicates) were expressed 
as percentage of maximal WT activity (WY14,643, 100 μM). (B) Effects of SRC-1 on 
NCoR/PPARα interactions. HeLa cells were co-transfected with chimeric VP16-WT, 
VP16-V227A (100ng) and Gal-NCoR (100ng) together with the (UASG)5-Luc reporter 
(500ng). Cells were exposed to WY14,643 (10 μM) for 48 h at increasing doses (50, 100, 
200ng) of full length SRC-1.  Fold interaction (mean ± SE of three replicates) was 
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 3.5.8 Role of V227A on NCoR-PPARα interaction in-vivo 
To compare corepressor binding between WT and V227A in vivo, immunoprecipitation 
of PPARα with NCoR was performed in HepG2 cells. Cell lysates were precipitated with 
PPARα antibody, and bound corepressor quantified by immunoblotting with anti-NCoR. 
In the absence of ligand, both WT and V227A PPARα bound NCoR (Fig. 3.5.8). The 
addition of 100 μM WY14,643 resulted in almost complete dissociation of NCoR from 
WT, whereas V227A retained observable NCoR, suggesting that ligand-dependent 
release of NCoR from V227A was reduced (Fig. 3.5.8, lowest panel). These data were in 
agreement to our observations previously.  
 
3.5.9 Role of V227A on recruitment of NCoR by PPARα on chromatin 
Combinatorial roles of multiple coregulator complexes are required for mediating 
transcription regulation (Perissi and Rosenfeld 2005). While we have established the role 
of NCoR in PPARα transcription and the interplay with SRC-1 in such context, we have 
yet to show the relevance of such dynamics on the chromatin in-vivo.  
To evaluate PPARα V227A-NCoR complex formation on the HMGCS2 promoter, 
we performed chromatin immunoprecipitation assays. HepG2 cells overexpressing WT or 
V227A were cultured in the presence or absence of ligand. Transcription factors 
interacting with genomic DNA were cross-linked with formaldehyde, and chromatin 
immunoprecipitated (ChIP) with specific antibodies for PPARα, p300, SRC-1 and NCoR. 
Genomic DNA fragments recovered after ChIP served as template for PCR reaction with 
primers for the PPRE of the HMGCS2 promoter. With anti-PPAR, the amount of PPRE 
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pulled down by WT or V227A PPARα was similar, indicating that receptor-DNA 
binding did not contribute to weaker transactivation activity of the V227A (Fig. 3.5.9).   
Binding of coactivator p300 to PPRE was not affected by the substitution. 
Interestingly both SRC-1 and NCoR were bound to the WT PPARα/PPRE complex 
without added ligand, suggesting partial activation by endogenous ligand in HepG2 cells. 
In comparison, V227A preferentially bound NCoR and much less SRC-1 (Fig. 3.5.9).  
The presence of ligand induced complete release of NCoR from the WT PPARα/PPRE 
transcription complex and its replacement by SRC-1, consistent with full transactivation 
function. In contrast, V227A recruited corepressor strongly to PPRE without added 
ligand, and exhibited defective NCoR release with exogenous ligand. Competition 
between NCoR and SRC-1 was evident in that complete activation of the WT 
PPARα/PPRE transcription complex by ligand was associated with complete release of 
NCoR and its replacement by SRC-1. In contrast, defective release of NCoR resulted in 
both NCoR and SRC-1 being present simultaneously in the V227A PPARα/PPRE 
transcription complex.  
This increased binding of corepressor in the presence, and absence, of hormone 
indicated that mechanism of reduced transactivation was due to increased binding of 
corepressor to chromatin as a result of the substitution. 
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Figure 3.5.8 Effect of V227A on PPARα interaction with NCoR  
HepG2 cells transfected with full length PPARα-WT or V227A (24μg) were incubated 
with anti-PPARα in the absence or presence of 100μM WY14,643 for 24 h. Precipitates 
were probed with anti-NCoR antibody. Inputs were 5% and 10% cell lysate western 

























Figure 3.5.9 Effects of V227A in the recruitment of coregulators to the HMGCS2 
promoter 
 
HepG2 cells were transfected with 24μg of full length PPARα-WT or V227A, with or 
without WY14,643 (100μM) for 24 h. ChIP analysis was carried out using antibodies 
against PPARα, p300, SRC-1, NCoR or rabbit IgG (Neg- negative control). PCR for the 
PPRE of the HMGCS2 promoter were performed up to 33 cycles. The input was a 
representative of soluble chromatin (1%) that was reverse cross-linked and amplified 






















3.5.10 Correlation of V227A gene expression with recruitment of NCoR to the PPRE of 
the HMGCS2 promoter 
To correlate PPARα-regulated gene expression with recruitment of NCoR to the PPRE of 
the HMGCS2 promoter, HepG2 cells were infected with adenovirus expressing PPARα 
WT, V227A or LacZ, and HMGCS2mRNA expression measured with quantitative real 
time RT-PCR. PPARα V227A regulated HMGCS2 mRNA expression was 60% lower 
compared to WT in the presence of WY14,643 (Fig 3.5.10A). Co-immunoprecipitation 
experiments performed on replicates indicated that decreased HMGCS2 mRNA 
expression in the presence of ligand was associated with defective release of NCoR from 
V227A (Fig. 3.5.10B). Simultaneous chromatin immunoprecipitation with anti-NCoR 
showed that decreased mRNA expression was associated with increased recruitment of 
NCoR to the PPRE in the HMGCS2 promoter (Fig. 3.5.10C). Increased binding of the 
V227A/NCoR complex to PPRE in the presence, and absence, of hormone was also 
evident in ChiP-re-ChiP experiments, wherein chromatin complexes were sequentially 
immunoprecipitated with antibodies to PPARα, and then NCoR (Fig. 3.5.10D).  
In aggregate, our experiments indicate that the mechanism of reduced 
transactivation of the substitution was due to increased binding of NCoR to V227A/PPRE 
chromatin complex. 
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Figure 3.5.10. Correlation of PPARα-regulated gene expression with recruitment of 
NCoR to PPRE in the HMGCS2 promoter  
 
HepG2 cells were infected with adenovirus expressing WT PPARα, V227A or empty 
LacZ vector and treated with, or without, WY14,643 for 24h. (A) HMGCS2 mRNA 
levels were measured by quantitative RT-PCR and normalized to 18S rRNA. Values are 
mean ± SD of three replicates, and expressed in relative quantities to LacZ in the absence 
of ligand. (B) Immunoprecipitation: Cells from representative replicates in (A) were 
incubated with anti-NCoR rabbit polyclonal antibody overnight, and precipitates probed 
with anti-PPARα mouse monoclonal antibody. The input was a representative of soluble 
chromatin (1%) that was reverse cross-linked and amplified under the same PCR 
conditions. (C) Recruitment of NCoR to HMGCS2 promoter. ChIP analyses were 
performed on parallel replicates depicted in (A), using antibodies against NCoR or rabbit 
IgG. Real time PCR was used to quantify amount of PPRE of the HMGCS2 promoter 
bound to NCoR. D) ChiP-re-ChIP experiments. ChIP experiments were carried out as in 
(C) and PPARα ChIP complexes were eluted and subjected again to the ChIP procedure 
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3.6 Summary of results 
Two aspects on transcriptional regulation of PPARα were addressed in this work. Dietary 
flavonoids and their parent botanicals as ligand modulators of PPARα function were first 
investigated. Extending from this aim, benefits of these flavonoids as dual 
PPARα/PPARγ agonists were evaluated. In the second part, the role of NCoR in PPARα 
function was revealed through the study of V227A, a natural PPARα polymorphism.   
Our work demonstrated that the purported anti-diabetic effects of the herb, PT, 
were in part due to its PPAR activation ability. Bioassay-guided fractionation resulted in 
the identity of daidzin, genistin, puerarin, daidzein and 2’hydroxy-daidzein as bioactive 
compounds from PT. Because of the clinical benefits of a dual PPARα/PPARγ agonist, 
we characterized the PPAR effects of isoflavones formononetin and calycosin isolated 
from another anti-diabetic herb, AM, together with daidzein from PT and 2 common 
isoflavones, genistein and biochanin A, using chimeric and full-length PPAR constructs 
in vitro.  
There was a subtle hierarchy of PPARα/PPARγ activities, indicating that 
biochanin A, formononetin, and genistein were more potent than calycosin and daidzein 
in chimeric as well as full-length receptor assays. Respective PPARα and PPARγ 
regulated gene expression levels reflected a similar trend. At low doses, only biochanin A 
and formononetin, but not genistein, calycosin, or daidzein, activated PPARγ-driven 
reporter-gene activity and induced differentiation of 3T3-L1 preadipocytes. Our data 
suggested the potential value of isoflavones, especially biochanin A and their parent 
botanicals, as anti-diabetic agents and for use in regulating lipid metabolism. Screening of 
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other structurally related compounds showed that flavones were the only other flavonoid 
group with PPAR activity. In particular, diosmetin was PPARγ selective.   
The functional significance of the V227A substitution on PPARα was also 
addressed. The polymorphism significantly attenuated PPARα-mediated transactivation 
of the CYP4A6 and HMGCS2 genes, with polyunsaturated fatty acids and the fibrate, 
WY14,643, in a dominant-negative manner. Lower transactivation of V227A was ligand 
dependent as it was only evident with WY14,643 and α-linolenic acid among the panel 
of PPARα ligands examined. This lower activity was localized to the ligand binding 
domain, was independent of its obligate partner, RXR, content, and was not due to a 
change in receptor ligand-binding properties, protein expression or sub-cellular 
localization.  
Screening of a panel of PPARα coregulators revealed that V227A enhanced 
recruitment of the nuclear corepressor, NCoR. Weaker transactivation activity of V227A 
could be restored by silencing NCoR, or by inhibition of HDAC activity. Deletion studies 
indicated that PPARα interacted with NCoR ID1, but not ID2 or ID3. This interaction 
was dependent on the intact consensus nonapeptide nuclear receptor interaction motif in 
NCoR ID1, and was enhanced by the adjacent 24 N-terminal residues.  Novel corepressor 
interaction determinants involving PPARα helices 1 and 2 were identified. V227A 
interact stronger with NCoR in vivo. The V227A substitution stabilized PPARα/NCoR 
interactions in the unliganded state, and caused defective corepressor/coactivator 
exchange in the presence of ligands, on the HMGCS2 promoter in hepatic cells. These 
results provided the first indication that defective function of a natural PPARα variant 
was due to increased corepressor binding. Our data suggest that the PPARα/NCoR 
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interaction is physiologically relevant, and can produce a discernable phenotype when the 
magnitude of the interaction is altered by a naturally occurring variation. 
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4.1 Botanicals as a rich source of PPAR active ligands 
Approximately one-third of the top-selling drugs in the world are natural products or their 
derivatives (Kartal 2007). Despite major scientific and technological progress in 
combinatorial chemistry, the cost of developing a synthetic drug still averages between 
USD 80 million to several billion and can take several years before final approval for use. 
Indeed, although over 50 Investigational New Drug applications have been filed for 
PPAR ligands with the FDA in the last 7 years, none has successfully reached the market 
(Shearer and Billin 2007). Natural products, on the other hand, offer unsurpassed 
chemical diversity, novelty, affinity characteristics and evolutionary selection for 
biological activity than synthetic drugs, and at a fraction of the cost (Chapman 2004). 
Consequently, attention is now returning to the wealth of compounds derived from 
natural products.  
The criteria for approval of herbal mixtures as medicines are starting to relax (Qiu 
2007). In June 2004, the FDA issued new guidelines that permit the approval of herbal 
mixtures if they can be shown to be safe and effective, even if the active constituents are 
not known. Indeed, the world market for such medicine has reached US$60 billion with 
annual growth rates between 5% and 15% (Kartal 2007).  Such commercial potential has 
lead to a boom in herbal research which is mirrored by an exponential increase in related 
patents at the US Patent and Trademark Office. 
 
Many of the herbal extracts exhibited multiple pharmacological actions. However, 
there is a general lack of scientific rigor on how these mixtures work in terms of efficacy 
and mechanism of action. Of these extracts, many contain phytochemicals with structural 
similarities that mimic endogenous molecules involved in nuclear receptor signaling. A 
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prototype of such structural similarity is the soy isoflavone, genistein and the ER 
hormone, estradiol.  
In search of novel activators for PPAR, we hypothesize that botanicals 
traditionally used in the treatment of anti-diabetic related diseases contain compounds 
which are PPAR active. Isolation and characterization of these PPAR active constituents 
may provide a means to assess the biological efficacy of herbal extracts purported to be 
anti-diabetic. 
We identified the roots of Pueraria thomsonii (PT) as a PPAR stimulator. At PT 
concentrations of > 30µg/ml, it mediated the dual activation of PPARα and PPARγ with 
a higher preference for PPARα (Fig 3.1.2). In a recent screening of 52 herbal extracts, 
others showed that nearly half of the screened herbs significantly activated PPARγ (Rau 
et al. 2006). Of these, 14 were also activators of PPARα and 3 of them activated all three 
isoforms. Together with our findings, the collective data suggest that botanicals are a 
natural source of PPAR activators.  
The roots of the Pueraria species is a popular herb for use in traditional Chinese 
medicine in the management of diabetes (Chen et al. 2007). The roots of Pueraria lobata 
and PT have been officially recorded in all editions of The Chinese Pharmacopoeia under 
the same monograph ‘Gegen’ (Radix Puerariae). However, in its 2005 edition, the two 
species were separated into individual monographs, namely ‘Gegen’ (Radix Puerariae 
Lobatae) and ‘Fenge’ (Radix Puerariae Thomsonii), respectively (Chinese 
Pharmacopoeia Committee 2005), due to their different chemical profiles (Chen et al. 
2006). While the roots of P. lobata are often used for clinical prescriptions with other 
supporting herbs (Sun et al. 2007), PT is used as a soup resource in southern China (Jiang 
 176
et al. 2005) and as dietary supplements in North America (Prasain et al. 2003). The wider 
application of PT is perhaps a reflection of lesser potential side effects since it can be 
taken regularly in food and as a single herb.   
Identification of PT as a PPAR stimulator had led to the isolation of several 
isoflavonoids with PPAR activity. Seven major isoflavonoids from the roots of the 
Pueraria species have been reported (Chen et al. 2007). They are 3′-hydroxypuerarin, 
puerarin, 3′-methoxypuerarin, daidzin, genistin, formononetin-7-glucoside and daidzein. 
Through the Gal-PPAR chimera reporter gene bioassay, we identified daidzin, genistin, 
puerarin, daidzein and 2’hydroxy-daidzein as PPAR active. Thus, of the 7 major 
isoflavonoids of the Pueraria species, we showed that at least 4 of them in PT are PPAR 
activators. This also provided mechanistic insights and a possible rationale for the 
traditional use of Pueraria species for their anti-diabetic properties.  
Among the PPAR active isoflavonoids identified in our study, daidzin, genistin 
and puerarin are glycosides of the aglycones daidzein, genistein and puerarein 
respectively. Most flavonoids occur in plants as glycosides and reach the stomach and 
small intestine intact before being absorbed after the removal of the sugar molecule 
(Erdman et al. 2007). Among the flavonoids, isoflavones are particularly well absorbed in 
humans and it is likely that the aglycones forms, of which the findings will be discussed 
in detail below, or the methylated, glucuronidated and sulfated metabolites are the 
molecules responsible for PPAR activity in the body. The total isoflavone content of the 
roots of Pueraria species had been reported to be approximately 30 times higher than that 
extracted from soybeans (Haluzik and Haluzik 2006). While soybeans has been the most 
prominent source of isoflavones in the diet (Erdman et al. 2007), botanicals such as PT 
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may provide an alternative supply of isoflavones. In this work, we showed that 
isoflavones in PT and another anti-diabetic herb, AM, are PPAR active and supports the 
hypothesis that botanicals are a rich source for PPAR active ligands.  
 
4.2 Isoflavones in anti-diabetic botanicals are PPARα/PPARγ dual agonists 
Isoflavonoids can be found in large abundance in the plant family of Leguminosae. Of 
the 13,000 species of legumes from this family, only about 20 are commonly consumed 
by humans (Mazur 1998). Studies on isoflavone levels of legume and non-legume based 
foods have been done. Table 4.1 lists common foods or botanicals containing significant 
amounts of the selected isoflavones examined in this work and their ranges (Mazur 1998; 
Ma et al. 2002; USDA 2002; Wu et al. 2003; Delmonte and Rader 2006). Focus has been 
typically on isoflavones in soy and its products. Although genistein and daidzein can be 
found in large quantities in soy, daidzein is also present in high amounts in the roots of 
the Pueraria species. Biochanin A and formononetin can be found mainly in legumes 
such as clover, pea and sprouts. An isoflavone less commonly found in food, calycosin, is 
found in clover and at high amounts in AM. While isoflavones are well characterized for 
their estrogenic properties, we demonstrated that isoflavones also have dual 
PPARα/PPARγ  activity.  
Our study documents that the “anti-diabetic” herbs AM and PT are dual PPARα/γ 
activators due to their isoflavone constituents. Furthermore closely-related isoflavones 
exhibited significant differences in transcriptional potencies and abilities to regulate 
adipocyte differentiation. In the chimeric PPARα assay, formononetin and biochanin A 
had potencies (EC50 of <1.0 μM and 1.3 μM respectively) (Table 3.2) that were  
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Table 4.1. Common botanicals/foods rich in selected isoflavones1 
 
Isoflavone Botanical name 




    
Calycosin Trifolium pratense 
   Red Clover 
21- 184 Wu et al. 2003 
 Astragalus membranaceus 
   Astragalus 
7400 Ma et al. 2002 
    
Formononetin Trifolium spp.  
   Clover Sprouts 
2.28 USDA 2002 
 Pueraria lobata 
   Kudzu Root 
7.09 Mazur et al. 1998 
 Medicago Sativa 
   Alfalfa Sprouts 
Trace- 261 USDA 2002 
 Trifolium pratense 
   Red Clover 
22.3- 1322 Mazur et al. 1998; USDA 2002; 
Wu et al. 2003 
    
Daidzein Glycine max 
   Soybean 
1- 562 
 - Tofu 1.15- 25.82 
 - Tempeh 4.67- 27.32 
 - Miso 7.1- 36.642 
USDA 2002 
 Trifolium pratense 
   Red Clover 
4- 99 Mazur et al. 1998; Wu et al. 2003 
 Pueraria lobata 
   Kudzu Root 
48.1- 185 Mazur et al. 1998 
    
Genistein Glycine max 
   Soybean 
4.6- 84.1 Mazur et al. 1998 
 - Tofu 2.89- 37.72 
 - Tempeh 1.11- 39.772 
 - Miso 11.7- 52.392 
USDA 2002 
 Trifolium pratense 
   Red Clover 
6- 580 Mazur et al. 1998; Wu et al. 2003 
 Pueraria lobata 
   Kudzu Root 
12.6- 56.1 Mazur et al. 1998 
    
Biochanin A Trifolium pratense 
   Red Clover 
20.4- 833 Mazur et al. 1998; USDA 2002  
 Pisum sativum 
   Chinese peas 
9.31 USDA 2002 
 Pueraria lobata 
   Kudzu Root 
1.4 Mazur et al. 1998 
 Cicer arietinum 
   Chickpea 
3.1- 0.8 Mazur et al. 1998 
    
1 For meaningful comparisons, only recent (since 1998) and comprehensive studies are included.  Figures 
expressed as a percentage of the dry weight of the food, unless otherwise stated.  




comparable to that reported for synthesized PPARα/γ agonists such as ragaglitazar (3 μM) 
(Lohray et al. 2001), tesaglitazar (3 μM) (Davis 2002) and muraglitazar (0.3 μM) 
(Devasthale et al. 2005). With respect to PPARγ, formononetin and biochanin A 
(EC50=2.6 μM and 3.7 μM respectively) (Table 3.2) were less potent compared to 
ragaglitazar (0.093 μM) (Lohray et al. 2001), tesaglitazar (0.149 μM) (Davis 2002) and 
muraglitazar (0.11 μM) (Devasthale et al. 2005). Nevertheless, these isoflavones 
exhibited balanced ratios of PPARα/PPARγ activity ratios of 1:3 in chimeric and almost 
1:1 in full-length PPARα/γ assays (Table 3.2). This balanced activity PPARα/PPARγ 
profile may potentially enhance the attractiveness of biochanin and formononetin, and 
foods containing them, in the management of the metabolic syndrome (Eckel et al. 2005).  
Synthetic dual PPARα/γ drugs exhibit considerable side effects including edema, 
carcinogenicity in rodent toxicity models and increased cardiovascular risks (Lohray et al. 
2001; Davis 2002; Saad et al. 2004; Barlocco 2005; Devasthale et al. 2005; Rubenstrunk 
et al. 2007). Although dual PPAR agonists like muraglitazar and tesaglitazar have elicited 
high hopes and were evaluated in large scale phase III clinical trials of type 2 diabetic 
patients, they have recently been discontinued for development (Nissen et al. 2005; 
Rubenstrunk et al. 2007).  
It is noteworthy that of the failed PPAR agonists, none were PPARα-preferential 
dual agonists (Rubenstrunk et al. 2007). For most, a higher concentration of dual agonist 
is required for PPARα activity to be maximal than for PPARγ. For example, 
PPARα/PPARγ activity ratio for ragaglitazar was 32:1 (Table 4.2). In contrast, 
PPARα/PPARγ activity ratio for the more balanced dual agonist, formononetin, was 
around 1:1. Indeed, most safety issues that led to development discontinuations were  
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Table 4.2 Comparisons of activity ratios between natural and synthetic dual 











Natural dual agonists1 
 
   
 
Calycosin 22 36 0.6:1 
Formononetin 3.7 4.3 0.9:1 
Genistein 9.5 12 0.8:1 
Biochanin A 
 <1 <1 ~ 1:1 
 
Synthetic dual agonists 
 
   
Ragaglitazar2 3 0.093 32:1 
Testaglitazar3 3 0.149 20:1 
Muraglitazar4 
 
0.3 0.11 3:1 
 
1 From Table 3.2, full length PPAR reporter assay 
2 Loray et al. 2001, chimera Gal-PPAR reporter assay 
3 Davis 2004, full length PPAR reporter assay 
4 Devasthale et al. 2005, full length PPAR reporter assay 
 
associated to over-activation of PPARγ rather than to the action of PPARα. This implies 
a potential role of PPARα preferential dual agonist or one with a more balanced activity 
ratio for a more efficient approach to PPAR activation with limited side effects.  
In this work, we identified isoflavonoids, and the parent botanical PT, to possess 
such favourable activity ratios.  Indeed, the discovery such herbs and isoflavones might 
lead to PPAR agonists with improved risk-benefit profiles. Furthermore these isoflavones 
and their parent foods are available immediately for clinical evaluation. 
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4.3 Flavonoid structure and PPAR activity 
Our data add to the increasing evidence (Dang et al. 2003; Kim et al. 2004; Ricketts et al. 
2005) that isoflavones are dual PPARα/γ activators. Besides being phytoestrogens, 
isoflavones exhibit antioxidant effects and perturb the action of DNA topoisomerase II 
(Ricketts et al. 2005). Our study indicates that closely-related isoflavones exhibit 
significant differences in bioactivities. Biochanin A differs from genistein by only an 
additional methyl moiety in the phenyl B ring but the former is several-fold more potent 
than the latter (Table 3.2 and Fig 4.1). Similarly formononetin, with an additional methyl 
moiety, was at least an order of magnitude more potent compared to its metabolite 
daidzein. The differences in transactivation potencies were consistently observed across 
several cells lines and on PPAR-regulated adipocyte differentiation, suggesting that they 
reflect bona fide functional differences. Differences in transactivation may be partly due 
to differences in binding affinity as clear differences in the ability of isoflavone to 
displace bound PPARγ-fluormone were observed. Biochanin A and genistein displayed 
the strongest binding affinity corresponding to their strong PPARγ transactivity. 
Flavonoids comprised of two aromatic rings (A and B) linked by an oxygenated 
heterocyclic ring (C) (Fig 4.1). Functional groups and oxidation state of the C ring 
differentiates flavonoids into different subclasses (Erdman et al. 2007). Although 
isoflavones are PPAR activators, not all closely-related flavonoids with the basic 
flavonoid structure are PPAR active. Together with diosmetin of the flavone group, we 
showed that among the flavonoids, only selected members of the flavone and isoflavone 
groups activate PPAR.  
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Both flavones and isoflavones share the same basic structure consisting of two 
benzene rings (A and B) linked by a heterocyclic pyrone ring (C). In correlation to the 
structures of biochanin A, genistein and diosmetin with their respective PPAR activity, 
the similarities suggested that the chromone structure (comprising of the benzene ring A 
and the heterocyclic pyrone ring C) may favour PPAR activation. Hydrophobicity of the 
chromone may also influence the strength of PPAR activity. The most marked example 
being genistein and daidzein which differs only by the additional hydroxyl group on the 
A ring of the chromone but the former is several-fold more potent than the latter (Table 
3.2 and Fig 4.1). In addition, isoflavones differ from flavones by having the B ring 
attached at position 3 on the C ring instead of position 2 like the latter. Comparing 
structures of biochanin A and diosmetin, differences of the position of the B ring and the 
type of chemical moieties attached to it may play a role in PPAR selectivity.  
Nonetheless, further molecular and structural studies are necessary to understand 
the mechanistic basis for these differences, whether they are related to different abilities 
to recruit co-activators or co-repressors (Guan et al. 2005), and/or cross-activation of 
other steroid receptors such as ER or RXR (Dang and Lowik 2004).   
 183












































4.4 Potential application of diosmetin as a selective PPARγ ligand 
The anti-inflammatory drug, Daflon, containing 90% diosmin and 10% hesperidin, has 
been used in the treatment of non-diabetic related diseases for many years. When diosmin 
was administered orally to healthy volunteers, only its aglycone, diosmetin, was detected 
in plasma (Struckmann and Nicolaides 1994). In this study, we identified diosmetin as a 
PPARγ selective ligand (Fig. 3.2.9)  
Although the drug Daflon is known to be anti-oxidative and inhibits 
prostaglandins biosynthesis, detailed molecular mechanism of Daflon’s efficacy remains 
poorly understood (Manthey 2000; Bergan et al. 2001). Our work extends on the 
biological properties of diosmetin and provides new evidences at the molecular level for 
new applications of the drug, Daflon.  
The current disappointing clinical outcomes in the development of PPAR dual 
agonist have hastened the quest for new selective PPAR modulating (SPPARM) drugs 
that can deliver improved therapeutic benefits (Shearer and Billin 2007). The principle of 
this application is that ligands which modulate the activity of PPAR receptors in a tissue 
and pharmacological specific manner would allow regulation of desired pathways while 
limiting undesirable side effect. SPPARMs are similar in concept to selective estrogen 
receptor modulators such as tamoxifen which displays tissue specific affects. One such 
SPPARM, Metaglidasen, is currently in Phase III clinical trial after demonstrating 
significant improvements in metabolic parameters without the side effects of edema or 
weight gain (Rubenstrunk et al. 2007). Although we only showed moderate activation by 
diosmetin on the adiponectin gene (Fig 3.2.10), we demonstrated that diosmetin activates 
PPARγ through ligand binding on a consensus PPRE (Fig 3.2.9). These results may 
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suggest that diosmetin, and the drug Daflon, may potentially function as a SPPARM on 
certain PPAR regulated genes yet to be examined.  
While more work is required to explore the detailed mechanism of diosmetin 
induced PPARγ activation, our study suggests the potential new applications of a safe 
drug already available on the market.  Although in comparison with other potent PPARγ 
agonists, diosmetin is only a mild PPARγ activator, less-potent ligands may be more 
beneficial for long term application especially in chronic diseases such as the metabolic 
syndrome.  
 
4.5 Potential application of flavonoids and their parent botanicals as PPAR 
activators 
Isoflavones from soy (Kirk et al. 1998; Mezei et al. 2003) and licorice (Mae et al. 2003) 
exert anti-diabetic and hypo-lipidemic effects in animal models. There is evidence that 
soy extracts have anti-lipidemic properties in humans (Bhathena and Velasquez 2002; 
Zhan and Ho 2005; Taku et al. 2007) and evidence is emerging that they play a beneficial 
role in obesity and diabetes (Li et al. 2005). The FDA recommends the consumption of at 
least 25g of soy protein daily for cardiovascular health. Soy-based diets can result in 
beneficial changes to measures of glycemic control in type II diabetics (Jayagopal et al. 
2002; Li et al. 2005). Nonetheless isoflavones are relatively poorly absorbed and serum 
levels seldom exceed 10μM (Bloedon et al. 2002; Takimoto et al. 2003). Our data 
indicate that genistein, although exerting strong maximal activity in vitro may not have 
much in vivo activity due to its high EC50 values (3.0-23 μM). Consumption of a soy 
beverage (90mg) high in genistein resulted in mean genistein levels of only 0.6μM (Van 
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Patten et al. 2002). Hence, it is not surprising that effects on dyslipidemia following 
administration of isoflavones based on soy products have been mixed (Hall et al. 2006; 
Sacks et al. 2006; Taku et al. 2007). Indeed, due to the conflicting reports, the American 
Heart Association has issued a summary statement not recommending isoflavone 
supplements in food or pills due to its nil effects on lipid risk factors (Sacks et al. 2006).   
Nonetheless, our data may help explain differences following administration of 
preparations enriched for biochanin A compared to formononetin on lipid levels (Nestel 
et al. 2004), based on the higher potency of the former. Although stimulation by 
biochanin A was weaker than that observed for pioglitazone, its effect on adipocyte 
differentiation was observed at a low dose of 1 μM, a property not observed for other 
isoflavones. The marked differences in potency between different isoflavones make it 
important that studies should be done with foods containing precisely defined amounts of 
isoflavones in an order that nutritional effects mediated through the PPAR pathway may 
be evident.  
While PPAR agonists are used for the treatment of risk factors associated with the 
metabolic syndrome and type 2 diabetes, they display side effects which limit their 
clinical development and therapeutic use. New concepts of specific and selective 
pharmacological modulation of PPAR activity have emerged (Gervois et al. 2007). 
Current strategies aimed at reducing side effects involved SPPARMs identification, 
partial PPAR agonists and the optimization of activity ratios between different PPAR 
isotype (Rubenstrunk et al. 2007). It is clear that the development of modulators which 
attain efficient therapeutic activity without PPAR related side effects will be important to 
fulfill unmet clinical needs in the treatment of metabolic disorders. Our study has 
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provided additional candidates for PPAR modulation that is in line with the current 
concepts in PPAR drug design. Not only are these isoflavones and their parent botanicals 
dual agonists, they also possess favourable activity ratios. Further work using micorarray 
analysis can determine the potential exploitation of flavonoids, especially diosmetin, as a 
SPPARM.  
 
4.6 Gene-environment interactions 
How genetic variations interact with the environment, and specifically dietary intake, to 
influence overall cardiovascular heart disease (CVD) risk is an area in which 
understanding is under rapid expansion (Ordovas 2006a). Gene–environment interaction 
refers to the differential phenotypic effects of different environments on individuals with 
the same genotype, or to the differential effects of the same environment on individuals 
with different genotypes (Ordovas 2006b). Dyslipidemia is one of the risk factors of 
CVD (Smith 2007). An important group of drugs used in the treatment of dyslipidemia 
are the fibrates, an agonist of PPARα (Duval et al. 2007).  
Recently, it has been suggested that gene–drug and gene–diet interactions may 
modulate the impact of the PPARα L162V polymorphism. For example, L162V may 
alter the response of HDL-c to gemfibrozil (Bosse et al. 2002) as well as to fenofibrate 
(Brisson et al. 2002). Furthermore, it has been suggested that the effect of the L162V on 
plasma TG and apoC-III concentrations is dependent on the dietary intake of PUFA (Tai 
et al. 2005). On the other hand, the PPARα V227A polymorphism was associated with 
perturbations in plasma lipid levels and modulated the association between dietary PUFA 
and HDL-c (Chan et al. 2006). 
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Although several natural PPARα variants are known (Naito et al. 2006), 
mechanistic studies have not been performed on any of them. This is the first 
demonstration that a natural PPARα variant attenuates transcription because of increased 
interaction with the corepressors. The V227A polymorphism induced significantly 
weaker transcriptional effects on a promoter containing the consensus CYP4A6-PPRE in 
presence of a fibrate drug (WY14,643) and a natural PUFA ligand (α-linolenic acid) in 
physiologically relevant cells (Fig 3.3.2). The transactivation defect was about 25%-49% 
weaker compared to the WT and was cell-type dependent. Furthermore, the V227A 
mutant exhibited significantly weaker activity on the HMGCS2 proximal promoter in 
reporter gene assays and lower mRNA expression in hepatic cells (Fig 3.3.6). 
While attenuation of PPARα V227A activity was consistently observed with 
WY14,643 and α-linolenic acid, such a trend was not evident with PPARα ligands like 
the isoflavones biochanin A and genistein (Fig 3.3.1), the fibrate fenofibrate and the 
PUFA linoleic acid (Fig 3.3.3). Indeed, different ligands make distinct contacts with 
PPARα, resulting in conformational alterations which facilitate interaction of the receptor 
with coregulators and/or the general transcription machinery that underlie the molecular 
basis of ligand-dependent transcriptional activation (Dowell et al. 1997b). In 
hyperlipidemic patients and human apolipoprotein AI (apoA-I) transgenic mice, while 
both fenofibrate and gemfibrozil increased HDL-c, the levels of PPARα regulated main 
constituent of HDL, apoA-I, was only increased by fenofibrate (Duez et al. 2005). This 
was due to more efficient coactivator recruitment by fenofibrate induction on the apoA-I 
promoter. Thus, our data suggest that with gene-drug interactions, it is unlikely that 
differences in response to fenofibrate will be observed between non-carriers and carriers 
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of the variant. Since WY14,643 was never employed clinically because of 
hepatocarcinogenesis (Zahradka 2007), ongoing studies comparing gemfibrozil and 
fenofibrate will shed light on whether carriers of the variant may respond differently to 
gemfibrozil.  
Although Asians consume a high amount of isoflavones compared to their 
western counterparts (Erdman et al. 2007), our data (Fig 3.3.1) suggest that with gene-
diet interactions, it is less likely that differences in PPARα regulated response to 
isoflavones will play a significant role in any distinction observed between non-carriers 
and carriers of the variant from their diet.  
While there was no distinction in PPARα transactivity between WT and V227A 
with linoleic acid (Fig 3.3.3), V227A was weaker than WT in the presence of α-linolenic 
acid (Fig 3.3.2). α-linolenic acid is a ω-3 PUFA while linoleic acid is a ω-6 PUFA. Gene-
diet interaction between ω-3 and ω-6 with another better studied PPARα polymorphism, 
L162V, has been described (Tai et al. 2005). Increased ω-6 intake in carriers of the L162 
variant was associated with a marked reduction in TG whereas this association was not 
observed in non-carriers. However, both experienced beneficial decrease in TG when ω-3 
intake was considered. In women who carried the V227A polymorphism, increasing 
dietary PUFA intake was associated with lower HDL cholesterol (Chan et al. 2006). Our 
transactivity data with one of the ω-3 PUFA found commonly in the diet were in 
agreement with Chan et al.’s observation as V227A activity was lower than WT in the 
presence of α-linolenic acid (Fig 3.3.2). While distinction between the type of PUFA 
intake was not made in Chan et al ’s association study and α-linolenic acid forms only a 
part of the total dietary PUFA intake, our data suggested that carriers with the V227A 
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polymorphism may experience less beneficial effects related to PPARα regulated lipid 
factors associated with increased ω-3 intake, since V227A activity was lower with α-
linolenic acid. In contrast, no such distinction may be observed in association with ω-6 
intake.  
While others have shown that PPAR activity of L162V was higher than WT, we 
show here that another PPARα variant, V227A, had reduced PPAR activity. Interestingly, 
the impact of the polymorphisms on plasma lipid/lipoprotein levels is similar on certain 
aspects (eg. association with lower TG levels) despite the contrast in PPARα activity. As 
the regulation of lipid metabolism is a complex process, further studies are needed to 
compare the differences in the regulation of PPARα specific genes (eg. apoA-I, ACO) by 
the two polymorphisms to explain such discrepancy.  
A major limitation of this work is that the study was dependent on the 
overexpression system. Furthermore, overexpression was largely carried out using 
HepG2 cells with a relatively high WT background. While no comparable cell line 
expressing the V227A variant is currently available, further understanding of V227A 
activity could be achieved through comparisons between the blood cell populations of 
carriers of this variant and the wild type. Indeed, differences of the two groups of blood 
cell populations in response to PPARα ligands and the effects on relevant PPARα 
regulated genes will provide a clearer characterization of V227A function. 
The importance of making a distinction between functional single nucleotide 
polymorphism (SNP) and nonfunctional SNPs to avoid the use of nonfunctional genetic 
variants in association studies has been strongly recommended (Humphries et al. 2004; 
Corella and Ordovas 2005). Here we provide the first example that V227A, a variant 
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which is present in relatively high frequency in populations of Asia, is functional. This 
paves the way for further studies to better understand the phenotypes associated with this 
polymorphism in health and diseases.  
 
4.7 Mechanism(s) for attenuated PPARα V227A activity  
In order to understand the mechanisms involved in PPARα V227A transcriptional 
attenuation, several aspects previously reported to affect transcription of PPARα and 
other nuclear receptors where first investigated. Although PPARα turnover by the 
proteasome system through post-translational ubiquitin modification has been shown to 
affect the ligand-induced expression level of its target genes (Blanquart et al. 2002; 
Blanquart et al. 2004a), we showed that lower V227A activity was not due to a decrease 
in its protein levels (Fig 3.4.3A and B). 
However, we did not investigate the effects of another post-translational 
modification, phosphorylation, on PPARα V227A activity. While MAPK and PKA 
phosphorylation occurs mainly at the N-terminal, PKC phosphorylation occurs at the 
hinge and LBD of PPARα (Blanquart et al. 2004b). In particular, inhibition of serine 
residue 230 phosphorylation impaired ligand activated PPARα transcription. However, 
the detailed mechanism for this repression is unclear. For the estrogen receptor, the 
mechanistic consequence of phosphorylation at its hinge altered receptor function 
through ligand, DNA, and coactivator binding (Likhite et al. 2006). DNA binding, 
through ChIP pulldown with antibodies against PPARα (Fig 3.5.9, second panel), and 
ligand binding, through radiolabelled competitive binding assays (Fig 3.4.1B), was not 
affected by V227A since there were minimal differences in comparison to WT. Thus, 
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while V227A’s effect on S230 phosphorylation status was not examined, our results 
suggest that V227A had minimal effect on the phosphorylation status of S230 even 
though it is in close proximity.  
It has been reported that a natural PPARα splice variant lacking the entire LBD 
resides in the cytoplasm and exhibits dominant negative activity when localized to the 
nucleus (Soderstrom et al. 1997). Interaction with Hsp90, a cytoplasmic protein, at the 
hinge and LBD of PPARα also represses PPARα activity (Sumanasekera et al. 2003a; 
Sumanasekera et al. 2003b). Activity and subcellular compartmentalization of PPARα 
was also altered by the centrosome-associated protein CAP350 although specific 
interaction domains were not investigated (Patel et al. 2005). Our data showed that the 
lower activity of V227A was not due to a difference in subcellular localization as V227A 
did not display distinction in co-localization like the PPARα splice variant or from a 
possible consequence of differential association with other PPARα interacting 
cytoplasmic proteins in the presence or absence of WY14,643 (Fig 3.4.3C).  
Overexpression of PPARα obligate partner, RXR, did not affect V227A’s 
transactivation (Fig 3.4.2). This suggests that V227A’s weaker activity was not 
stoichiometrically limited by RXR. The N-terminal of PPAR has been reported to limit 
receptor activity through interaction with different PPAR domains (Hummasti and 
Tontonoz 2006). Using the chimeric Gal-PPARα LBD, we show that the reduction in 
transcriptional activity of V227A was not dependent on interdomain N-C interactions as 
differences in WT and V227A activity remained in the absence of the N-terminal (Fig 
3.4.1A). Hence, this suggested that AF-1 at the N-terminal was not involved in the 
mediation of V227A’s weaker activity. However, the impaired ligand induction of 
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V227A was not due to a change in ligand binding properties at concentration ≥ 5nm (Fig 
3.4.1B). This is surprising because crystallization studies on PPARβ suggested that the 
region where the mutation lies defined the entrance of the PPARα ligand binding pocket 
(Fyffe et al. 2006). Collectively, our data suggest that while ligand binding properties for 
WT and V227A remained the same, protein conformation changes upon ligand binding 
and the subsequent recruitment of various transcriptional proteins, especially coregulators, 
may contribute to the contrast in V227A activity.  
 
4.8 Coactivators and PPARα interaction 
The combinatorial roles of multiple coregulator complexes are required for the finely 
tuned modulation of nuclear receptor mediated regulation on a highly specific and 
diversified set of genes (Perissi and Rosenfeld 2005). PPARα has been reported to 
interact with various groups of coregulators (Table 4.3) (Dowell et al. 1997a; Zhu et al. 
1997; Miyata et al. 1998; Dowell et al. 1999; Vega et al. 2000; Zhu et al. 2000; Xu et al. 
2001; Surapureddi et al. 2002; Xu et al. 2002a; Tien et al. 2004) to achieve this intricate 
control over gene activation and repression.  
To evaluate the involvement of coregulators on V227A attenuation, we compared 
interactions of WT and V227A with major coregulator proteins known to interact with 
PPARα (Dowell et al. 1997a; Voegel et al. 1998; Dowell et al. 1999; Caira et al. 2000; 
Vega et al. 2000; Xu et al. 2002a; Yu and Reddy 2007) (Table 3.3).  
There was no obvious distinction between WT and V227A recruitment of the 
coactivators SRC-1, TIF2, PGC-1, p300 and PRIP, in the absence or presence of ligand 
(Table 3.3). This was the case even for coactivators, p300 and SRC-1 (Dowell et al. 
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1997a), previously reported to interact near or within the region where the V227A 
mutation lies. Among the coactivators, interaction with p300 was highest for both WT 
and V227A. In concordance with observations made by others (Zhou et al. 1998; 
Mukherjee et al. 2002; Feige et al. 2006), p300/CBP’s high affinity highlights the 
important role it plays in PPARα activation. Consistent with previous report (Dowell et 
al. 1997a), there was strong interaction between p300 and the hinge-LBD of WT and 
which was only modestly enhanced by WY14,643. No significant difference in 
interaction with p300, especially in the presence of ligand, was observed for WT and 
V227A, thus suggesting that p300 interaction may not be a major factor contributing to 
the reduction of V227A activity.  
In agreement with others (Dowell et al. 1997a),  SRC-1 interacted with WT in the 
absence of ligand. Interaction with SRC-1 was similar between WT and V227A in the 
presence of ligand (Table 3.3). However, comparing respective SRC-1 interactions in the 
presence and absence of ligand, the increase in interaction with WY14,643 was higher  
in WT (~70% increase) than in V227A (~20%). This suggested that the V227A LBD is 
less sensitive to ligand induced SRC-1 recruitment. This impaired ligand induced 
recruitment of SRC-1 may contribute in part to the attenuation of V227A transcriptional 
activity. Crystallographic data indicated that the second interaction motif of SRC-1 
contacts with helix 3 and AF2 of PPARα in the presence of ligand (Xu et al. 2001). This 
model does not support a role of helix 2, where the mutation lies.  However, SRC-1 has 
more than one receptor interaction motif (Ding et al. 1998; McInerney et al. 1998). While 
the crystallographic study examined the interaction of a single SRC-1 motif on PPARα 
(Xu et al. 2001), our mammalian-two-hybrid system, with a truncation fragment that 
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Table 4.3 Summary of coregulator interaction of PPARα 
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included three of the four reported interaction domains of SRC-1 fused to Gal, provided 
the summated effect of interaction between this SRC-1 fragment and PPARα. Thus, 
V227A’s effects on the recruitment of SRC-1 may suggest the role of other helices, like 
helix 2, in SRC-1-PPARα interaction, not revealed by the crystal.  
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 4.9 Corepressors and PPARα interaction 
The most marked difference in coregulator interaction between WT and V227A occurred 
with the corepressors (Table 3.4). Presence of the V227A mutation markedly increased 
interaction with NCoR in the absence and at low doses of ligand (Fig 3.4.4). There have 
been limited studies of corepressors recruitment by PPAR (Table 4.4). For PPARα, 
studies were few and conflicting. Ligand dependent interaction between PPARα and 
NCoR has been shown in yeast-two-hybrid assay and this NCoR interaction suppressed 
the reporter activity of a PPRE driven plasmid in HEK 293 cells (Dowell et al. 1999). 
However, NCoR did not suppress PPARα activity on the PPRE in other cell lines (Lim et 
al. 2004). On the other hand, a PPARα-Gal fusion protein could not repress constitutive 
reporter activity in CV-1 cells which indicated the lack of corepressor recruitment of 
PPARα (Shi et al. 2002). The same group was unable to detect DNA-bound PPARα-
RXR-SMRT complexes. PPARα-SMRT interaction has been shown in the presence of an 
antagonist (Xu et al. 2002a) and partial agonist (Leesnitzer et al. 2002). Adding to these 
conflicting results is the observation that minimal interaction was detected for C-terminal 
NCoR and SMRT with PPARα in a mammalian-two-hybrid assay (Semple et al. 2005).  
The roles of corepressors in a closely related protein, PPARγ, have also been 
controversial. Similar to PPARα, others were unable to detect DNA-bound PPARγ-RXR-
SMRT complexes and DNA-bound PPARγ-RXR-NCoR complexes (Zamir et al. 1997; 
Shi et al. 2002). Similar to SMRT interaction with PPARγ (Lavinsky et al. 1998; Agostini 
et al. 2004; Wang et al. 2004), NCoR-PPARγ interaction has also been shown through 
GST-pull down assays and mammalian-two-hybrid (DiRenzo et al. 1997; Zamir et al. 
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1997; Gurnell et al. 2000). The functional relevance of NCoR-PPARγ’s interaction in 
solution, in contrast to the interaction on DNA, was demonstrated with NF-κB regulated 
inflammatory gene promoters where sumoylated PPARγ  prevented the degradation of 
NCoR complexes on these promoters and target genes were maintained in a repressed 
state (Pascual et al. 2005). The role of corepressors on the repression of PPARγ mediated 
transcriptional activity on specific promoters was only recently shown on the glycerol 
kinase promoter in adipocytes (Guan et al. 2005) and in the ability to inhibit adipocyte 
differentiation (Yu et al. 2005). However, studies on corepressor-PPARα interaction are 
conflicting and the function on specific PPARα target genes is lacking.  
We have shown in our study that V227A on PPARα enhanced the interaction of 
PPARα and NCoR as determined by the mammalian-two-hybrid assay. Subsequently, we 
demonstrated that the recruitment of NCoR on the PPRE of the HMGCS2 promoter by 
ChIP and the interaction in solution with NCoR by Co-IP was more with PPARα V227A. 
These results highlight a role of NCoR transcriptional mediation of PPARα and support 
the need for ongoing studies on the functional significance of PPARα-NCoR interaction 
in solution, such as PPARα transrepressive role in T cells and B lymphocytes in 
inflammation (Jones et al. 2002; Jones et al. 2003; Dunn et al. 2007); and on the 
chromatin, such as PPARα transrepression of AGP (Mouthiers et al. 2005), fibrinogen β 
(Gervois et al. 2001) , apoC3 (Gervois et al. 1999) and hepatic SCARB1 (Mardones et al. 
2003). 
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4.10 NCoR ID and PPARα interaction 
NCoR is a modular protein that contains N-terminal repression domains and C-terminal 
nuclear receptor interaction domains (IDs) (Horlein et al. 1995; Seol et al. 1996; Zamir et 
al. 1996; Cohen et al. 1998; Webb et al. 2000). The NCoR possess three nuclear receptor 
IDs (Seol et al. 1996; Webb et al. 2000). Although the IDs show much homology, they 
mediate interactions with nuclear receptors differently.  
There is preliminary evidence that PPARα interacts with ID1 (Dowell et al. 1999) 
but the specific ID preference pattern for PPARα is still uncertain, as interaction studies 
comparing all three IDs have not been performed.  Here we show conclusively that 
NCoR ID1, not ID 2 or ID3, was necessary and sufficient for maximal PPARα-NCoR 
interactions in mammalian two-hybrid (Fig 3.5.4) and GST-pull down assays (Fig 3.5.5).  
An intact CoRNR box was necessary, because deletion of the terminal 4 residues of the 
ID1 CoRNR box nonapeptide abolished PPARα-NCoR interactions (Fig 3.5.4). In 
addition, our deletion mutants indicate the importance of the N-terminal sequences 
(2251-2274) flanking the CoRNR box, as their deletion leads to weaker PPARα/NCoR 
interactions. Interaction with PPARα was lower with NCoR fragment G8 (residues 1575-
2453) compared to G4 (2039-2453) suggesting a potential suppressive function in NCoR 
residues 1575-2039. Intriguingly this fragment has been reported to harbor a 
sin3/HDAC3 recruiting site (Heinzel et al. 1997; Li et al. 2000).  
Nuclear receptors have distinct binding preferences for the three IDs of NCoR 
(Table 4.5). The TR specifically requires the presence of all three ID1, ID2, ID3 all of 
which act cooperatively to induce maximal TR-NCoR interaction (Horlein et al. 1995; 
Seol et al. 1996; Hu and Lazar 1999; Cohen et al. 2000; Webb et al. 2000; Cohen et al. 
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2001; Hu et al. 2001; Makowski et al. 2003). On the other hand, RAR requires ID2 and 
interacts only minimally with ID1 (Seol et al. 1996; Hu et al. 2001), whilst its 
heterodimeric partner RXR interacts with ID1 not ID2 (Hu and Lazar 1999; Hu et al. 
2001), giving rise to the model that RXR/RAR heterodimer could be bound to the same 
corepressor molecule via the two adjacent ID1 and ID2. However this model is not 
applicable to PPARα, since both PPARα and its heterodimeric partner RXR interacts 
with ID1, and not ID2. Detailed knowledge of the ID preferences of PPARα may lead to 
the design of peptidomimetics that can block one of the other of NCoR IDs resulting in 
targeted effects on PPARα function (Mettu et al. 2007). 
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Table 4.5 Summary of NCoR interaction domain (ID) binding preferences to 
selected nuclear receptors 
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4.11 Function of PPARα hinge in corepressor interaction 
The role of the hinge in PPAR is not well studied. Artificial mutations of PPARα in the 
C-terminal helix 12 are known to increase interactions with NCoR. Deletion of the 
terminal 13 residues encoding helix 12, results in a truncation mutant (PPARα∆13) that 
was able to bind agonists, but did not stimulate transcription (Michalik et al. 2005). This 
PPARα∆13 mutant exerted dominant-negative effects, in that it was able to repress the 
activity of co-expressed WT PPAR. Similarly substitutions in PPARα helix 12  (L459A 
and G462A), which were created based on PPARγ variants associated with severe insulin 
resistance, diabetes mellitus, and hypertension (Barroso et al. 1999), resulted in an 
artificial dominant-negative PPARα mutant that recruited NCoR in a ligand-dissociable 
manner (Semple et al. 2005). These mutations may block helix 12 from assuming an 
active conformation resulting in a larger pocket that can accommodate the three-turn 
corepressor motif, as was observed for antagonist bound PPARα (Xu et al. 2002a).  
Besides helix 12, our data indicate that the N-terminal portion of LBD, the short 
hinge region that begins at the termination of DBD and extending to helix 2 (Huber et al. 
2003), plays an important repressor role in PPARα function. Evidence exists from other 
nuclear receptors that the hinge region plays a key role in receptor/NCoR interactions. 
Deletion of the AR hinge results in a mutant that is hyperactive, suggesting a repressor 
function in this domain (Wang et al. 2001). The ERα (Webb et al. 2003) and PR (Jackson 
et al. 1997) hinge regions recruit NCoR in the presence of partial agonists, and hinge 
deletion mutants abolished interactions with NCoR. The role of the N-terminal helix in 
TR and other receptors known to interact with NCoR had been established previously 
(Horlein et al. 1995). Termed the CoR box (Fig 4.2), this box is well conserved between 
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Figure 4.2 Sequence alignment of the NCoR box of TR against PPAR and other 
nuclear receptors 
 
Sequence alignment of TRβ CoR box (residues 211-240) (Horlein et al. 1995) with 
selected nuclear receptors according to Wurtz et al. 1996. Conserved residues between 
TRβ and other nuclear receptors highlighted in grey. Natural point mutations on TRβ 




                               CoR Box 
 
hTRβ 211 KPEPTDEEWELIKTVTEAHVATNAQGSHWKQKRKFL 246 
hRARα 177 SYTLTPEVGELIEKVRKAHQETFPALCQLGKYTTNN 212 
hVDR 125 RPKLSEEQQRIIAILLDAHHKTYD.PTYSDFCQRPP 160 
hRXRα 221 ESTSSANEDMPVERILEAELAVEPKTETYVEANMGL 256 
            .         .         .*  
hPPARα 196 EDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSG 231 
hPPARγ 204 LNPESADLRALAKHLYDSYIKSFPLTKAKARAILTG 239 
hPPARβ 168 YNPQVADLKAFSKHIYNAYLKNFNMTKKKARSILTG 203 
    
hER 305 SLALSLTADQMVSALLDAEPPILYSEYDPTRP---- 336 
hPR 677 PGQDIQLIPPLINLLMSIEPDVIYAGHDNTKP---- 708 
hAR 664 HIEGYECQPIFLNVLEAIEPGVVCAGHDNNQP---- 695 
 
 
TR and RAR and identifies a regulatory domain in a region which was previously 
considered to be poorly conserved on the nuclear receptor (Horlein et al. 1995). However, 
it has been noted by others that a conserved CoR box on PPAR is missing (DiRenzo et al. 
1997) (Fig 4.2). This CoR box is also missing on steroid receptors, ER, AR and PR, even 
though interaction with NCoR had been reported (Jackson et al. 1997; Wang et al. 2001; 
Webb et al. 2003). Furthermore, NCoR failed to interact with VDR, which is highly 
conserved within the CoR box, and suggest the possibility of additional requirements for 
high affinity interaction within the N-terminal portion of the LBD (Horlein et al. 1995), 
like helix 2 of PPARα.  
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Intriguingly, sequence alignment indicates that PPARα residue 227 is located 
between two TRβ hinge residues 234 and 243 that were encountered in patients with 
resistance to thyroid hormone (Safer et al. 1998). Like the TRβ mutants, our V227A 
PPARα mutant exhibited dominant negative activity. High resolution crystallography 
indicates that mutations affecting TRβ hinge residues 234 and 243 modulated the 
flexibility of the N-terminal region such that higher concentrations of ligand are required 
for optimal LBD assembly and stability (Huber et al. 2003). Others noted that many of 
the PPARα residues involved in SMRT interaction of the PPARα-SMRT crystal (Xu et 
al. 2002a) are not conserved in the LBD of other NRs and suggest that if the structure of 
the LBD is sufficiently altered, the recruitment of corepressors may be substantially 
altered as well (Makowski et al. 2003). Indeed, defective release of NCoR by hinge 
mutants of the TR (Safer et al. 1998) involved residues A234 and R243 which are not 
well conserved among NR. Furthermore, R243 also lies outside the reported TR NCoR 
box (Horlein et al. 1995). 
It is also interesting to note that the equivalent PPARα 227 residue on PPARγ 
(residue 235) is already an alanine. The distinction at this single residue between the two 
PPARs may provide some insights into coregulator (eg. NCoR) affinity and preferences, 
even though disparity at other residues are likely to be involved as well.   
Here we show that PPARα helices 1 and 2, but not the residues preceding helix 1, 
make important contributions to NCoR interactions, and that the V227A substitution 
enhances this interaction (Fig 3.5.6). The exact structural basis whereby V227A in helix 2 
mediates increased corepressor recruitment, whether by directly modifying contact points 
with NCoR or as a secondary structural determinant, requires crystallographic analysis. 
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4.12 Molecular mechanism of attenuated PPARα V227A transcription 
The crystal structure of antagonist-bound PPARα revealed that the CoRNR motif fits 
tightly into a groove formed by PPARα helices 3, 3’, 4 and 5 (Xu et al. 2002a). 
Interestingly, this corepressor groove has also been identified as the critical docking site 
for coactivators. Although there is overlap, the co-repressor site has a larger interaction 
interface occupied by the three α-helical turns generated by LXXI/HIXXXI/L of the 
CoRNR motif, compared to two turns of the SRC-1 coactivator motif, LXXLL (Figure 
1.6). It is hypothesized that nuclear receptors distinguish corepressors from coactivators 
by the length of their interaction motifs. Consistent with this model, our data indicate that 
NCoR and SRC-1 competed for the same PPARα binding site in solution and in 
chromatin, and that the V227A substitution favored the binding of the corepressor, 
resulting in defective recruitment of the coactivator, SRC-1 (Fig 3.5.7). 
The dynamic interactions between coactivators and corepressors in PPARα-
regulated promoters are controversial. TRβ, RAR, RXR, and PPARγ receptors interact 
with SMRT and/or NCoR in the absence of hormone. Others, such as the androgen, 
estrogen and progesterone receptors bind corepressors in the presence of hormone 
antagonists. Whereas it is clear that PPARα can interact with corepressor in solution 
(Dowell et al. 1999) or in the presence of antagonists (Xu et al. 2002b), it has not been 
demonstrated conclusively that NCoR-PPARα binding occurs in PPRE and their presence 
in chromatin is controversial (Dowell et al. 1999; Semple et al. 2005). It has been 
suggested that WT PPARα, like PPARγ  (Zamir et al. 1997), interacts with SMRT and 
NCoR in solution, but not on DNA. Our chromatin immunoprecipitation assays show that 
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WT PPARα interacts with NCoR on the HMGCS2 promoter in the unliganded state, and 
exogenous ligands induced complete release of NCoR and the simultaneous recruitment 
of SRC-1 (Fig 3.5.9). The V227A substitution disrupted this process causing incomplete 
release of NCoR. Defective V227A transactivation function observed with high doses of 
ligand where NCoR no longer binds to V227A suggest that corepressors other than 
NCoR may have a role in defective mutant function (Fig 3.4.4). One such corepressor 
may be SMRT which also binds avidly to V227A (Table 3.4). Ligand dependent 
corepressors such as RIP140 may play a role as well.  
 
The conventional view that receptors remain stably bound on their DNA response 
element has been challenged in the past few years (Perissi and Rosenfeld 2005). ChIP 
analysis of promoter occupancy by nuclear receptors, such as ERα binding on the pS2 
promoter (Reid et al. 2003), have shown that binding of the receptor, together with its 
coregulators, to DNA is characterized by cycles of recruitment and release. Due to the 
kinetics of coregulator recruitment, the simultaneous occupancy of a chromatin region 
with corepressors and coactivators is possible, as observed in this work and that of others 
(Degenhardt et al. 2006). Interestingly, on the recently identified PPARα regulated 
IGFBP gene (Degenhardt et al. 2006), co-occupancy by corepressor, NCoR, and 
coactivator, PGC-1α, on the PPRE were observed at various time points in the presence 
of ligand. On the other hand, since either PPARα or RXR agonist alone is enough to 
activate transcription of the PPAR/RXR heterodimer (Keller et al. 1993), recruitment of 
corepressor and coactivator separately by each member of the heterodimer, may account 
for the co-occupancy of both types of coregulators on the PPRE in the presence or 
absence of PPARα ligand.  
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Unliganded ERα were reported to cycle on the promoter and is thought to keep 
the target gene ready for activation when ligand stimulation occurs (Metivier et al. 2004). 
Such an observation is compatible to the recently proposed genome scanning model of 
NR mediated activation that is largely derived from live cell imaging data (Feige et al. 
2006). Indeed, in genome scanning, PPAR may transiently interact with the chromatin 
even in the absence of ligand. Furthermore, mobility of the constitutively associated 
PPAR/RXR complex indicated the association of large complexes such as corepressor or 
coactivators complexes during genome scanning (Feige et al. 2005). In addition, these 
large PPAR coregulator complexes were already pre-assembled before binding onto 
chromatin and provide a new paradigm in the functional role of coregulator-receptor 
interaction in solution. Based on this current model of genome scanning and the data 
derived from our study, we hereby propose a molecular mechanism of action for V227A 
in Figure 4.3.  
While live cell imaging techniques reflect the complexity of a single cell, the 
ChIP technique reflects overall conditions on a population of cell. Ongoing studies on the 
nuclear behavior of V227A with coregulators and/or chromatin in living cells will shed 
light on the mutant’s mode of action in the extremely dynamic and multi-
compartmentalized nucleus. Indeed, understanding the behavior of NRs in the nucleus of 
living cells and the underlying impact on transcription will necessitate the combination of 
microscopy techniques with ChIP experiments. Together this can further facilitate the 
revelation of potential novel mechanisms of PPARα by the V227A variant. 
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Figure 4.3 Proposed molecular mechanism of V227A using the genome scanning model 
The ChIP technique reflects overall conditions in a population of cells. In our model, total cell population is represented by the black 
box. Live cell imaging, where the genome scanning model has been largely derived from, reflects a single cell. Here, a single cell is 
represented by a coloured circle within the black box. The colour of the circle reflects PPARα-coregulator association within each 
single cell. Thus, PPARα-corepressor complex is red and PPARα-coactivator-complex is green. In the absence of ligand, our ChIP 
data for WT suggest that a similar portion of the cell population has WT PPARα associated with either corepressors (eg. NCoR) or 
coactivators (eg. SRC-1). These WT-coregulator complexes roam the nucleus where they interact transiently with chromatin, both on 
genuine PPREs, as suggested in our ChIP data, and unspecific binding sites. Since there is no ligand, WT-coactivator complexes does 
not activate transcription on genuine PPREs and is thus silent like WT-corepressor-PPRE complexes. Upon ligand binding, WT-
corepressors exchange for the coactivator complexes and a higher proportion of the cell population now has WT-coactivator 
complexes for association on PPREs, as reflected in our ChIP data. WT-coactivator complexes may transiently bind to "non-specific" 
sites on chromatin, performing a three dimensional-scanning of the genome, until they encounter a genuine response element in a 
promoter, at which chromatin remodeling and transcription are initiated. Interestingly, our data suggests a different story for V227A.  
 
Our mammalian-two-hybrid, GST-pull down and Co-IP data all indicate that V227A associates stronger in solution with corepressors 
(eg. NCoR) in the absence of ligand. Consequently, this may suggest a larger portion of the cell population has primarily V227A 
PPARα-corepressor complexes. These V227A-corepressor complexes roam the nucleus where they interact transiently with chromatin 
on genuine PPREs and unspecific binding sites as suggested by our ChIP data. Genuine PPRE remains silent and basal transcription 
activity of V227A is comparable to that of WT as reflected in our reporter gene assays. In the presence of ligand, V227A-corepressors 
exchange for the coactivator complexes. However, due to the additional interaction introduced by V227A, release of corepressors is 
impaired and coactivator recruitment becomes aberrant. Thus, proportion of the cell population that is associated with coactivator is 
lesser than WT. Lesser proportion of cells will have V227A-coactivator complexes available for association with their genuine PPRE 
during genome scanning and this results in lower total transcription. In addition, defective V227A activity observed at high doses of ligand 










































Our data and that of others extend the number of potential PPAR active compounds since 
isoflavones are present in many herbs and foods of botanical origins. Traditional PPARγ 
drugs such as pioglitazone are potent but have serious adverse effects such as obesity and 
edema. Preliminary data suggest that less potent drugs may still be efficacious while 
avoiding adverse effects associated with more potent ligands (Liu et al. 2005). The 
challenge of the future is to determine whether isoflavones with different PPARα/γ  
potencies and their parent botanicals have any enhanced benefit-risk profiles for 
management of the epidemic of diabetes, dyslipidemia and the metabolic syndrome. 
The physiological consequences of PPAR activity in the absence of ligand are still 
unclear (Feige et al. 2006) and we have just begun to understand the relevance of 
abrogated ligand dependent and independent activity in PPARα through V227A. The 
importance of corepressor interaction for PPARα is currently poorly understood and 
there is a clear need to study the actions of corepressors on specific PPARα target genes. 
While we have provided the first available information about the important role of NCoR 
in the mediation of transcriptional activity of PPARα on the HMGCS2 gene, we have 
also identified a population of human subjects bearing this aberrant ligand independent 
activity with further ligand dependent consequences that permits us a chance to further 
dissect the role of PPARα in various diseases. This study further allows for the design of 






Adams, M., Reginato, M.J., Shao, D., Lazar, M.A., and Chatterjee, V.K. 1997. 
Transcriptional activation by peroxisome proliferator-activated receptor gamma is 
inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. 
J Biol Chem 272(8): 5128-5132. 
Adlercreutz, H., Markkanen, H., and Watanabe, S. 1993. Plasma concentrations of phyto-
oestrogens in Japanese men. Lancet 342(8881): 1209-1210. 
Agostini, M., Gurnell, M., Savage, D.B., Wood, E.M., Smith, A.G., Rajanayagam, O., 
Garnes, K.T., Levinson, S.H., Xu, H.E., Schwabe, J.W., Willson, T.M., O'Rahilly, 
S., and Chatterjee, V.K. 2004. Tyrosine agonists reverse the molecular defects 
associated with dominant-negative mutations in human peroxisome proliferator-
activated receptor gamma. Endocrinology 145(4): 1527-1538. 
Aldridge, T.C., Tugwood, J.D., and Green, S. 1995. Identification and characterization of 
DNA elements implicated in the regulation of CYP4A1 transcription. Biochem J 
306 (Pt 2): 473-479. 
Amri, E.Z., Bonino, F., Ailhaud, G., Abumrad, N.A., and Grimaldi, P.A. 1995. Cloning 
of a protein that mediates transcriptional effects of fatty acids in preadipocytes. 
Homology to peroxisome proliferator-activated receptors. J Biol Chem 270(5): 
2367-2371. 
Anonymous. 1980. W.H.O. cooperative trial on primary prevention of ischaemic heart 
disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of 
the Committee of Principal Investigators. Lancet 2(8191): 379-385. 
Anonymous. 2000. Secondary prevention by raising HDL cholesterol and reducing 
triglycerides in patients with coronary artery disease: the Bezafibrate Infarction 
Prevention (BIP) study. Circulation 102(1): 21-27. 
Aoyama, T., Peters, J.M., Iritani, N., Nakajima, T., Furihata, K., Hashimoto, T., and 
Gonzalez, F.J. 1998. Altered constitutive expression of fatty acid-metabolizing 
enzymes in mice lacking the peroxisome proliferator-activated receptor alpha 
(PPARalpha). J Biol Chem 273(10): 5678-5684. 
Arakawa, K., Ishihara, T., Aoto, M., Inamasu, M., Kitamura, K., and Saito, A. 2004. An 
antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac 
volume overload in rats. Clin Exp Pharmacol Physiol 31(1-2): 8-13. 
Bajaj, M., Suraamornkul, S., Hardies, L.J., Pratipanawatr, T., and DeFronzo, R.A. 2004. 
Plasma resistin concentration, hepatic fat content, and hepatic and peripheral 
insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat 
Metab Disord 28(6): 783-789. 
Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A., 
and Evans, R.M. 1999. PPAR gamma is required for placental, cardiac, and 
adipose tissue development. Mol Cell 4(4): 585-595. 
Barger, P.M., Browning, A.C., Garner, A.N., and Kelly, D.P. 2001. p38 mitogen-
activated protein kinase activates peroxisome proliferator-activated receptor alpha: 
a potential role in the cardiac metabolic stress response. J Biol Chem 276(48): 
44495-44501. 
Barish, G.D., Narkar, V.A., and Evans, R.M. 2006. PPAR delta: a dagger in the heart of 
the metabolic syndrome. J Clin Invest 116(3): 590-597. 
 213
Barlocco, D. 2005. Muraglitazar (Bristol-Myers Squibb/Merck). Curr Opin Investig 
Drugs 6(4): 427-434. 
Barroso, I., Gurnell, M., Crowley, V.E., Agostini, M., Schwabe, J.W., Soos, M.A., 
Maslen, G.L., Williams, T.D., Lewis, H., Schafer, A.J., Chatterjee, V.K., and 
O'Rahilly, S. 1999. Dominant negative mutations in human PPARgamma 
associated with severe insulin resistance, diabetes mellitus and hypertension. 
Nature 402(6764): 880-883. 
Beecher, G.R. 2003. Overview of dietary flavonoids: nomenclature, occurrence and 
intake. J Nutr 133(10): 3248S-3254S. 
Behr, M. and Loos, U. 1992. A point mutation (Ala229 to Thr) in the hinge domain of the 
c-erbA beta thyroid hormone receptor gene in a family with generalized thyroid 
hormone resistance. Mol Endocrinol 6(7): 1119-1126. 
Bergan, J.J., Schmid-Schonbein, G.W., and Takase, S. 2001. Therapeutic approach to 
chronic venous insufficiency and its complications: place of Daflon 500 mg. 
Angiology 52 Suppl 1: S43-47. 
Berger, J., Bailey, P., Biswas, C., Cullinan, C.A., Doebber, T.W., Hayes, N.S., Saperstein, 
R., Smith, R.G., and Leibowitz, M.D. 1996. Thiazolidinediones produce a 
conformational change in peroxisomal proliferator-activated receptor-gamma: 
binding and activation correlate with antidiabetic actions in db/db mice. 
Endocrinology 137(10): 4189-4195. 
Berger, J. and Moller, D.E. 2002. The mechanisms of action of PPARs. Annu Rev Med 53: 
409-435. 
Bhathena, S.J. and Velasquez, M.T. 2002. Beneficial role of dietary phytoestrogens in 
obesity and diabetes. Am J Clin Nutr 76(6): 1191-1201. 
Blanquart, C., Barbier, O., Fruchart, J.C., Staels, B., and Glineur, C. 2002. Peroxisome 
proliferator-activated receptor alpha (PPARalpha) turnover by the ubiquitin-
proteasome system controls the ligand-induced expression level of its target genes. 
J Biol Chem 277(40): 37254-37259. 
Blanquart, C., Mansouri, R., Fruchart, J.C., Staels, B., and Glineur, C. 2004a. Different 
ways to regulate the PPARalpha stability. Biochem Biophys Res Commun 319(2): 
663-670. 
Blanquart, C., Mansouri, R., Paumelle, R., Fruchart, J.C., Staels, B., and Glineur, C. 
2004b. The protein kinase C signaling pathway regulates a molecular switch 
between transactivation and transrepression activity of the peroxisome 
proliferator-activated receptor alpha. Mol Endocrinol 18(8): 1906-1918. 
Bloedon, L.T., Jeffcoat, A.R., Lopaczynski, W., Schell, M.J., Black, T.M., Dix, K.J., 
Thomas, B.F., Albright, C., Busby, M.G., Crowell, J.A., and Zeisel, S.H. 2002. 
Safety and pharmacokinetics of purified soy isoflavones: single-dose 
administration to postmenopausal women. Am J Clin Nutr 76(5): 1126-1137. 
Bosse, Y., Pascot, A., Dumont, M., Brochu, M., Prud'homme, D., Bergeron, J., Despres, 
J.P., and Vohl, M.C. 2002. Influences of the PPAR alpha-L162V polymorphism 
on plasma HDL(2)-cholesterol response of abdominally obese men treated with 
gemfibrozil. Genet Med 4(4): 311-315. 
Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W. 1996. Differential 
expression of peroxisome proliferator-activated receptors (PPARs): tissue 
 214
distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 
137(1): 354-366. 
Brisson, D., Ledoux, K., Bosse, Y., St-Pierre, J., Julien, P., Perron, P., Hudson, T.J., Vohl, 
M.C., and Gaudet, D. 2002. Effect of apolipoprotein E, peroxisome proliferator-
activated receptor alpha and lipoprotein lipase gene mutations on the ability of 
fenofibrate to improve lipid profiles and reach clinical guideline targets among 
hypertriglyceridemic patients. Pharmacogenetics 12(4): 313-320. 
Brown, J.D. and Plutzky, J. 2007. Peroxisome proliferator-activated receptors as 
transcriptional nodal points and therapeutic targets. Circulation 115(4): 518-533. 
Brown, P.J., Smith-Oliver, T.A., Charifson, P.S., Tomkinson, N.C., Fivush, A.M., 
Sternbach, D.D., Wade, L.E., Orband-Miller, L., Parks, D.J., Blanchard, S.G., 
Kliewer, S.A., Lehmann, J.M., and Willson, T.M. 1997. Identification of 
peroxisome proliferator-activated receptor ligands from a biased chemical library. 
Chem Biol 4(12): 909-918. 
Brown, P.J., Stuart, L.W., Hurley, K.P., Lewis, M.C., Winegar, D.A., Wilson, J.G., 
Wilkison, W.O., Ittoop, O.R., and Willson, T.M. 2001. Identification of a subtype 
selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med 
Chem Lett 11(9): 1225-1227. 
Brown, P.J., Winegar, D.A., Plunket, K.D., Moore, L.B., Lewis, M.C., Wilson, J.G., 
Sundseth, S.S., Koble, C.S., Wu, Z., Chapman, J.M., Lehmann, J.M., Kliewer, 
S.A., and Willson, T.M. 1999. A ureido-thioisobutyric acid (GW9578) is a 
subtype-selective PPARalpha agonist with potent lipid-lowering activity. J Med 
Chem 42(19): 3785-3788. 
Caira, F., Antonson, P., Pelto-Huikko, M., Treuter, E., and Gustafsson, J.A. 2000. 
Cloning and characterization of RAP250, a novel nuclear receptor coactivator. J 
Biol Chem 275(8): 5308-5317. 
Chambon, P. 2005. The nuclear receptor superfamily: a personal retrospect on the first 
two decades. Mol Endocrinol 19(6): 1418-1428. 
Chan, E., Tan, C.S., Deurenberg-Yap, M., Chia, K.S., Chew, S.K., and Tai, E.S. 2006. 
The V227A polymorphism at the PPARA locus is associated with serum lipid 
concentrations and modulates the association between dietary polyunsaturated 
fatty acid intake and serum high density lipoprotein concentrations in Chinese 
women. Atherosclerosis 187(2): 309-315. 
Chan, M.Y., Wai Man, G., Chen, Z.Y., Wang, J., and Leung, L.K. 2007. Oestrogen 
receptor alpha is required for biochanin A-induced apolipoprotein A-1 mRNA 
expression in HepG2 cells. Br J Nutr: 1-6. 
Chapman, T. 2004. Drug discovery: the leading edge. Nature 430(6995): 109-115. 
Chawla, A., Schwarz, E.J., Dimaculangan, D.D., and Lazar, M.A. 1994. Peroxisome 
proliferator-activated receptor (PPAR) gamma: adipose-predominant expression 
and induction early in adipocyte differentiation. Endocrinology 135(2): 798-800. 
Chen, H., Lin, R.J., Schiltz, R.L., Chakravarti, D., Nash, A., Nagy, L., Privalsky, M.L., 
Nakatani, Y., and Evans, R.M. 1997. Nuclear receptor coactivator ACTR is a 
novel histone acetyltransferase and forms a multimeric activation complex with 
P/CAF and CBP/p300. Cell 90(3): 569-580. 
Chen, J.D. and Evans, R.M. 1995. A transcriptional co-repressor that interacts with 
nuclear hormone receptors. Nature 377(6548): 454-457. 
 215
Chen, S.B., Liu, H.P., Tian, R.T., Yang, D.J., Chen, S.L., Xu, H.X., Chan, A.S., and Xie, 
P.S. 2006. High-performance thin-layer chromatographic fingerprints of 
isoflavonoids for distinguishing between Radix Puerariae Lobate and Radix 
Puerariae Thomsonii. J Chromatogr A 1121(1): 114-119. 
Chen, S.B., Yang, D.J., Chen, S.L., Xu, H.X., and Chan, A.S. 2007. Seasonal variations 
in the isoflavonoids of Radix Puerariae. Phytochemical Analysis 18: 245-250. 
Cheung, C., Akiyama, T.E., Ward, J.M., Nicol, C.J., Feigenbaum, L., Vinson, C., and 
Gonzalez, F.J. 2004. Diminished hepatocellular proliferation in mice humanized 
for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer 
Res 64(11): 3849-3854. 
Chinese Pharmacopoeia Committee. 2005. Radix Puerariae. The Chinese Pharmacopoeia: 
Vol 1. Chemical Industry Publishing House: Beijing: 233-234. 
Chinetti, G., Gbaguidi, F.G., Griglio, S., Mallat, Z., Antonucci, M., Poulain, P., Chapman, 
J., Fruchart, J.C., Tedgui, A., Najib-Fruchart, J., and Staels, B. 2000. CLA-1/SR-
BI is expressed in atherosclerotic lesion macrophages and regulated by activators 
of peroxisome proliferator-activated receptors. Circulation 101(20): 2411-2417. 
Chinetti, G., Lestavel, S., Bocher, V., Remaley, A.T., Neve, B., Torra, I.P., Teissier, E., 
Minnich, A., Jaye, M., Duverger, N., Brewer, H.B., Fruchart, J.C., Clavey, V., 
and Staels, B. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol 
removal from human macrophage foam cells through stimulation of the ABCA1 
pathway. Nat Med 7(1): 53-58. 
Chui, P.C., Guan, H.P., Lehrke, M., and Lazar, M.A. 2005. PPARgamma regulates 
adipocyte cholesterol metabolism via oxidized LDL receptor 1. J Clin Invest 
115(8): 2244-2256. 
Cohen, R.N., Brzostek, S., Kim, B., Chorev, M., Wondisford, F.E., and Hollenberg, A.N. 
2001. The specificity of interactions between nuclear hormone receptors and 
corepressors is mediated by distinct amino acid sequences within the interacting 
domains. Mol Endocrinol 15(7): 1049-1061. 
Cohen, R.N., Putney, A., Wondisford, F.E., and Hollenberg, A.N. 2000. The nuclear 
corepressors recognize distinct nuclear receptor complexes. Mol Endocrinol 14(6): 
900-914. 
Cohen, R.N., Wondisford, F.E., and Hollenberg, A.N. 1998. Two separate NCoR 
(nuclear receptor corepressor) interaction domains mediate corepressor action on 
thyroid hormone response elements. Mol Endocrinol 12(10): 1567-1581. 
Committee, N.R.N. 1999. A unified nomenclature system for the nuclear receptor 
superfamily. Cell 97(2): 161-163. 
Corella, D. and Ordovas, J.M. 2005. Single nucleotide polymorphisms that influence 
lipid metabolism: Interaction with Dietary Factors. Annu Rev Nutr 25: 341-390. 
Costet, P., Legendre, C., More, J., Edgar, A., Galtier, P., and Pineau, T. 1998. 
Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to 
progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol 
Chem 273(45): 29577-29585. 
Dang, Z. and Lowik, C.W. 2004. The balance between concurrent activation of ERs and 
PPARs determines daidzein-induced osteogenesis and adipogenesis. J Bone 
Miner Res 19(5): 853-861. 
 216
Dang, Z.C., Audinot, V., Papapoulos, S.E., Boutin, J.A., and Lowik, C.W. 2003. 
Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular 
target for the soy phytoestrogen genistein. J Biol Chem 278(2): 962-967. 
Darimont, B.D., Wagner, R.L., Apriletti, J.W., Stallcup, M.R., Kushner, P.J., Baxter, J.D., 
Fletterick, R.J., and Yamamoto, K.R. 1998. Structure and specificity of nuclear 
receptor-coactivator interactions. Genes Dev 12(21): 3343-3356. 
Davis, T. 2002. Tesaglitazar AstraZeneca. IDrugs 5(9): 924-926. 
De Vos, P., Lefebvre, A.M., Miller, S.G., Guerre-Millo, M., Wong, K., Saladin, R., 
Hamann, L.G., Staels, B., Briggs, M.R., and Auwerx, J. 1996. Thiazolidinediones 
repress ob gene expression in rodents via activation of peroxisome proliferator-
activated receptor gamma. J Clin Invest 98(4): 1004-1009. 
Degenhardt, T., Matilainen, M., Herzig, K.H., Dunlop, T.W., and Carlberg, C. 2006. The 
insulin-like growth factor-binding protein 1 gene is a primary target of 
peroxisome proliferator-activated receptors. J Biol Chem 281(51): 39607-39619. 
Delmonte, P. and Rader, J.I. 2006. Analysis of isoflavones in foods and dietary 
supplements. J AOAC Int 89(4): 1138-1146. 
Desvergne, B., Michalik, L., and Wahli, W. 2006. Transcriptional regulation of 
metabolism. Physiol Rev 86(2): 465-514. 
Desvergne, B. and Wahli, W. 1999. Peroxisome proliferator-activated receptors: nuclear 
control of metabolism. Endocr Rev 20(5): 649-688. 
Devasthale, P.V., Chen, S., Jeon, Y., Qu, F., Shao, C., Wang, W., Zhang, H., Cap, M., 
Farrelly, D., Golla, R., Grover, G., Harrity, T., Ma, Z., Moore, L., Ren, J., 
Seethala, R., Cheng, L., Sleph, P., Sun, W., Tieman, A., Wetterau, J.R., Doweyko, 
A., Chandrasena, G., Chang, S.Y., Humphreys, W.G., Sasseville, V.G., Biller, 
S.A., Ryono, D.E., Selan, F., Hariharan, N., and Cheng, P.T. 2005. Design and 
synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel 
peroxisome proliferator-activated receptor alpha/gamma dual agonist with 
efficacious glucose and lipid-lowering activities. J Med Chem 48(6): 2248-2250. 
Devchand, P.R., Keller, H., Peters, J.M., Vazquez, M., Gonzalez, F.J., and Wahli, W. 
1996. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 
384(6604): 39-43. 
Ding, X.F., Anderson, C.M., Ma, H., Hong, H., Uht, R.M., Kushner, P.J., and Stallcup, 
M.R. 1998. Nuclear receptor-binding sites of coactivators glucocorticoid receptor 
interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple 
motifs with different binding specificities. Mol Endocrinol 12(2): 302-313. 
DiRenzo, J., Soderstrom, M., Kurokawa, R., Ogliastro, M.H., Ricote, M., Ingrey, S., 
Horlein, A., Rosenfeld, M.G., and Glass, C.K. 1997. Peroxisome proliferator-
activated receptors and retinoic acid receptors differentially control the 
interactions of retinoid X receptor heterodimers with ligands, coactivators, and 
corepressors. Mol Cell Biol 17(4): 2166-2176. 
Djouadi, F., Weinheimer, C.J., Saffitz, J.E., Pitchford, C., Bastin, J., Gonzalez, F.J., and 
Kelly, D.P. 1998. A gender-related defect in lipid metabolism and glucose 
homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice. J 
Clin Invest 102(6): 1083-1091. 
 217
Dowell, P., Ishmael, J.E., Avram, D., Peterson, V.J., Nevrivy, D.J., and Leid, M. 1997a. 
p300 functions as a coactivator for the peroxisome proliferator-activated receptor 
alpha. J Biol Chem 272(52): 33435-33443. 
Dowell, P., Peterson, V.J., Zabriskie, T.M., and Leid, M. 1997b. Ligand-induced 
peroxisome proliferator-activated receptor alpha conformational change. J Biol 
Chem 272(3): 2013-2020. 
Dowell, P., Ishmael, J.E., Avram, D., Peterson,V.J., Nevrivy, D.J., and Leid, M. 1999. 
Identification of nuclear receptor corepressor as a peroxisome proliferator-
activated receptor alpha interacting protein. J Biol Chem 274(22): 15901-15907. 
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., and Wahli, W. 1992. Control 
of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone 
receptors. Cell 68(5): 879-887. 
Duez, H., Lefebvre, B., Poulain, P., Torra, I.P., Percevault, F., Luc, G., Peters, J.M., 
Gonzalez, F.J., Gineste, R., Helleboid, S., Dzavik, V., Fruchart, J.C., Fievet, C., 
Lefebvre, P., and Staels, B. 2005. Regulation of human apoA-I by gemfibrozil 
and fenofibrate through selective peroxisome proliferator-activated receptor alpha 
modulation. Arterioscler Thromb Vasc Biol 25(3): 585-591. 
Dunn, S.E., Ousman, S.S., Sobel, R.A., Zuniga, L., Baranzini, S.E., Youssef, S., Crowell, 
A., Loh, J., Oksenberg, J., and Steinman, L. 2007. Peroxisome proliferator-
activated receptor (PPAR)alpha expression in T cells mediates gender differences 
in development of T cell-mediated autoimmunity. J Exp Med 204(2): 321-330. 
Duval, C., Muller, M., and Kersten, S. 2007. PPARalpha and dyslipidemia. Biochim 
Biophys Acta 1771(8): 961-971. 
Eckel, R.H., Grundy, S.M., and Zimmet, P.Z. 2005. The metabolic syndrome. Lancet 
365(9468): 1415-1428. 
Elbrecht, A., Chen, Y., Adams, A., Berger, J., Griffin, P., Klatt, T., Zhang, B., Menke, J., 
Zhou, G., Smith, R.G., and Moller, D.E. 1999. L-764406 is a partial agonist of 
human peroxisome proliferator-activated receptor gamma. The role of Cys313 in 
ligand binding. J Biol Chem 274(12): 7913-7922. 
Elbrecht, A., Chen, Y., Cullinan, C.A., Hayes, N., Leibowitz, M., Moller, D.E., and 
Berger, J. 1996. Molecular cloning, expression and characterization of human 
peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem 
Biophys Res Commun 224(2): 431-437. 
Erdman, J.W., Jr., Balentine, D., Arab, L., Beecher, G., Dwyer, J.T., Folts, J., Harnly, J., 
Hollman, P., Keen, C.L., Mazza, G., Messina, M., Scalbert, A., Vita, J., 
Williamson, G., and Burrowes, J. 2007. Flavonoids and Heart Health: proceedings 
of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, 
Washington, DC. J Nutr 137(3): 718S-737S. 
Eriksson, M., Carlson, L.A., Miettinen, T.A., and Angelin, B. 1999. Stimulation of fecal 
steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential 
reverse cholesterol transport in humans. Circulation 100(6): 594-598. 
Evans, D., Aberle, J., Wendt, D., Wolf, A., Beisiegel, U., and Mann, W.A. 2001. A 
polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha 
(PPARalpha) gene is associated with lower body mass index in patients with non-
insulin-dependent diabetes mellitus. J Mol Med 79(4): 198-204. 
 218
Evans, R.M. 2005. The nuclear receptor superfamily: a rosetta stone for physiology. Mol 
Endocrinol 19(6): 1429-1438. 
Fagerberg, B., Edwards, S., Halmos, T., Lopatynski, J., Schuster, H., Stender, S., Stoa-
Birketvedt, G., Tonstad, S., Halldorsdottir, S., and Gause-Nilsson, I. 2005. 
Tesaglitazar, a novel dual peroxisome proliferator-activated receptor 
alpha/gamma agonist, dose-dependently improves the metabolic abnormalities 
associated with insulin resistance in a non-diabetic population. Diabetologia 48(9): 
1716-1725. 
Feige, J.N., Gelman, L., Michalik, L., Desvergne, B., and Wahli, W. 2006. From 
molecular action to physiological outputs: peroxisome proliferator-activated 
receptors are nuclear receptors at the crossroads of key cellular functions. Prog 
Lipid Res 45(2): 120-159. 
Feige, J.N., Gelman, L., Tudor, C., Engelborghs, Y., Wahli, W., and Desvergne, B. 2005. 
Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-
activated receptor/retinoid X receptor heterodimers in the absence and presence of 
ligand. J Biol Chem 280(18): 17880-17890. 
Fernandes, I., Bastien, Y., Wai, T., Nygard, K., Lin, R., Cormier, O., Lee, H.S., Eng, F., 
Bertos, N.R., Pelletier, N., Mader, S., Han, V.K., Yang, X.J., and White, J.H. 
2003. Ligand-dependent nuclear receptor corepressor LCoR functions by histone 
deacetylase-dependent and -independent mechanisms. Mol Cell 11(1): 139-150. 
Fievet, C., Fruchart, J.C., and Staels, B. 2006. PPARalpha and PPARgamma dual 
agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr 
Opin Pharmacol 6(6): 606-614. 
Flavell, D.M., Jamshidi, Y., Hawe, E., Pineda Torra, I., Taskinen, M.R., Frick, M.H., 
Nieminen, M.S., Kesaniemi, Y.A., Pasternack, A., Staels, B., Miller, G., 
Humphries, S.E., Talmud, P.J., and Syvanne, M. 2002. Peroxisome proliferator-
activated receptor alpha gene variants influence progression of coronary 
atherosclerosis and risk of coronary artery disease. Circulation 105(12): 1440-
1445. 
Flavell, D.M., Pineda Torra, I., Jamshidi, Y., Evans, D., Diamond, J.R., Elkeles, R.S., 
Bujac, S.R., Miller, G., Talmud, P.J., Staels, B., and Humphries, S.E. 2000. 
Variation in the PPARalpha gene is associated with altered function in vitro and 
plasma lipid concentrations in Type II diabetic subjects. Diabetologia 43(5): 673-
680. 
Floyd, Z.E. and Stephens, J.M. 2002. Interferon-gamma-mediated activation and 
ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J 
Biol Chem 277(6): 4062-4068. 
Forman, B.M., Chen, J., and Evans, R.M. 1997. Hypolipidemic drugs, polyunsaturated 
fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated 
receptors alpha and delta. Proc Natl Acad Sci U S A 94(9): 4312-4317. 
Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, B.M., and Evans, R.M. 
1995a. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte 
determination factor PPAR gamma. Cell 83(5): 803-812. 
Forman, B.M., Umesono, K., Chen, J., and Evans, R.M. 1995b. Unique response 
pathways are established by allosteric interactions among nuclear hormone 
receptors. Cell 81(4): 541-550. 
 219
Fruchart, J.C. 2001. Peroxisome proliferator-activated receptor-alpha activation and high-
density lipoprotein metabolism. Am J Cardiol 88(12A): 24N-29N. 
Fruchart, J.C. and Duriez, P. 2006. Mode of action of fibrates in the regulation of 
triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 42(1): 39-64. 
Fu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodriguez De Fonseca, F., 
Rosengarth, A., Luecke, H., Di Giacomo, B., Tarzia, G., and Piomelli, D. 2003. 
Oleylethanolamide regulates feeding and body weight through activation of the 
nuclear receptor PPAR-alpha. Nature 425(6953): 90-93. 
Fyffe, S.A., Alphey, M.S., Buetow, L., Smith, T.K., Ferguson, M.A., Sorensen, M.D., 
Bjorkling, F., and Hunter, W.N. 2006. Recombinant human PPAR-beta/delta 
ligand-binding domain is locked in an activated conformation by endogenous 
fatty acids. J Mol Biol 356(4): 1005-1013. 
Gampe, R.T., Jr., Montana, V.G., Lambert, M.H., Miller, A.B., Bledsoe, R.K., Milburn, 
M.V., Kliewer, S.A., Willson, T.M., and Xu, H.E. 2000. Asymmetry in the 
PPARgamma/RXRalpha crystal structure reveals the molecular basis of 
heterodimerization among nuclear receptors. Mol Cell 5(3): 545-555. 
Gearing, K.L., Gottlicher, M., Teboul, M., Widmark, E., and Gustafsson, J.A. 1993. 
Interaction of the peroxisome-proliferator-activated receptor and retinoid X 
receptor. Proc Natl Acad Sci U S A 90(4): 1440-1444. 
Gelman, L., Feige, J.N., Tudor, C., Engelborghs, Y., Wahli, W., and Desvergne, B. 2006. 
Integrating nuclear receptor mobility in models of gene regulation. Nucl Recept 
Signal 4: e010. 
Gelman, L., Michalik, L., Desvergne, B., and Wahli, W. 2005. Kinase signaling cascades 
that modulate peroxisome proliferator-activated receptors. Curr Opin Cell Biol 
17(2): 216-222. 
Germain, P., Staels, B., Dacquet, C., Spedding, M., and Laudet, V. 2006. Overview of 
nomenclature of nuclear receptors. Pharmacol Rev 58(4): 685-704. 
Gervois, P., Chopin-Delannoy, S., Fadel, A., Dubois, G., Kosykh, V., Fruchart, J.C., 
Najib, J., Laudet, V., and Staels, B. 1999a. Fibrates increase human REV-
ERBalpha expression in liver via a novel peroxisome proliferator-activated 
receptor response element. Mol Endocrinol 13(3): 400-409. 
Gervois, P., Fruchart, J.C., and Staels, B. 2007. Drug Insight: mechanisms of action and 
therapeutic applications for agonists of peroxisome proliferator-activated 
receptors. Nat Clin Pract Endocrinol Metab 3(2): 145-156. 
Gervois, P., Torra, I.P., Chinetti, G., Grotzinger, T., Dubois, G., Fruchart, J.C., Fruchart-
Najib, J., Leitersdorf, E., and Staels, B. 1999b. A truncated human peroxisome 
proliferator-activated receptor alpha splice variant with dominant negative activity. 
Mol Endocrinol 13(9): 1535-1549. 
Gervois, P., Vu-Dac, N., Kleemann, R., Kockx, M., Dubois, G., Laine, B., Kosykh, V., 
Fruchart, J.C., Kooistra, T., and Staels, B. 2001. Negative regulation of human 
fibrinogen gene expression by peroxisome proliferator-activated receptor alpha 
agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol 
Chem 276(36): 33471-33477. 
Giguere, V., McBroom, L.D., and Flock, G. 1995. Determinants of target gene specificity 
for ROR alpha 1: monomeric DNA binding by an orphan nuclear receptor. Mol 
Cell Biol 15(5): 2517-2526. 
 220
Glass, C.K. 1994. Differential recognition of target genes by nuclear receptor monomers, 
dimers, and heterodimers. Endocr Rev 15(3): 391-407. 
Gonzalez, S., Jayagopal, V., Kilpatrick, E.S., Chapman, T., and Atkin, S.L. 2007. Effects 
of isoflavone dietary supplementation on cardiovascular risk factors in type 2 
diabetes. Diabetes Care 30(7): 1871-1873. 
Goodman-Gruen, D. and Kritz-Silverstein, D. 2001. Usual dietary isoflavone intake is 
associated with cardiovascular disease risk factors in postmenopausal women. J 
Nutr 131(4): 1202-1206. 
Goodson, M., Jonas, B.A., and Privalsky, M.A. 2005. Corepressors: custom tailoring and 
alterations while you wait. Nucl Recept Signal 3: e003. 
Gottlicher, M., Widmark, E., Li, Q., and Gustafsson, J.A. 1992. Fatty acids activate a 
chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. 
Proc Natl Acad Sci U S A 89(10): 4653-4657. 
Gouni-Berthold, I., Giannakidou, E., Muller-Wieland, D., Faust, M., Kotzka, J., Berthold, 
H.K., and Krone, W. 2004. Association between the PPARalpha L162V 
polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients 
with diabetes mellitus type 2 and in nondiabetic controls. Am Heart J 147(6): 
1117-1124. 
Gray, J.P., Burns, K.A., Leas, T.L., Perdew, G.H., and Vanden Heuvel, J.P. 2005. 
Regulation of peroxisome proliferator-activated receptor alpha by protein kinase 
C. Biochemistry 44(30): 10313-10321. 
Gray, J.P., Davis, J.W., 2nd, Gopinathan, L., Leas, T.L., Nugent, C.A., and Vanden 
Heuvel, J.P. 2006. The ribosomal protein rpL11 associates with and inhibits the 
transcriptional activity of peroxisome proliferator-activated receptor-alpha. 
Toxicol Sci 89(2): 535-546. 
Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J.M., Argos, P., and Chambon, P. 
1986. Human oestrogen receptor cDNA: sequence, expression and homology to 
v-erb-A. Nature 320(6058): 134-139. 
Greene, G.L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., and Shine, J. 1986. 
Sequence and expression of human estrogen receptor complementary DNA. 
Science 231(4742): 1150-1154. 
Gremlich, S., Nolan, C., Roduit, R., Burcelin, R., Peyot, M.L., Delghingaro-Augusto, V., 
Desvergne, B., Michalik, L., Prentki, M., and Wahli, W. 2005. Pancreatic islet 
adaptation to fasting is dependent on peroxisome proliferator-activated receptor 
alpha transcriptional up-regulation of fatty acid oxidation. Endocrinology 146(1): 
375-382. 
Gronemeyer, H., Gustafsson, J.A., and Laudet, V. 2004. Principles for modulation of the 
nuclear receptor superfamily. Nat Rev Drug Discov 3(11): 950-964. 
Grossman, S.R., Deato, M.E., Brignone, C., Chan, H.M., Kung, A.L., Tagami, H., 
Nakatani, Y., and Livingston, D.M. 2003. Polyubiquitination of p53 by a 
ubiquitin ligase activity of p300. Science 300(5617): 342-344. 
Guan, H.P., Ishizuka, T., Chui, P.C., Lehrke, M., and Lazar, M.A. 2005. Corepressors 
selectively control the transcriptional activity of PPARgamma in adipocytes. 
Genes Dev 19(4): 453-461. 
 221
Gulick, T., Cresci, S., Caira, T., Moore, D.D., and Kelly, D.P. 1994. The peroxisome 
proliferator-activated receptor regulates mitochondrial fatty acid oxidative 
enzyme gene expression. Proc Natl Acad Sci U S A 91(23): 11012-11016. 
Gurnell, M., Wentworth, J.M., Agostini, M., Adams, M., Collingwood, T.N., Provenzano, 
C., Browne, P.O., Rajanayagam, O., Burris, T.P., Schwabe, J.W., Lazar, M.A., 
and Chatterjee, V.K. 2000. A dominant-negative peroxisome proliferator-
activated receptor gamma (PPARgamma) mutant is a constitutive repressor and 
inhibits PPARgamma-mediated adipogenesis. J Biol Chem 275(8): 5754-5759. 
Hall, W.L., Vafeiadou, K., Hallund, J., Bugel, S., Reimann, M., Koebnick, C., Zunft, H.J., 
Ferrari, M., Branca, F., Dadd, T., Talbot, D., Powell, J., Minihane, A.M., Cassidy, 
A., Nilsson, M., Dahlman-Wright, K., Gustafsson, J.A., and Williams, C.M. 2006. 
Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in 
postmenopausal women: interactions with genotype and equol production. Am J 
Clin Nutr 83(3): 592-600. 
Haluzik, M.M. and Haluzik, M. 2006. PPAR-alpha and insulin sensitivity. Physiol Res 
55(2): 115-122. 
Hara, M., Wang, X., Paz, V.P., Iwasaki, N., Honda, M., Iwamoto, Y., and Bell, G.I. 2001. 
Identification of three missense mutations in the peroxisome proliferator-activated 
receptor alpha gene in Japanese subjects with maturity-onset diabetes of the 
young. J Hum Genet 46(5): 285-288. 
Harding, H.P. and Lazar, M.A. 1995. The monomer-binding orphan receptor Rev-Erb 
represses transcription as a dimer on a novel direct repeat. Mol Cell Biol 15(9): 
4791-4802. 
Hauser, S., Adelmant, G., Sarraf, P., Wright, H.M., Mueller, E., and Spiegelman, B.M. 
2000. Degradation of the peroxisome proliferator-activated receptor gamma is 
linked to ligand-dependent activation. J Biol Chem 275(24): 18527-18533. 
He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, 
J.M., and Evans, R.M. 2003. Adipose-specific peroxisome proliferator-activated 
receptor gamma knockout causes insulin resistance in fat and liver but not in 
muscle. Proc Natl Acad Sci U S A 100(26): 15712-15717. 
Hegardt, F.G. 1999. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control 
enzyme in ketogenesis. Biochem J 338 (Pt 3): 569-582. 
Heinzel, T., Lavinsky, R.M., Mullen, T.M., Soderstrom, M., Laherty, C.D., Torchia, J., 
Yang, W.M., Brard, G., Ngo, S.D., Davie, J.R., Seto, E., Eisenman, R.N., Rose, 
D.W., Glass, C.K., and Rosenfeld, M.G. 1997. A complex containing N-CoR, 
mSin3 and histone deacetylase mediates transcriptional repression. Nature 
387(6628): 43-48. 
Hennuyer, N., Poulain, P., Madsen, L., Berge, R.K., Houdebine, L.M., Branellec, D., 
Fruchart, J.C., Fievet, C., Duverger, N., and Staels, B. 1999. Beneficial effects of 
fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome 
proliferative response. Circulation 99(18): 2445-2451. 
Hermansen, K., Sondergaard, M., Hoie, L., Carstensen, M., and Brock, B. 2001. 
Beneficial effects of a soy-based dietary supplement on lipid levels and 
cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 24(2): 228-
233. 
 222
Hermanson, O., Jepsen, K., and Rosenfeld, M.G. 2002. N-CoR controls differentiation of 
neural stem cells into astrocytes. Nature 419(6910): 934-939. 
Hi, R., Osada, S., Yumoto, N., and Osumi, T. 1999. Characterization of the amino-
terminal activation domain of peroxisome proliferator-activated receptor alpha. 
Importance of alpha-helical structure in the transactivating function. J Biol Chem 
274(49): 35152-35158. 
Hirotani, M., Tsukamoto, T., Bourdeaux, J., Sadano, H., and Osumi, T. 2001. 
Stabilization of peroxisome proliferator-activated receptor alpha by the ligand. 
Biochem Biophys Res Commun 288(1): 106-110. 
Hofmann, C., Lorenz, K., Braithwaite, S.S., Colca, J.R., Palazuk, B.J., Hotamisligil, G.S., 
and Spiegelman, B.M. 1994. Altered gene expression for tumor necrosis factor-
alpha and its receptors during drug and dietary modulation of insulin resistance. 
Endocrinology 134(1): 264-270. 
Hollenberg, S.M., Weinberger, C., Ong, E.S., Cerelli, G., Oro, A., Lebo, R., Thompson, 
E.B., Rosenfeld, M.G., and Evans, R.M. 1985. Primary structure and expression 
of a functional human glucocorticoid receptor cDNA. Nature 318(6047): 635-641. 
Horlein, A.J., Naar, A.M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., 
Kamei, Y., Soderstrom, M., Glass, C.K., and et al. 1995. Ligand-independent 
repression by the thyroid hormone receptor mediated by a nuclear receptor co-
repressor. Nature 377(6548): 397-404. 
Hsu, F.L., Liu, I.M., Kuo, D.H., Chen, W.C., Su, H.C., and Cheng, J.T. 2003. 
Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats. J 
Nat Prod 66(6): 788-792. 
Hu, E., Kim, J.B., Sarraf, P., and Spiegelman, B.M. 1996. Inhibition of adipogenesis 
through MAP kinase-mediated phosphorylation of PPARgamma. Science 
274(5295): 2100-2103. 
Hu, X. and Lazar, M.A. 1999. The CoRNR motif controls the recruitment of corepressors 
by nuclear hormone receptors. Nature 402(6757): 93-96. 
Hu, X., Li, Y., and Lazar, M.A. 2001. Determinants of CoRNR-dependent repression 
complex assembly on nuclear hormone receptors. Mol Cell Biol 21(5): 1747-1758. 
Huber, B.R., Desclozeaux, M., West, B.L., Cunha-Lima, S.T., Nguyen, H.T., Baxter, J.D., 
Ingraham, H.A., and Fletterick, R.J. 2003. Thyroid hormone receptor-beta 
mutations conferring hormone resistance and reduced corepressor release exhibit 
decreased stability in the N-terminal ligand-binding domain. Mol Endocrinol 
17(1): 107-116. 
Hummasti, S. and Tontonoz, P. 2006. The peroxisome proliferator-activated receptor N-
terminal domain controls isotype-selective gene expression and adipogenesis. Mol 
Endocrinol 20(6): 1261-1275. 
Humphries, S.E., Ridker, P.M., and Talmud, P.J. 2004. Genetic testing for cardiovascular 
disease susceptibility: a useful clinical management tool or possible 
misinformation? Arterioscler Thromb Vasc Biol 24(4): 628-636. 
Huppertz, C., Fischer, B.M., Kim, Y.B., Kotani, K., Vidal-Puig, A., Slieker, L.J., Sloop, 
K.W., Lowell, B.B., and Kahn, B.B. 2001. Uncoupling protein 3 (UCP3) 
stimulates glucose uptake in muscle cells through a phosphoinositide 3-kinase-
dependent mechanism. J Biol Chem 276(16): 12520-12529. 
 223
IJpenberg, A., Jeannin, E., Wahli, W., and Desvergne, B. 1997. Polarity and specific 
sequence requirements of peroxisome proliferator-activated receptor 
(PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of 
the malic enzyme gene PPAR response element. J Biol Chem 272(32): 20108-
20117. 
IJpenberg, A., Tan, N.S., Gelman, L., Kersten, S., Seydoux, J., Xu, J., Metzger, D., 
Canaple, L., Chambon, P., Wahli, W., and Desvergne, B. 2004. In vivo activation 
of PPAR target genes by RXR homodimers. Embo J 23(10): 2083-2091. 
Imhof, A. 2003. Histone modifications: an assembly line for active chromatin? Curr Biol 
13(1): R22-24. 
Issemann, I. and Green, S. 1990. Activation of a member of the steroid hormone receptor 
superfamily by peroxisome proliferators. Nature 347(6294): 645-650. 
Iwaki, M., Matsuda, M., Maeda, N., Funahashi, T., Matsuzawa, Y., Makishima, M., and 
Shimomura, I. 2003. Induction of adiponectin, a fat-derived antidiabetic and 
antiatherogenic factor, by nuclear receptors. Diabetes 52(7): 1655-1663. 
Jackson, T.A., Richer, J.K., Bain, D.L., Takimoto, G.S., Tung, L., and Horwitz, K.B. 
1997. The partial agonist activity of antagonist-occupied steroid receptors is 
controlled by a novel hinge domain-binding coactivator L7/SPA and the 
corepressors N-CoR or SMRT. Mol Endocrinol 11(6): 693-705. 
Jalouli, M., Carlsson, L., Ameen, C., Linden, D., Ljungberg, A., Michalik, L., Eden, S., 
Wahli, W., and Oscarsson, J. 2003. Sex difference in hepatic peroxisome 
proliferator-activated receptor alpha expression: influence of pituitary and 
gonadal hormones. Endocrinology 144(1): 101-109. 
Jaradat, M.S., Wongsud, B., Phornchirasilp, S., Rangwala, S.M., Shams, G., Sutton, M., 
Romstedt, K.J., Noonan, D.J., and Feller, D.R. 2001. Activation of peroxisome 
proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) 
synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 62(12): 
1587-1595. 
Jayagopal, V., Albertazzi, P., Kilpatrick, E.S., Howarth, E.M., Jennings, P.E., Hepburn, 
D.A., and Atkin, S.L. 2002. Beneficial effects of soy phytoestrogen intake in 
postmenopausal women with type 2 diabetes. Diabetes Care 25(10): 1709-1714. 
Jenster, G., Spencer, T.E., Burcin, M.M., Tsai, S.Y., Tsai, M.J., and O'Malley, B.W. 1997. 
Steroid receptor induction of gene transcription: a two-step model. Proc Natl 
Acad Sci U S A 94(15): 7879-7884. 
Jenuwein, T. and Allis, C.D. 2001. Translating the histone code. Science 293(5532): 
1074-1080. 
Jia, Y., Qi, C., Kashireddi, P., Surapureddi, S., Zhu, Y.J., Rao, M.S., Le Roith, D., 
Chambon, P., Gonzalez, F.J., and Reddy, J.K. 2004. Transcription coactivator 
PBP, the peroxisome proliferator-activated receptor (PPAR)-binding protein, is 
required for PPARalpha-regulated gene expression in liver. J Biol Chem 279(23): 
24427-24434. 
Jiang, R.W., Lau, K.M., Lam, H.M., Yam, W.S., Leung, L.K., Choi, K.L., Waye, M.M., 
Mak, T.C., Woo, K.S., and Fung, K.P. 2005. A comparative study on aqueous 
root extracts of Pueraria thomsonii and Pueraria lobata by antioxidant assay and 
HPLC fingerprint analysis. J Ethnopharmacol 96(1-2): 133-138. 
 224
Jonas, B.A. and Privalsky, M.L. 2004. SMRT and N-CoR corepressors are regulated by 
distinct kinase signaling pathways. J Biol Chem 279(52): 54676-54686. 
Jones, D.C., Ding, X., and Daynes, R.A. 2002. Nuclear receptor peroxisome proliferator-
activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. 
The PPARalpha in T and B lymphocytes is both transactivation and 
transrepression competent. J Biol Chem 277(9): 6838-6845. 
Jones, D.C., Ding, X., Zhang, T.Y., and Daynes, R.A. 2003. Peroxisome proliferator-
activated receptor alpha negatively regulates T-bet transcription through 
suppression of p38 mitogen-activated protein kinase activation. J Immunol 171(1): 
196-203. 
Juge-Aubry, C., Pernin, A., Favez, T., Burger, A.G., Wahli, W., Meier, C.A., and 
Desvergne, B. 1997. DNA binding properties of peroxisome proliferator-activated 
receptor subtypes on various natural peroxisome proliferator response elements. 
Importance of the 5'-flanking region. J Biol Chem 272(40): 25252-25259. 
Juge-Aubry, C.E., Hammar, E., Siegrist-Kaiser, C., Pernin, A., Takeshita, A., Chin, 
W.W., Burger, A.G., and Meier, C.A. 1999. Regulation of the transcriptional 
activity of the peroxisome proliferator-activated receptor alpha by 
phosphorylation of a ligand-independent trans-activating domain. J Biol Chem 
274(15): 10505-10510. 
Jung, M., Park, M., Lee, H.C., Kang, Y.H., Kang, E.S., and Kim, S.K. 2006. Antidiabetic 
agents from medicinal plants. Curr Med Chem 13(10): 1203-1218. 
Kalkhoven, E. 2004. CBP and p300: HATs for different occasions. Biochem Pharmacol 
68(6): 1145-1155. 
Kallen, C.B. and Lazar, M.A. 1996. Antidiabetic thiazolidinediones inhibit leptin (ob) 
gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 93(12): 5793-
5796. 
Kartal, M. 2007. Intellectual property protection in the natural product drug discovery, 
traditional herbal medicine and herbal medicinal products. Phytother Res 21(2): 
113-119. 
Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., and Wahli, W. 1993. Fatty 
acids and retinoids control lipid metabolism through activation of peroxisome 
proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad 
Sci U S A 90(6): 2160-2164. 
Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne, B., and Wahli, W. 1999. 
Peroxisome proliferator-activated receptor alpha mediates the adaptive response 
to fasting. J Clin Invest 103(11): 1489-1498. 
Kim, S., Shin, H.J., Kim, S.Y., Kim, J.H., Lee, Y.S., Kim, D.H., and Lee, M.O. 2004. 
Genistein enhances expression of genes involved in fatty acid catabolism through 
activation of PPARalpha. Mol Cell Endocrinol 220(1-2): 51-58. 
King, R.A. and Bursill, D.B. 1998. Plasma and urinary kinetics of the isoflavones 
daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 67(5): 
867-872. 
Kirk, E.A., Sutherland, P., Wang, S.A., Chait, A., and LeBoeuf, R.C. 1998. Dietary 
isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but 
not LDL receptor-deficient mice. J Nutr 128(6): 954-959. 
 225
Klein, F.A., Atkinson, R.A., Potier, N., Moras, D., and Cavarelli, J. 2005. Biochemical 
and NMR mapping of the interface between CREB-binding protein and ligand 
binding domains of nuclear receptor: beyond the LXXLL motif. J Biol Chem 
280(7): 5682-5692. 
Kliewer, S.A., Forman, B.M., Blumberg, B., Ong, E.S., Borgmeyer, U., Mangelsdorf, 
D.J., Umesono, K., and Evans, R.M. 1994. Differential expression and activation 
of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad 
Sci U S A 91(15): 7355-7359. 
Kliewer, S.A., Lenhard, J.M., Willson, T.M., Patel, I., Morris, D.C., and Lehmann, J.M. 
1995. A prostaglandin J2 metabolite binds peroxisome proliferator-activated 
receptor gamma and promotes adipocyte differentiation. Cell 83(5): 813-819. 
Kliewer, S.A., Sundseth, S.S., Jones, S.A., Brown, P.J., Wisely, G.B., Koble, C.S., 
Devchand, P., Wahli, W., Willson, T.M., Lenhard, J.M., and Lehmann, J.M. 1997. 
Fatty acids and eicosanoids regulate gene expression through direct interactions 
with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl 
Acad Sci U S A 94(9): 4318-4323. 
Kliewer, S.A., Umesono, K., Noonan, D.J., Heyman, R.A., and Evans, R.M. 1992. 
Convergence of 9-cis retinoic acid and peroxisome proliferator signalling 
pathways through heterodimer formation of their receptors. Nature 358(6389): 
771-774. 
Knutti, D., Kressler, D., and Kralli, A. 2001. Regulation of the transcriptional coactivator 
PGC-1 via MAPK-sensitive interaction with a repressor. Proc Natl Acad Sci U S 
A 98(17): 9713-9718. 
Koo, S.H., Satoh, H., Herzig, S., Lee, C.H., Hedrick, S., Kulkarni, R., Evans, R.M., 
Olefsky, J., and Montminy, M. 2004. PGC-1 promotes insulin resistance in liver 
through PPAR-alpha-dependent induction of TRB-3. Nat Med 10(5): 530-534. 
Krey, G., Braissant, O., L'Horset, F., Kalkhoven, E., Perroud, M., Parker, M.G., and 
Wahli, W. 1997. Fatty acids, eicosanoids, and hypolipidemic agents identified as 
ligands of peroxisome proliferator-activated receptors by coactivator-dependent 
receptor ligand assay. Mol Endocrinol 11(6): 779-791. 
Krey, G., Keller, H., Mahfoudi, A., Medin, J., Ozato, K., Dreyer, C., and Wahli, W. 1993. 
Xenopus peroxisome proliferator activated receptors: genomic organization, 
response element recognition, heterodimer formation with retinoid X receptor and 
activation by fatty acids. J Steroid Biochem Mol Biol 47(1-6): 65-73. 
Kroetz, D.L., Yook, P., Costet, P., Bianchi, P., and Pineau, T. 1998. Peroxisome 
proliferator-activated receptor alpha controls the hepatic CYP4A induction 
adaptive response to starvation and diabetes. J Biol Chem 273(47): 31581-31589. 
Krogsdam, A.M., Nielsen, C.A., Neve, S., Holst, D., Helledie, T., Thomsen, B., Bendixen, 
C., Mandrup, S., and Kristiansen, K. 2002. Nuclear receptor corepressor-
dependent repression of peroxisome-proliferator-activated receptor delta-
mediated transactivation. Biochem J 363(Pt 1): 157-165. 
Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., 
Nakano, R., Ishii, C., Sugiyama, T., Eto, K., Tsubamoto, Y., Okuno, A., 
Murakami, K., Sekihara, H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., 
Shiota, K., Kitamura, T., Fujita, T., Ezaki, O., Aizawa, S., Kadowaki, T., and et al. 
 226
1999. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and 
insulin resistance. Mol Cell 4(4): 597-609. 
Kumar, V., Green, S., Staub, A., and Chambon, P. 1986. Localisation of the oestradiol-
binding and putative DNA-binding domains of the human oestrogen receptor. 
Embo J 5(9): 2231-2236. 
Lacquemant, C., Lepretre, F., Pineda Torra, I., Manraj, M., Charpentier, G., Ruiz, J., 
Staels, B., and Froguel, P. 2000. Mutation screening of the PPARalpha gene in 
type 2 diabetes associated with coronary heart disease. Diabetes Metab 26(5): 
393-401. 
Lavinsky, R.M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.M., Schiff, R., Del-Rio, 
A.L., Ricote, M., Ngo, S., Gemsch, J., Hilsenbeck, S.G., Osborne, C.K., Glass, 
C.K., Rosenfeld, M.G., and Rose, D.W. 1998. Diverse signaling pathways 
modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc 
Natl Acad Sci U S A 95(6): 2920-2925. 
Lazennec, G., Canaple, L., Saugy, D., and Wahli, W. 2000. Activation of peroxisome 
proliferator-activated receptors (PPARs) by their ligands and protein kinase A 
activators. Mol Endocrinol 14(12): 1962-1975. 
Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fernandez-
Salguero, P.M., Westphal, H., and Gonzalez, F.J. 1995. Targeted disruption of the 
alpha isoform of the peroxisome proliferator-activated receptor gene in mice 
results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol 
Cell Biol 15(6): 3012-3022. 
Leesnitzer, L.M., Parks, D.J., Bledsoe, R.K., Cobb, J.E., Collins, J.L., Consler, T.G., 
Davis, R.G., Hull-Ryde, E.A., Lenhard, J.M., Patel, L., Plunket, K.D., Shenk, J.L., 
Stimmel, J.B., Therapontos, C., Willson, T.M., and Blanchard, S.G. 2002. 
Functional consequences of cysteine modification in the ligand binding sites of 
peroxisome proliferator activated receptors by GW9662. Biochemistry 41(21): 
6640-6650. 
Lefebvre, P., Chinetti, G., Fruchart, J.C., and Staels, B. 2006. Sorting out the roles of 
PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116(3): 
571-580. 
Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M., and 
Kliewer, S.A. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for 
peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 
270(22): 12953-12956. 
Lehrke, M. and Lazar, M.A. 2005. The many faces of PPARgamma. Cell 123(6): 993-
999. 
Lemberger, T., Saladin, R., Vazquez, M., Assimacopoulos, F., Staels, B., Desvergne, B., 
Wahli, W., and Auwerx, J. 1996. Expression of the peroxisome proliferator-
activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. 
J Biol Chem 271(3): 1764-1769. 
Lemberger, T., Staels, B., Saladin, R., Desvergne, B., Auwerx, J., and Wahli, W. 1994. 
Regulation of the peroxisome proliferator-activated receptor alpha gene by 
glucocorticoids. J Biol Chem 269(40): 24527-24530. 
Leo, C. and Chen, J.D. 2000. The SRC family of nuclear receptor coactivators. Gene 
245(1): 1-11. 
 227
Leone, T.C., Weinheimer, C.J., and Kelly, D.P. 1999. A critical role for the peroxisome 
proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: 
the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl 
Acad Sci U S A 96(13): 7473-7478. 
Lewis, B.A. and Reinberg, D. 2003. The mediator coactivator complex: functional and 
physical roles in transcriptional regulation. J Cell Sci 116(Pt 18): 3667-3675. 
Li, J., Wang, J., Wang, J., Nawaz, Z., Liu, J.M., Qin, J., and Wong, J. 2000. Both 
corepressor proteins SMRT and N-CoR exist in large protein complexes 
containing HDAC3. Embo J 19(16): 4342-4350. 
Li, W.L., Zheng, H.C., Bukuru, J., and De Kimpe, N. 2004. Natural medicines used in the 
traditional Chinese medical system for therapy of diabetes mellitus. J 
Ethnopharmacol 92(1): 1-21. 
Li, Z., Hong, K., Saltsman, P., DeShields, S., Bellman, M., Thames, G., Liu, Y., Wang, 
H.J., Elashoff, R., and Heber, D. 2005. Long-term efficacy of soy-based meal 
replacements vs an individualized diet plan in obese type II DM patients: relative 
effects on weight loss, metabolic parameters, and C-reactive protein. Eur J Clin 
Nutr 59(3): 411-418. 
Likhite, V.S., Stossi, F., Kim, K., Katzenellenbogen, B.S., and Katzenellenbogen, J.A. 
2006. Kinase-specific phosphorylation of the estrogen receptor changes receptor 
interactions with ligand, deoxyribonucleic acid, and coregulators associated with 
alterations in estrogen and tamoxifen activity. Mol Endocrinol 20(12): 3120-3132. 
Lim, H.J., Moon, I., and Han, K. 2004. Transcriptional cofactors exhibit differential 
preference toward peroxisome proliferator-activated receptors alpha and delta in 
uterine cells. Endocrinology 145(6): 2886-2895. 
Lim, J., Ghadessy, F.J., Abdullah, A.A., Pinsky, L., Trifiro, M., and Yong, E.L. 2000. 
Human androgen receptor mutation disrupts ternary interactions between ligand, 
receptor domains, and the coactivator TIF2 (transcription intermediary factor 2). 
Mol Endocrinol 14(8): 1187-1197. 
Lin, B.C., Hong, S.H., Krig, S., Yoh, S.M., and Privalsky, M.L. 1997. A conformational 
switch in nuclear hormone receptors is involved in coupling hormone binding to 
corepressor release. Mol Cell Biol 17(10): 6131-6138. 
Liu, K., Black, R.M., Acton, J.J., 3rd, Mosley, R., Debenham, S., Abola, R., Yang, M., 
Tschirret-Guth, R., Colwell, L., Liu, C., Wu, M., Wang, C.F., MacNaul, K.L., 
McCann, M.E., Moller, D.E., Berger, J.P., Meinke, P.T., Jones, A.B., and Wood, 
H.B. 2005. Selective PPARgamma modulators with improved pharmacological 
profiles. Bioorg Med Chem Lett 15(10): 2437-2440. 
Lohray, B.B., Lohray, V.B., Bajji, A.C., Kalchar, S., Poondra, R.R., Padakanti, S., 
Chakrabarti, R., Vikramadithyan, R.K., Misra, P., Juluri, S., Mamidi, N.V., and 
Rajagopalan, R. 2001. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-
ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent 
antihyperglycemic and lipid modulating activity. J Med Chem 44(16): 2675-2678. 
Lopez, G.N., Turck, C.W., Schaufele, F., Stallcup, M.R., and Kushner, P.J. 2001. Growth 
factors signal to steroid receptors through mitogen-activated protein kinase 
regulation of p160 coactivator activity. J Biol Chem 276(25): 22177-22182. 
Low, Y.L. and Tai, E.S. 2007. Understanding diet-gene interactions: Lessons from 
studying nutrigenomics and cardiovascular disease. Mutat Res 622(1-2): 7-13. 
 228
Loy, C.J., Sim, K.S., and Yong, E.L. 2003. Filamin-A fragment localizes to the nucleus 
to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci U S A 
100(8): 4562-4567. 
Luisi, B.F., Xu, W.X., Otwinowski, Z., Freedman, L.P., Yamamoto, K.R., and Sigler, P.B. 
1991. Crystallographic analysis of the interaction of the glucocorticoid receptor 
with DNA. Nature 352(6335): 497-505. 
Ma, X., Zhang, T., Wei, Y., Tu, P., Chen, Y., and Ito, Y. 2002. Preparative isolation and 
purification of calycosin from Astragalus membranaceus Bge. var. mongholicus 
(Bge.) Hsiao by high-speed counter-current chromatography. J Chromatogr A 
962(1-2): 243-247. 
Mackowiak, P., Nogowski, L., and Nowak, K.W. 1999. Effect of isoflavone genistein on 
insulin receptors in perfused liver of ovariectomized rats. J Recept Signal 
Transduct Res 19(1-4): 283-292. 
Mae, T., Kishida, H., Nishiyama, T., Tsukagawa, M., Konishi, E., Kuroda, M., Mimaki, 
Y., Sashida, Y., Takahashi, K., Kawada, T., Nakagawa, K., and Kitahara, M. 2003. 
A licorice ethanolic extract with peroxisome proliferator-activated receptor-
gamma ligand-binding activity affects diabetes in KK-Ay mice, abdominal 
obesity in diet-induced obese C57BL mice and hypertension in spontaneously 
hypertensive rats. J Nutr 133(11): 3369-3377. 
Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., 
Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., 
Nakamura, T., Shimomura, I., and Matsuzawa, Y. 2001. PPARgamma ligands 
increase expression and plasma concentrations of adiponectin, an adipose-derived 
protein. Diabetes 50(9): 2094-2099. 
Mak, H.Y., Hoare, S., Henttu, P.M., and Parker, M.G. 1999. Molecular determinants of 
the estrogen receptor-coactivator interface. Mol Cell Biol 19(5): 3895-3903. 
Makowski, A., Brzostek, S., Cohen, R.N., and Hollenberg, A.N. 2003. Determination of 
nuclear receptor corepressor interactions with the thyroid hormone receptor. Mol 
Endocrinol 17(2): 273-286. 
Manach, C., Mazur, A., and Scalbert, A. 2005. Polyphenols and prevention of 
cardiovascular diseases. Curr Opin Lipidol 16(1): 77-84. 
Mandard, S., Muller, M., and Kersten, S. 2004. Peroxisome proliferator-activated 
receptor alpha target genes. Cell Mol Life Sci 61(4): 393-416. 
Mangelsdorf, D.J. and Evans, R.M. 1995. The RXR heterodimers and orphan receptors. 
Cell 83(6): 841-850. 
Manthey, J.A. 2000. Biological properties of flavonoids pertaining to inflammation. 
Microcirculation 7(6 Pt 2): S29-34. 
Marcus, S.L., Miyata, K.S., Zhang, B., Subramani, S., Rachubinski, R.A., and Capone, 
J.P. 1993. Diverse peroxisome proliferator-activated receptors bind to the 
peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase 
and fatty acyl-CoA oxidase genes but differentially induce expression. Proc Natl 
Acad Sci U S A 90(12): 5723-5727. 
Mardones, P., Pilon, A., Bouly, M., Duran, D., Nishimoto, T., Arai, H., Kozarsky, K.F., 
Altayo, M., Miquel, J.F., Luc, G., Clavey, V., Staels, B., and Rigotti, A. 2003. 
Fibrates down-regulate hepatic scavenger receptor class B type I protein 
expression in mice. J Biol Chem 278(10): 7884-7890. 
 229
Martin, G., Schoonjans, K., Lefebvre, A.M., Staels, B., and Auwerx, J. 1997. Coordinate 
regulation of the expression of the fatty acid transport protein and acyl-CoA 
synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 
272(45): 28210-28217. 
Mascaro, C., Acosta, E., Ortiz, J.A., Marrero, P.F., Hegardt, F.G., and Haro, D. 1998. 
Control of human muscle-type carnitine palmitoyltransferase I gene transcription 
by peroxisome proliferator-activated receptor. J Biol Chem 273(15): 8560-8563. 
Mazur, W. 1998. Phytoestrogen content in foods. Baillieres Clin Endocrinol Metab 12(4): 
729-742. 
McInerney, E.M., Rose, D.W., Flynn, S.E., Westin, S., Mullen, T.M., Krones, A., 
Inostroza, J., Torchia, J., Nolte, R.T., Assa-Munt, N., Milburn, M.V., Glass, C.K., 
and Rosenfeld, M.G. 1998. Determinants of coactivator LXXLL motif specificity 
in nuclear receptor transcriptional activation. Genes Dev 12(21): 3357-3368. 
McKenna, N.J. and O'Malley, B.W. 2002. Combinatorial control of gene expression by 
nuclear receptors and coregulators. Cell 108(4): 465-474. 
Messina, M., Nagata, C., and Wu, A.H. 2006. Estimated Asian adult soy protein and 
isoflavone intakes. Nutr Cancer 55(1): 1-12. 
Metivier, R., Penot, G., Carmouche, R.P., Hubner, M.R., Reid, G., Denger, S., Manu, D., 
Brand, H., Kos, M., Benes, V., and Gannon, F. 2004. Transcriptional complexes 
engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes. Embo 
J 23(18): 3653-3666. 
Mettu, N.B., Stanley, T.B., Dwyer, M.A., Jansen, M.S., Allen, J.E., Hall, J.M., and 
McDonnell, D.P. 2007. The Nuclear Receptor-Coactivator Interaction Surface as 
a Target for Peptide Antagonists of the Peroxisome Proliferator Activated 
Receptors. Mol Endocrinol. 
Mezei, O., Banz, W.J., Steger, R.W., Peluso, M.R., Winters, T.A., and Shay, N. 2003. 
Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR 
pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 133(5): 1238-
1243. 
Michalik, L., Auwerx, J., Berger, J.P., Chatterjee, V.K., Glass, C.K., Gonzalez, F.J., 
Grimaldi, P.A., Kadowaki, T., Lazar, M.A., O'Rahilly, S., Palmer, C.N., Plutzky, 
J., Reddy, J.K., Spiegelman, B.M., Staels, B., and Wahli, W. 2006. International 
Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. 
Pharmacol Rev 58(4): 726-741. 
Michalik, L., Feige, J.N., Gelman, L., Pedrazzini, T., Keller, H., Desvergne, B., and 
Wahli, W. 2005. Selective expression of a dominant-negative form of peroxisome 
proliferator-activated receptor in keratinocytes leads to impaired epidermal 
healing. Mol Endocrinol 19(9): 2335-2348. 
Misra, P., Owuor, E.D., Li, W., Yu, S., Qi, C., Meyer, K., Zhu, Y.J., Rao, M.S., Kong, 
A.N., and Reddy, J.K. 2002a. Phosphorylation of transcriptional coactivator 
peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP). 
Stimulation of transcriptional regulation by mitogen-activated protein kinase. J 
Biol Chem 277(50): 48745-48754. 
Misra, P., Qi, C., Yu, S., Shah, S.H., Cao, W.Q., Rao, M.S., Thimmapaya, B., Zhu, Y., 
and Reddy, J.K. 2002b. Interaction of PIMT with transcriptional coactivators CBP, 
 230
p300, and PBP differential role in transcriptional regulation. J Biol Chem 277(22): 
20011-20019. 
Miyata, K.S., McCaw, S.E., Meertens, L.M., Patel, H.V., Rachubinski, R.A., and Capone, 
J.P. 1998. Receptor-interacting protein 140 interacts with and inhibits 
transactivation by, peroxisome proliferator-activated receptor alpha and liver-X-
receptor alpha. Mol Cell Endocrinol 146(1-2): 69-76. 
Miyazaki, Y., Mahankali, A., Wajcberg, E., Bajaj, M., Mandarino, L.J., and DeFronzo, 
R.A. 2004. Effect of pioglitazone on circulating adipocytokine levels and insulin 
sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89(9): 4312-4319. 
Molnar, F., Matilainen, M., and Carlberg, C. 2005. Structural determinants of the agonist-
independent association of human peroxisome proliferator-activated receptors 
with coactivators. J Biol Chem 280(28): 26543-26556. 
Monsalve, M., Wu, Z., Adelmant, G., Puigserver, P., Fan, M., and Spiegelman, B.M. 
2000. Direct coupling of transcription and mRNA processing through the 
thermogenic coactivator PGC-1. Mol Cell 6(2): 307-316. 
Moras, D. and Gronemeyer, H. 1998. The nuclear receptor ligand-binding domain: 
structure and function. Curr Opin Cell Biol 10(3): 384-391. 
Motojima, K., Passilly, P., Peters, J.M., Gonzalez, F.J., and Latruffe, N. 1998. Expression 
of putative fatty acid transporter genes are regulated by peroxisome proliferator-
activated receptor alpha and gamma activators in a tissue- and inducer-specific 
manner. J Biol Chem 273(27): 16710-16714. 
Mouthiers, A., Baillet, A., Delomenie, C., Porquet, D., and Mejdoubi-Charef, N. 2005. 
Peroxisome proliferator-activated receptor alpha physically interacts with 
CCAAT/enhancer binding protein (C/EBPbeta) to inhibit C/EBPbeta-responsive 
alpha1-acid glycoprotein gene expression. Mol Endocrinol 19(5): 1135-1146. 
Mukherjee, R., Davies, P.J., Crombie, D.L., Bischoff, E.D., Cesario, R.M., Jow, L., 
Hamann, L.G., Boehm, M.F., Mondon, C.E., Nadzan, A.M., Paterniti, J.R., Jr., 
and Heyman, R.A. 1997a. Sensitization of diabetic and obese mice to insulin by 
retinoid X receptor agonists. Nature 386(6623): 407-410. 
Mukherjee, R., Jow, L., Croston, G.E., and Paterniti, J.R., Jr. 1997b. Identification, 
characterization, and tissue distribution of human peroxisome proliferator-
activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and 
activation with retinoid X receptor agonists and antagonists. J Biol Chem 272(12): 
8071-8076. 
Mukherjee, R., Sun, S., Santomenna, L., Miao, B., Walton, H., Liao, B., Locke, K., 
Zhang, J.H., Nguyen, S.H., Zhang, L.T., Murphy, K., Ross, H.O., Xia, M.X., 
Teleha, C., Chen, S.Y., Selling, B., Wynn, R., Burn, T., and Young, P.R. 2002. 
Ligand and coactivator recruitment preferences of peroxisome proliferator 
activated receptor alpha. J Steroid Biochem Mol Biol 81(3): 217-225. 
Muscat, G.E., Burke, L.J., and Downes, M. 1998. The corepressor N-CoR and its variants 
RIP13a and RIP13Delta1 directly interact with the basal transcription factors 
TFIIB, TAFII32 and TAFII70. Nucleic Acids Res 26(12): 2899-2907. 
Nagy, L., Kao, H.Y., Love, J.D., Li, C., Banayo, E., Gooch, J.T., Krishna, V., Chatterjee, 
K., Evans, R.M., and Schwabe, J.W. 1999. Mechanism of corepressor binding and 
release from nuclear hormone receptors. Genes Dev 13(24): 3209-3216. 
 231
Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H., and Evans, R.M. 1998. Oxidized LDL 
regulates macrophage gene expression through ligand activation of PPARgamma. 
Cell 93(2): 229-240. 
Naito, H., Yamanoshita, O., Kamijima, M., Katoh, T., Matsunaga, T., Lee, C.H., Kim, H., 
Aoyama, T., Gonzalez, F.J., and Nakajima, T. 2006. Association of V227A 
PPARalpha polymorphism with altered serum biochemistry and alcohol drinking 
in Japanese men. Pharmacogenet Genomics 16(8): 569-577. 
Nestel, P., Cehun, M., Chronopoulos, A., DaSilva, L., Teede, H., and McGrath, B. 2004. 
A biochanin-enriched isoflavone from red clover lowers LDL cholesterol in men. 
Eur J Clin Nutr 58(3): 403-408. 
Nissen, S.E., Wolski, K., and Topol, E.J. 2005. Effect of muraglitazar on death and major 
adverse cardiovascular events in patients with type 2 diabetes mellitus. Jama 
294(20): 2581-2586. 
Nogowski, L., Mackowiak, P., Kandulska, K., Szkudelski, T., and Nowak, K.W. 1998. 
Genistein-induced changes in lipid metabolism of ovariectomized rats. Ann Nutr 
Metab 42(6): 360-366. 
Nolte, R.T., Wisely, G.B., Westin, S., Cobb, J.E., Lambert, M.H., Kurokawa, R., 
Rosenfeld, M.G., Willson, T.M., Glass, C.K., and Milburn, M.V. 1998. Ligand 
binding and co-activator assembly of the peroxisome proliferator-activated 
receptor-gamma. Nature 395(6698): 137-143. 
Oakes, N.D., Thalen, P.G., Jacinto, S.M., and Ljung, B. 2001. Thiazolidinediones 
increase plasma-adipose tissue FFA exchange capacity and enhance insulin-
mediated control of systemic FFA availability. Diabetes 50(5): 1158-1165. 
Ogawa, S., Inoue, S., Watanabe, T., Orimo, A., Hosoi, T., Ouchi, Y., and Muramatsu, M. 
1998. Molecular cloning and characterization of human estrogen receptor betacx: 
a potential inhibitor ofestrogen action in human. Nucleic Acids Res 26(15): 3505-
3512. 
Ohshima, T., Koga, H., and Shimotohno, K. 2004. Transcriptional activity of peroxisome 
proliferator-activated receptor gamma is modulated by SUMO-1 modification. J 
Biol Chem 279(28): 29551-29557. 
Oishi, K., Shirai, H., and Ishida, N. 2005. CLOCK is involved in the circadian 
transactivation of peroxisome-proliferator-activated receptor alpha (PPARalpha) 
in mice. Biochem J 386(Pt 3): 575-581. 
Onigata, K., Yagi, H., Sakurai, A., Nagashima, T., Nomura, Y., Nagashima, K., 
Hashizume, K., and Morikawa, A. 1995. A novel point mutation (R243Q) in exon 
7 of the c-erbA beta thyroid hormone receptor gene in a family with resistance to 
thyroid hormone. Thyroid 5(5): 355-358. 
Ordentlich, P., Downes, M., and Evans, R.M. 2001. Corepressors and nuclear hormone 
receptor function. Curr Top Microbiol Immunol 254: 101-116. 
Ordovas, J.M. 2006a. Genetic interactions with diet influence the risk of cardiovascular 
disease. Am J Clin Nutr 83(2): 443S-446S. 
Ordovas, J.M. 2006b. Nutrigenetics, plasma lipids, and cardiovascular risk. J Am Diet 
Assoc 106(7): 1074-1081; quiz 1083. 
Osada, S., Tsukamoto, T., Takiguchi, M., Mori, M., and Osumi, T. 1997. Identification of 
an extended half-site motif required for the function of peroxisome proliferator-
activated receptor alpha. Genes Cells 2(5): 315-327. 
 232
Ososki, A.L. and Kennelly, E.J. 2003. Phytoestrogens: a review of the present state of 
research. Phytother Res 17(8): 845-869. 
Palmer, C.N., Hsu, M.H., Griffin, H.J., and Johnson, E.F. 1995. Novel sequence 
determinants in peroxisome proliferator signaling. J Biol Chem 270(27): 16114-
16121. 
Palmer, C.N., Hsu, M.H., Griffin, K.J., Raucy, J.L., and Johnson, E.F. 1998. Peroxisome 
proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 
53(1): 14-22. 
Paradis, A.M., Fontaine-Bisson, B., Bosse, Y., Robitaille, J., Lemieux, S., Jacques, H., 
Lamarche, B., Tchernof, A., Couture, P., and Vohl, M.C. 2005. The peroxisome 
proliferator-activated receptor alpha Leu162Val polymorphism influences the 
metabolic response to a dietary intervention altering fatty acid proportions in 
healthy men. Am J Clin Nutr 81(2): 523-530. 
Pascual, G., Fong, A.L., Ogawa, S., Gamliel, A., Li, A.C., Perissi, V., Rose, D.W., 
Willson, T.M., Rosenfeld, M.G., and Glass, C.K. 2005. A SUMOylation-
dependent pathway mediates transrepression of inflammatory response genes by 
PPAR-gamma. Nature 437(7059): 759-763. 
Patel, H., Truant, R., Rachubinski, R.A., and Capone, J.P. 2005. Activity and subcellular 
compartmentalization of peroxisome proliferator-activated receptor alpha are 
altered by the centrosome-associated protein CAP350. J Cell Sci 118(Pt 1): 175-
186. 
Patsouris, D., Mandard, S., Voshol, P.J., Escher, P., Tan, N.S., Havekes, L.M., Koenig, 
W., Marz, W., Tafuri, S., Wahli, W., Muller, M., and Kersten, S. 2004. 
PPARalpha governs glycerol metabolism. J Clin Invest 114(1): 94-103. 
Perissi, V. and Rosenfeld, M.G. 2005. Controlling nuclear receptors: the circular logic of 
cofactor cycles. Nat Rev Mol Cell Biol 6(7): 542-554. 
Perissi, V., Staszewski, L.M., McInerney, E.M., Kurokawa, R., Krones, A., Rose, D.W., 
Lambert, M.H., Milburn, M.V., Glass, C.K., and Rosenfeld, M.G. 1999. 
Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev 
13(24): 3198-3208. 
Peters, J.M., Hennuyer, N., Staels, B., Fruchart, J.C., Fievet, C., Gonzalez, F.J., and 
Auwerx, J. 1997. Alterations in lipoprotein metabolism in peroxisome 
proliferator-activated receptor alpha-deficient mice. J Biol Chem 272(43): 27307-
27312. 
Phair, R.D., Scaffidi, P., Elbi, C., Vecerova, J., Dey, A., Ozato, K., Brown, D.T., Hager, 
G., Bustin, M., and Misteli, T. 2004. Global nature of dynamic protein-chromatin 
interactions in vivo: three-dimensional genome scanning and dynamic interaction 
networks of chromatin proteins. Mol Cell Biol 24(14): 6393-6402. 
Picard, F., Gehin, M., Annicotte, J., Rocchi, S., Champy, M.F., O'Malley, B.W., 
Chambon, P., and Auwerx, J. 2002. SRC-1 and TIF2 control energy balance 
between white and brown adipose tissues. Cell 111(7): 931-941. 
Pineda Torra, I., Jamshidi, Y., Flavell, D.M., Fruchart, J.C., and Staels, B. 2002. 
Characterization of the human PPARalpha promoter: identification of a functional 
nuclear receptor response element. Mol Endocrinol 16(5): 1013-1028. 
Plutzky, J. 2003. Peroxisome proliferator-activated receptors as therapeutic targets in 
inflammation. J Am Coll Cardiol 42(10): 1764-1766. 
 233
Poirier, H., Niot, I., Monnot, M.C., Braissant, O., Meunier-Durmort, C., Costet, P., 
Pineau, T., Wahli, W., Willson, T.M., and Besnard, P. 2001. Differential 
involvement of peroxisome-proliferator-activated receptors alpha and delta in 
fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-
binding protein in the liver and the small intestine. Biochem J 355(Pt 2): 481-488. 
Prasain, J.K., Jones, K., Kirk, M., Wilson, L., Smith-Johnson, M., Weaver, C., and 
Barnes, S. 2003. Profiling and quantification of isoflavonoids in kudzu dietary 
supplements by high-performance liquid chromatography and electrospray 
ionization tandem mass spectrometry. J Agric Food Chem 51(15): 4213-4218. 
Privalsky, M.L. 2004. The role of corepressors in transcriptional regulation by nuclear 
hormone receptors. Annu Rev Physiol 66: 315-360. 
Puigserver, P., Adelmant, G., Wu, Z., Fan, M., Xu, J., O'Malley, B., and Spiegelman, 
B.M. 1999. Activation of PPARgamma coactivator-1 through transcription factor 
docking. Science 286(5443): 1368-1371. 
Puigserver, P., Rhee, J., Lin, J., Wu, Z., Yoon, J.C., Zhang, C.Y., Krauss, S., Mootha, 
V.K., Lowell, B.B., and Spiegelman, B.M. 2001. Cytokine stimulation of energy 
expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. 
Mol Cell 8(5): 971-982. 
Puigserver, P. and Spiegelman, B.M. 2003. Peroxisome proliferator-activated receptor-
gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and 
metabolic regulator. Endocr Rev 24(1): 78-90. 
Qi, C., Chang, J., Zhu, Y., Yeldandi, A.V., Rao, S.M., and Zhu, Y.J. 2002. Identification 
of protein arginine methyltransferase 2 as a coactivator for estrogen receptor 
alpha. J Biol Chem 277(32): 28624-28630. 
Qi, C., Surapureddi, S., Zhu, Y.J., Yu, S., Kashireddy, P., Rao, M.S., and Reddy, J.K. 
2003. Transcriptional coactivator PRIP, the peroxisome proliferator-activated 
receptor gamma (PPARgamma)-interacting protein, is required for PPARgamma-
mediated adipogenesis. J Biol Chem 278(28): 25281-25284. 
Qi, C., Zhu, Y., Pan, J., Yeldandi, A.V., Rao, M.S., Maeda, N., Subbarao, V., Pulikuri, S., 
Hashimoto, T., and Reddy, J.K. 1999. Mouse steroid receptor coactivator-1 is not 
essential for peroxisome proliferator-activated receptor alpha-regulated gene 
expression. Proc Natl Acad Sci U S A 96(4): 1585-1590. 
Qiu, J. 2007. Traditional medicine: a culture in the balance. Nature 448(7150): 126-128. 
Rangwala, S.M. and Lazar, M.A. 2004. Peroxisome proliferator-activated receptor 
gamma in diabetes and metabolism. Trends Pharmacol Sci 25(6): 331-336. 
Rau, O., Wurglics, M., Dingermann, T., Abdel-Tawab, M., and Schubert-Zsilavecz, M. 
2006. Screening of herbal extracts for activation of the human peroxisome 
proliferator-activated receptor. Pharmazie 61(11): 952-956. 
Ravnskjaer, K., Boergesen, M., Rubi, B., Larsen, J.K., Nielsen, T., Fridriksson, J., 
Maechler, P., and Mandrup, S. 2005. Peroxisome proliferator-activated receptor 
alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-
stimulated insulin secretion in pancreatic beta-cells. Endocrinology 146(8): 3266-
3276. 
Reid, G., Hubner, M.R., Metivier, R., Brand, H., Denger, S., Manu, D., Beaudouin, J., 
Ellenberg, J., and Gannon, F. 2003. Cyclic, proteasome-mediated turnover of 
 234
unliganded and liganded ERalpha on responsive promoters is an integral feature 
of estrogen signaling. Mol Cell 11(3): 695-707. 
Ricketts, M.L., Moore, D.D., Banz, W.J., Mezei, O., and Shay, N.F. 2005. Molecular 
mechanisms of action of the soy isoflavones includes activation of promiscuous 
nuclear receptors. A review. J Nutr Biochem 16(6): 321-330. 
Rieusset, J., Seydoux, J., Anghel, S.I., Escher, P., Michalik, L., Soon Tan, N., Metzger, 
D., Chambon, P., Wahli, W., and Desvergne, B. 2004. Altered growth in male 
peroxisome proliferator-activated receptor gamma (PPARgamma) heterozygous 
mice: involvement of PPARgamma in a negative feedback regulation of growth 
hormone action. Mol Endocrinol 18(10): 2363-2377. 
Robins, S.J., Rubins, H.B., Faas, F.H., Schaefer, E.J., Elam, M.B., Anderson, J.W., and 
Collins, D. 2003. Insulin resistance and cardiovascular events with low HDL 
cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes 
Care 26(5): 1513-1517. 
Robinson-Rechavi, M., Escriva Garcia, H., and Laudet, V. 2003. The nuclear receptor 
superfamily. J Cell Sci 116(Pt 4): 585-586. 
Rodriguez, J.C., Gil-Gomez, G., Hegardt, F.G., and Haro, D. 1994. Peroxisome 
proliferator-activated receptor mediates induction of the mitochondrial 3-
hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem 269(29): 
18767-18772. 
Roduit, R., Morin, J., Masse, F., Segall, L., Roche, E., Newgard, C.B., Assimacopoulos-
Jeannet, F., and Prentki, M. 2000. Glucose down-regulates the expression of the 
peroxisome proliferator-activated receptor-alpha gene in the pancreatic beta -cell. 
J Biol Chem 275(46): 35799-35806. 
Rowan, B.G., Weigel, N.L., and O'Malley, B.W. 2000. Phosphorylation of steroid 
receptor coactivator-1. Identification of the phosphorylation sites and 
phosphorylation through the mitogen-activated protein kinase pathway. J Biol 
Chem 275(6): 4475-4483. 
Rubenstrunk, A., Hanf, R., Hum, D.W., Fruchart, J.C., and Staels, B. 2007. Safety issues 
and prospects for future generations of PPAR modulators. Biochim Biophys Acta. 
Rubins, H.B., Robins, S.J., Collins, D., Nelson, D.B., Elam, M.B., Schaefer, E.J., Faas, 
F.H., and Anderson, J.W. 2002. Diabetes, plasma insulin, and cardiovascular 
disease: subgroup analysis from the Department of Veterans Affairs high-density 
lipoprotein intervention trial (VA-HIT). Arch Intern Med 162(22): 2597-2604. 
Saad, M.F., Greco, S., Osei, K., Lewin, A.J., Edwards, C., Nunez, M., and Reinhardt, R.R. 
2004. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic 
subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an 
open pioglitazone arm. Diabetes Care 27(6): 1324-1329. 
Sacks, F.M., Lichtenstein, A., Van Horn, L., Harris, W., Kris-Etherton, P., and Winston, 
M. 2006. Soy protein, isoflavones, and cardiovascular health: an American Heart 
Association Science Advisory for professionals from the Nutrition Committee. 
Circulation 113(7): 1034-1044. 
Safer, J.D., Cohen, R.N., Hollenberg, A.N., and Wondisford, F.E. 1998. Defective release 
of corepressor by hinge mutants of the thyroid hormone receptor found in patients 
with resistance to thyroid hormone. J Biol Chem 273(46): 30175-30182. 
 235
Salma, N., Xiao, H., Mueller, E., and Imbalzano, A.N. 2004. Temporal recruitment of 
transcription factors and SWI/SNF chromatin-remodeling enzymes during 
adipogenic induction of the peroxisome proliferator-activated receptor gamma 
nuclear hormone receptor. Mol Cell Biol 24(11): 4651-4663. 
Sanders, T.A., Dean, T.S., Grainger, D., Miller, G.J., and Wiseman, H. 2002. Moderate 
intakes of intact soy protein rich in isoflavones compared with ethanol-extracted 
soy protein increase HDL but do not influence transforming growth factor beta(1) 
concentrations and hemostatic risk factors for coronary heart disease in healthy 
subjects. Am J Clin Nutr 76(2): 373-377. 
Sapone, A., Peters, J.M., Sakai, S., Tomita, S., Papiha, S.S., Dai, R., Friedman, F.K., and 
Gonzalez, F.J. 2000. The human peroxisome proliferator-activated receptor alpha 
gene: identification and functional characterization of two natural allelic variants. 
Pharmacogenetics 10(4): 321-333. 
Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A.M., Heyman, R.A., Briggs, M., Deeb, 
S., Staels, B., and Auwerx, J. 1996a. PPARalpha and PPARgamma activators 
direct a distinct tissue-specific transcriptional response via a PPRE in the 
lipoprotein lipase gene. Embo J 15(19): 5336-5348. 
Schoonjans, K., Staels, B., and Auwerx, J. 1996b. Role of the peroxisome proliferator-
activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on 
gene expression. J Lipid Res 37(5): 907-925. 
Schoonjans, K., Watanabe, M., Suzuki, H., Mahfoudi, A., Krey, G., Wahli, W., Grimaldi, 
P., Staels, B., Yamamoto, T., and Auwerx, J. 1995. Induction of the acyl-
coenzyme A synthetase gene by fibrates and fatty acids is mediated by a 
peroxisome proliferator response element in the C promoter. J Biol Chem 270(33): 
19269-19276. 
Schulman, I.G., Shao, G., and Heyman, R.A. 1998. Transactivation by retinoid X 
receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) 
heterodimers: intermolecular synergy requires only the PPARgamma hormone-
dependent activation function. Mol Cell Biol 18(6): 3483-3494. 
Seimandi, M., Lemaire, G., Pillon, A., Perrin, A., Carlavan, I., Voegel, J.J., Vignon, F., 
Nicolas, J.C., and Balaguer, P. 2005. Differential responses of PPARalpha, 
PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic 
ligands. Anal Biochem 344(1): 8-15. 
Semple, R.K., Meirhaeghe, A., Vidal-Puig, A.J., Schwabe, J.W., Wiggins, D., Gibbons, 
G.F., Gurnell, M., Chatterjee, V.K., and O'Rahilly, S. 2005. A dominant negative 
human peroxisome proliferator-activated receptor (PPAR){alpha} is a constitutive 
transcriptional corepressor and inhibits signaling through all PPAR isoforms. 
Endocrinology 146(4): 1871-1882. 
Seol, W., Mahon, M.J., Lee, Y.K., and Moore, D.D. 1996. Two receptor interacting 
domains in the nuclear hormone receptor corepressor RIP13/N-CoR. Mol 
Endocrinol 10(12): 1646-1655. 
Shao, D., Rangwala, S.M., Bailey, S.T., Krakow, S.L., Reginato, M.J., and Lazar, M.A. 
1998. Interdomain communication regulating ligand binding by PPAR-gamma. 
Nature 396(6709): 377-380. 
Shearer, B.G. and Billin, A.N. 2007. The next generation of PPAR drugs: Do we have the 
tools to find them? Biochim Biophys Acta: doi:10.1016/j.bbalip.2007.1005.1005. 
 236
Shi, Y., Hon, M., and Evans, R.M. 2002. The peroxisome proliferator-activated receptor 
delta, an integrator of transcriptional repression and nuclear receptor signaling. 
Proc Natl Acad Sci U S A 99(5): 2613-2618. 
Shiau, A.K., Barstad, D., Loria, P.M., Cheng, L., Kushner, P.J., Agard, D.A., and Greene, 
G.L. 1998. The structural basis of estrogen receptor/coactivator recognition and 
the antagonism of this interaction by tamoxifen. Cell 95(7): 927-937. 
Smith, S.C., Jr. 2007. Multiple risk factors for cardiovascular disease and diabetes 
mellitus. Am J Med 120(3 Suppl 1): S3-S11. 
Soderstrom, M., Vo, A., Heinzel, T., Lavinsky, R.M., Yang, W.M., Seto, E., Peterson, 
D.A., Rosenfeld, M.G., and Glass, C.K. 1997. Differential effects of nuclear 
receptor corepressor (N-CoR) expression levels on retinoic acid receptor-
mediated repression support the existence of dynamically regulated corepressor 
complexes. Mol Endocrinol 11(6): 682-692. 
Solomon, C., White, J.H., and Kremer, R. 1999. Mitogen-activated protein kinase inhibits 
1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating 
human retinoid X receptor alpha. J Clin Invest 103(12): 1729-1735. 
Spencer, T.E., Jenster, G., Burcin, M.M., Allis, C.D., Zhou, J., Mizzen, C.A., McKenna, 
N.J., Onate, S.A., Tsai, S.Y., Tsai, M.J., and O'Malley, B.W. 1997. Steroid 
receptor coactivator-1 is a histone acetyltransferase. Nature 389(6647): 194-198. 
Staels, B. 2005. Fluid retention mediated by renal PPARgamma. Cell Metab 2(2): 77-78. 
Staels, B. and Fruchart, J.C. 2005. Therapeutic roles of peroxisome proliferator-activated 
receptor agonists. Diabetes 54(8): 2460-2470. 
Staels, B., Vu-Dac, N., Kosykh, V.A., Saladin, R., Fruchart, J.C., Dallongeville, J., and 
Auwerx, J. 1995. Fibrates downregulate apolipoprotein C-III expression 
independent of induction of peroxisomal acyl coenzyme A oxidase. A potential 
mechanism for the hypolipidemic action of fibrates. J Clin Invest 95(2): 705-712. 
Stanley, T.B., Leesnitzer, L.M., Montana, V.G., Galardi, C.M., Lambert, M.H., Holt, J.A., 
Xu, H.E., Moore, L.B., Blanchard, S.G., and Stimmel, J.B. 2003. Subtype specific 
effects of peroxisome proliferator-activated receptor ligands on corepressor 
affinity. Biochemistry 42(31): 9278-9287. 
Steineger, H.H., Sorensen, H.N., Tugwood, J.D., Skrede, S., Spydevold, O., and Gautvik, 
K.M. 1994. Dexamethasone and insulin demonstrate marked and opposite 
regulation of the steady-state mRNA level of the peroxisomal proliferator-
activated receptor (PPAR) in hepatic cells. Hormonal modulation of fatty-acid-
induced transcription. Eur J Biochem 225(3): 967-974. 
Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, 
H.R., Ahima, R.S., and Lazar, M.A. 2001. The hormone resistin links obesity to 
diabetes. Nature 409(6818): 307-312. 
Struckmann, J.R. and Nicolaides, A.N. 1994. Flavonoids. A review of the pharmacology 
and therapeutic efficacy of Daflon 500 mg in patients with chronic venous 
insufficiency and related disorders. Angiology 45(6): 419-428. 
Sumanasekera, W.K., Tien, E.S., Davis, J.W., 2nd, Turpey, R., Perdew, G.H., and 
Vanden Heuvel, J.P. 2003a. Heat shock protein-90 (Hsp90) acts as a repressor of 
peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta 
activity. Biochemistry 42(36): 10726-10735. 
 237
Sumanasekera, W.K., Tien, E.S., Turpey, R., Vanden Heuvel, J.P., and Perdew, G.H. 
2003b. Evidence that peroxisome proliferator-activated receptor alpha is 
complexed with the 90-kDa heat shock protein and the hepatitis virus B X-
associated protein 2. J Biol Chem 278(7): 4467-4473. 
Sun, Y., Shaw, P.C., and Fung, K.P. 2007. Molecular authentication of Radix Puerariae 
Lobatae and Radix Puerariae Thomsonii by ITS and 5S rRNA spacer sequencing. 
Biol Pharm Bull 30(1): 173-175. 
Surapureddi, S., Yu, S., Bu, H., Hashimoto, T., Yeldandi, A.V., Kashireddy, P., 
Cherkaoui-Malki, M., Qi, C., Zhu, Y.J., Rao, M.S., and Reddy, J.K. 2002. 
Identification of a transcriptionally active peroxisome proliferator-activated 
receptor alpha -interacting cofactor complex in rat liver and characterization of 
PRIC285 as a coactivator. Proc Natl Acad Sci U S A 99(18): 11836-11841. 
Tagami, T., Gu, W.X., Peairs, P.T., West, B.L., and Jameson, J.L. 1998. A novel natural 
mutation in the thyroid hormone receptor defines a dual functional domain that 
exchanges nuclear receptor corepressors and coactivators. Mol Endocrinol 12(12): 
1888-1902. 
Tai, E.S., Collins, D., Robins, S.J., O'Connor, J.J., Jr., Bloomfield, H.E., Ordovas, J.M., 
Schaefer, E.J., and Brousseau, M.E. 2006. The L162V polymorphism at the 
peroxisome proliferator activated receptor alpha locus modulates the risk of 
cardiovascular events associated with insulin resistance and diabetes mellitus: the 
Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 187(1): 153-
160. 
Tai, E.S., Corella, D., Demissie, S., Cupples, L.A., Coltell, O., Schaefer, E.J., Tucker, 
K.L., and Ordovas, J.M. 2005. Polyunsaturated fatty acids interact with the 
PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-
III concentrations in the Framingham Heart Study. J Nutr 135(3): 397-403. 
Tai, E.S., Demissie, S., Cupples, L.A., Corella, D., Wilson, P.W., Schaefer, E.J., and 
Ordovas, J.M. 2002. Association between the PPARA L162V polymorphism and 
plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc 
Biol 22(5): 805-810. 
Takimoto, C.H., Glover, K., Huang, X., Hayes, S.A., Gallot, L., Quinn, M., Jovanovic, 
B.D., Shapiro, A., Hernandez, L., Goetz, A., Llorens, V., Lieberman, R., Crowell, 
J.A., Poisson, B.A., and Bergan, R.C. 2003. Phase I pharmacokinetic and 
pharmacodynamic analysis of unconjugated soy isoflavones administered to 
individuals with cancer. Cancer Epidemiol Biomarkers Prev 12(11 Pt 1): 1213-
1221. 
Taku, K., Umegaki, K., Sato, Y., Taki, Y., Endoh, K., and Watanabe, S. 2007. Soy 
isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 
11 randomized controlled trials. Am J Clin Nutr 85(4): 1148-1156. 
Tenenbaum, A., Motro, M., and Fisman, E.Z. 2005. Dual and pan-peroxisome 
proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. 
Cardiovasc Diabetol 4: 14. 
Tenkanen, L., Manttari, M., and Manninen, V. 1995. Some coronary risk factors related 
to the insulin resistance syndrome and treatment with gemfibrozil. Experience 
from the Helsinki Heart Study. Circulation 92(7): 1779-1785. 
 238
Tien, E.S., Davis, J.W., and Vanden Heuvel, J.P. 2004. Identification of the CREB-
binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-
activated receptor alpha coregulator. J Biol Chem 279(23): 24053-24063. 
Tontonoz, P., Graves, R.A., Budavari, A.I., Erdjument-Bromage, H., Lui, M., Hu, E., 
Tempst, P., and Spiegelman, B.M. 1994a. Adipocyte-specific transcription factor 
ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR 
gamma and RXR alpha. Nucleic Acids Res 22(25): 5628-5634. 
Tontonoz, P., Hu, E., Devine, J., Beale, E.G., and Spiegelman, B.M. 1995. PPAR gamma 
2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. 
Mol Cell Biol 15(1): 351-357. 
Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., and Spiegelman, B.M. 1994b. 
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 
8(10): 1224-1234. 
Treuter, E., Albrektsen, T., Johansson, L., Leers, J., and Gustafsson, J.A. 1998. A 
regulatory role for RIP140 in nuclear receptor activation. Mol Endocrinol 12(6): 
864-881. 
Tsao, W.C., Wu, H.M., Chi, K.H., Chang, Y.H., and Lin, W.W. 2005. Proteasome 
inhibitors induce peroxisome proliferator-activated receptor transactivation 
through RXR accumulation and a protein kinase C-dependent pathway. Exp Cell 
Res 304(1): 234-243. 
Tu, A.Y. and Albers, J.J. 2001. Glucose regulates the transcription of human genes 
relevant to HDL metabolism: responsive elements for peroxisome proliferator-
activated receptor are involved in the regulation of phospholipid transfer protein. 
Diabetes 50(8): 1851-1856. 
Tudor, C., Feige, J.N., Pingali, H., Lohray, V.B., Wahli, W., Desvergne, B., Engelborghs, 
Y., and Gelman, L. 2007. Association with coregulators is the major determinant 
governing peroxisome proliferator-activated receptor mobility in living cells. J 
Biol Chem 282(7): 4417-4426. 
Tugwood, J.D., Issemann, I., Anderson, R.G., Bundell, K.R., McPheat, W.L., and Green, 
S. 1992. The mouse peroxisome proliferator activated receptor recognizes a 
response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. 
Embo J 11(2): 433-439. 
Umesono, K. and Evans, R.M. 1989. Determinants of target gene specificity for 
steroid/thyroid hormone receptors. Cell 57(7): 1139-1146. 
Uppenberg, J., Svensson, C., Jaki, M., Bertilsson, G., Jendeberg, L., and Berkenstam, A. 
1998. Crystal structure of the ligand binding domain of the human nuclear 
receptor PPARgamma. J Biol Chem 273(47): 31108-31112. 
USDA. 2002. USDA-Iowa State University Database on the Isoflavone Contents of 
Foods, Release 1.3-2002. 
http://www.nal.usda.gov/fnic/foodcomp/Data/isoflav/isoflav.html. 
Van Patten, C.L., Olivotto, I.A., Chambers, G.K., Gelmon, K.A., Hislop, T.G., 
Templeton, E., Wattie, A., and Prior, J.C. 2002. Effect of soy phytoestrogens on 
hot flashes in postmenopausal women with breast cancer: a randomized, 
controlled clinical trial. J Clin Oncol 20(6): 1449-1455. 
 239
Vedavanam, K., Srijayanta, S., O'Reilly, J., Raman, A., and Wiseman, H. 1999. 
Antioxidant action and potential antidiabetic properties of an isoflavonoid-
containing soyabean phytochemical extract (SPE). Phytother Res 13(7): 601-608. 
Vega, R.B., Huss, J.M., and Kelly, D.P. 2000. The coactivator PGC-1 cooperates with 
peroxisome proliferator-activated receptor alpha in transcriptional control of 
nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 
20(5): 1868-1876. 
Verschure, P.J., Visser, A.E., and Rots, M.G. 2006. Step out of the groove: epigenetic 
gene control systems and engineered transcription factors. Adv Genet 56: 163-204. 
Voegel, J.J., Heine, M.J., Tini, M., Vivat, V., Chambon, P., and Gronemeyer, H. 1998. 
The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates 
transactivation through CBP binding-dependent and -independent pathways. 
Embo J 17(2): 507-519. 
Vohl, M.C., Lepage, P., Gaudet, D., Brewer, C.G., Betard, C., Perron, P., Houde, G., 
Cellier, C., Faith, J.M., Despres, J.P., Morgan, K., and Hudson, T.J. 2000. 
Molecular scanning of the human PPARa gene: association of the L162v mutation 
with hyperapobetalipoproteinemia. J Lipid Res 41(6): 945-952. 
Vu-Dac, N., Chopin-Delannoy, S., Gervois, P., Bonnelye, E., Martin, G., Fruchart, J.C., 
Laudet, V., and Staels, B. 1998. The nuclear receptors peroxisome proliferator-
activated receptor alpha and Rev-erbalpha mediate the species-specific regulation 
of apolipoprotein A-I expression by fibrates. J Biol Chem 273(40): 25713-25720. 
Vu-Dac, N., Gervois, P., Jakel, H., Nowak, M., Bauge, E., Dehondt, H., Staels, B., 
Pennacchio, L.A., Rubin, E.M., Fruchart-Najib, J., and Fruchart, J.C. 2003. 
Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly 
responsive to peroxisome proliferator-activated receptor alpha activators. J Biol 
Chem 278(20): 17982-17985. 
Vu-Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Fruchart, J.C., Staels, B., and 
Auwerx, J. 1995. Fibrates increase human apolipoprotein A-II expression through 
activation of the peroxisome proliferator-activated receptor. J Clin Invest 96(2): 
741-750. 
Vu-Dac, N., Schoonjans, K., Laine, B., Fruchart, J.C., Auwerx, J., and Staels, B. 1994. 
Negative regulation of the human apolipoprotein A-I promoter by fibrates can be 
attenuated by the interaction of the peroxisome proliferator-activated receptor 
with its response element. J Biol Chem 269(49): 31012-31018. 
Wagner, R.L., Apriletti, J.W., McGrath, M.E., West, B.L., Baxter, J.D., and Fletterick, 
R.J. 1995. A structural role for hormone in the thyroid hormone receptor. Nature 
378(6558): 690-697. 
Walter, D.H., Cejna, M., Diaz-Sandoval, L., Willis, S., Kirkwood, L., Stratford, P.W., 
Tietz, A.B., Kirchmair, R., Silver, M., Curry, C., Wecker, A., Yoon, Y.S., 
Heidenreich, R., Hanley, A., Kearney, M., Tio, F.O., Kuenzler, P., Isner, J.M., 
and Losordo, D.W. 2004. Local gene transfer of phVEGF-2 plasmid by gene-
eluting stents: an alternative strategy for inhibition of restenosis. Circulation 
110(1): 36-45. 
Wang, L.H., Yang, X.Y., Zhang, X., Huang, J., Hou, J., Li, J., Xiong, H., Mihalic, K., 
Zhu, H., Xiao, W., and Farrar, W.L. 2004. Transcriptional inactivation of STAT3 
 240
by PPARgamma suppresses IL-6-responsive multiple myeloma cells. Immunity 
20(2): 205-218. 
Wang, Q., Lu, J., and Yong, E.L. 2001. Ligand- and coactivator-mediated transactivation 
function (AF2) of the androgen receptor ligand-binding domain is inhibited by the 
cognate hinge region. J Biol Chem 276(10): 7493-7499. 
Wang, X., Wu, J., Chiba, H., Umegaki, K., Yamada, K., and Ishimi, Y. 2003a. Puerariae 
radix prevents bone loss in ovariectomized mice. J Bone Miner Metab 21(5): 268-
275. 
Wang, Y.X., Lee, C.H., Tiep, S., Yu, R.T., Ham, J., Kang, H., and Evans, R.M. 2003b. 
Peroxisome-proliferator-activated receptor delta activates fat metabolism to 
prevent obesity. Cell 113(2): 159-170. 
Wangen, K.E., Duncan, A.M., Xu, X., and Kurzer, M.S. 2001. Soy isoflavones improve 
plasma lipids in normocholesterolemic and mildly hypercholesterolemic 
postmenopausal women. Am J Clin Nutr 73(2): 225-231. 
Watts, G.F., Barrett, P.H., Ji, J., Serone, A.P., Chan, D.C., Croft, K.D., Loehrer, F., and 
Johnson, A.G. 2003. Differential regulation of lipoprotein kinetics by atorvastatin 
and fenofibrate in subjects with the metabolic syndrome. Diabetes 52(3): 803-811. 
Way, J.M., Harrington, W.W., Brown, K.K., Gottschalk, W.K., Sundseth, S.S., Mansfield, 
T.A., Ramachandran, R.K., Willson, T.M., and Kliewer, S.A. 2001. 
Comprehensive messenger ribonucleic acid profiling reveals that peroxisome 
proliferator-activated receptor gamma activation has coordinate effects on gene 
expression in multiple insulin-sensitive tissues. Endocrinology 142(3): 1269-1277. 
Webb, P., Anderson, C.M., Valentine, C., Nguyen, P., Marimuthu, A., West, B.L., Baxter, 
J.D., and Kushner, P.J. 2000. The nuclear receptor corepressor (N-CoR) contains 
three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). 
Mol Endocrinol 14(12): 1976-1985. 
Webb, P., Nguyen, P., and Kushner, P.J. 2003. Differential SERM effects on corepressor 
binding dictate ERalpha activity in vivo. J Biol Chem 278(9): 6912-6920. 
Werman, A., Hollenberg, A., Solanes, G., Bjorbaek, C., Vidal-Puig, A.J., and Flier, J.S. 
1997. Ligand-independent activation domain in the N terminus of peroxisome 
proliferator-activated receptor gamma (PPARgamma). Differential activity of 
PPARgamma1 and -2 isoforms and influence of insulin. J Biol Chem 272(32): 
20230-20235. 
White, J.H., Fernandes, I., Mader, S., and Yang, X.J. 2004. Corepressor recruitment by 
agonist-bound nuclear receptors. Vitam Horm 68: 123-143. 
Willson, T.M., Brown, P.J., Sternbach, D.D., and Henke, B.R. 2000. The PPARs: from 
orphan receptors to drug discovery. J Med Chem 43(4): 527-550. 
Willson, T.M., Cobb, J.E., Cowan, D.J., Wiethe, R.W., Correa, I.D., Prakash, S.R., Beck, 
K.D., Moore, L.B., Kliewer, S.A., and Lehmann, J.M. 1996. The structure-
activity relationship between peroxisome proliferator-activated receptor gamma 
agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 
39(3): 665-668. 
Woo, J., Lau, E., Ho, S.C., Cheng, F., Chan, C., Chan, A.S., Haines, C.J., Chan, T.Y., Li, 
M., and Sham, A. 2003. Comparison of Pueraria lobata with hormone 
replacement therapy in treating the adverse health consequences of menopause. 
Menopause 10(4): 352-361. 
 241
Wu, P., Peters, J.M., and Harris, R.A. 2001. Adaptive increase in pyruvate 
dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-
activated receptor alpha. Biochem Biophys Res Commun 287(2): 391-396. 
Wu, Q., Wang, M., and Simon, J.E. 2003a. Determination of isoflavones in red clover 
and related species by high-performance liquid chromatography combined with 
ultraviolet and mass spectrometric detection. J Chromatogr A 1016(2): 195-209. 
Wu, Y., Chin, W.W., Wang, Y., and Burris, T.P. 2003b. Ligand and coactivator identity 
determines the requirement of the charge clamp for coactivation of the 
peroxisome proliferator-activated receptor gamma. J Biol Chem 278(10): 8637-
8644. 
Xu, H.E., Lambert, M.H., Montana, V.G., Parks, D.J., Blanchard, S.G., Brown, P.J., 
Sternbach, D.D., Lehmann, J.M., Wisely, G.B., Willson, T.M., Kliewer, S.A., and 
Milburn, M.V. 1999. Molecular recognition of fatty acids by peroxisome 
proliferator-activated receptors. Mol Cell 3(3): 397-403. 
Xu, H.E., Lambert, M.H., Montana, V.G., Plunket, K.D., Moore, L.B., Collins, J.L., 
Oplinger, J.A., Kliewer, S.A., Gampe, R.T., Jr., McKee, D.D., Moore, J.T., and 
Willson, T.M. 2001. Structural determinants of ligand binding selectivity between 
the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 98(24): 
13919-13924. 
Xu, H.E., Stanley, T.B., Montana, V.G., Lambert, M.H., Shearer, B.G., Cobb, J.E., 
McKee, D.D., Galardi, C.M., Plunket, K.D., Nolte, R.T., Parks, D.J., Moore, J.T., 
Kliewer, S.A., Willson, T.M., and Stimmel, J.B. 2002a. Structural basis for 
antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 
415(6873): 813-817. 
Xu, J. and Li, Q. 2003. Review of the in vivo functions of the p160 steroid receptor 
coactivator family. Mol Endocrinol 17(9): 1681-1692. 
Xu, J., Xiao, G., Trujillo, C., Chang, V., Blanco, L., Joseph, S.B., Bassilian, S., Saad, 
M.F., Tontonoz, P., Lee, W.N., and Kurland, I.J. 2002b. Peroxisome proliferator-
activated receptor alpha (PPARalpha) influences substrate utilization for hepatic 
glucose production. J Biol Chem 277(52): 50237-50244. 
Xu, X., Wang, H.J., Murphy, P.A., and Hendrich, S. 2000. Neither background diet nor 
type of soy food affects short-term isoflavone bioavailability in women. J Nutr 
130(4): 798-801. 
Yaacob, N.S., Norazmi, M.N., Gibson, G.G., and Kass, G.E. 2001. The transcription of 
the peroxisome proliferator-activated receptor alpha gene is regulated by protein 
kinase C. Toxicol Lett 125(1-3): 133-141. 
Yagi, H., Pohlenz, J., Hayashi, Y., Sakurai, A., and Refetoff, S. 1997. Resistance to 
thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q 
and R243W, with marked impairment of function that cannot be explained by 
altered in vitro 3,5,3'-triiodothyroinine binding affinity. J Clin Endocrinol Metab 
82(5): 1608-1614. 
Yamakawa-Kobayashi, K., Ishiguro, H., Arinami, T., Miyazaki, R., and Hamaguchi, H. 
2002. A Val227Ala polymorphism in the peroxisome proliferator activated 
receptor alpha (PPARalpha) gene is associated with variations in serum lipid 
levels. J Med Genet 39(3): 189-191. 
 242
Yamashita, D., Yamaguchi, T., Shimizu, M., Nakata, N., Hirose, F., and Osumi, T. 2004. 
The transactivating function of peroxisome proliferator-activated receptor gamma 
is negatively regulated by SUMO conjugation in the amino-terminal domain. 
Genes Cells 9(11): 1017-1029. 
Yamashita, T., Sasahara, T., Pomeroy, S.E., Collier, G., and Nestel, P.J. 1998. Arterial 
compliance, blood pressure, plasma leptin, and plasma lipids in women are 
improved with weight reduction equally with a meat-based diet and a plant-based 
diet. Metabolism 47(11): 1308-1314. 
Yamauchi, T., Kamon, J., Waki, H., Murakami, K., Motojima, K., Komeda, K., Ide, T., 
Kubota, N., Terauchi, Y., Tobe, K., Miki, H., Tsuchida, A., Akanuma, Y., Nagai, 
R., Kimura, S., and Kadowaki, T. 2001. The mechanisms by which both 
heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) 
deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 
276(44): 41245-41254. 
Yang, W., Rachez, C., and Freedman, L.P. 2000. Discrete roles for peroxisome 
proliferator-activated receptor gamma and retinoid X receptor in recruiting 
nuclear receptor coactivators. Mol Cell Biol 20(21): 8008-8017. 
Yu, C., Markan, K., Temple, K.A., Deplewski, D., Brady, M.J., and Cohen, R.N. 2005. 
The nuclear receptor corepressors NCoR and SMRT decrease peroxisome 
proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 
adipogenesis. J Biol Chem 280(14): 13600-13605. 
Yu, J.G., Javorschi, S., Hevener, A.L., Kruszynska, Y.T., Norman, R.A., Sinha, M., and 
Olefsky, J.M. 2002. The effect of thiazolidinediones on plasma adiponectin levels 
in normal, obese, and type 2 diabetic subjects. Diabetes 51(10): 2968-2974. 
Yu, K., Bayona, W., Kallen, C.B., Harding, H.P., Ravera, C.P., McMahon, G., Brown, 
M., and Lazar, M.A. 1995. Differential activation of peroxisome proliferator-
activated receptors by eicosanoids. J Biol Chem 270(41): 23975-23983. 
Yu, S. and Reddy, J.K. 2007. Transcription coactivators for peroxisome proliferator-
activated receptors. Biochim Biophys Acta. 
Zahradka, P. 2007. Cardiovascular actions of the peroxisome proliferator-activated 
receptor-alpha (PPARalpha) agonist Wy14,643. Cardiovasc Drug Rev 25(2): 99-
122. 
Zamir, I., Harding, H.P., Atkins, G.B., Horlein, A., Glass, C.K., Rosenfeld, M.G., and 
Lazar, M.A. 1996. A nuclear hormone receptor corepressor mediates 
transcriptional silencing by receptors with distinct repression domains. Mol Cell 
Biol 16(10): 5458-5465. 
Zamir, I., Zhang, J., and Lazar, M.A. 1997. Stoichiometric and steric principles 
governing repression by nuclear hormone receptors. Genes Dev 11(7): 835-846. 
Zhan, S. and Ho, S.C. 2005. Meta-analysis of the effects of soy protein containing 
isoflavones on the lipid profile. Am J Clin Nutr 81(2): 397-408. 
Zhang, B., Marcus, S.L., Miyata, K.S., Subramani, S., Capone, J.P., and Rachubinski, 
R.A. 1993. Characterization of protein-DNA interactions within the peroxisome 
proliferator-responsive element of the rat hydratase-dehydrogenase gene. J Biol 
Chem 268(17): 12939-12945. 
Zhang, J., Hu, X., and Lazar, M.A. 1999. A novel role for helix 12 of retinoid X receptor 
in regulating repression. Mol Cell Biol 19(9): 6448-6457. 
 243
Zhang, X., Krutchinsky, A., Fukuda, A., Chen, W., Yamamura, S., Chait, B.T., and 
Roeder, R.G. 2005. MED1/TRAP220 exists predominantly in a TRAP/ Mediator 
subpopulation enriched in RNA polymerase II and is required for ER-mediated 
transcription. Mol Cell 19(1): 89-100. 
Zhou, G., Cummings, R., Li, Y., Mitra, S., Wilkinson, H.A., Elbrecht, A., Hermes, J.D., 
Schaeffer, J.M., Smith, R.G., and Moller, D.E. 1998a. Nuclear receptors have 
distinct affinities for coactivators: characterization by fluorescence resonance 
energy transfer. Mol Endocrinol 12(10): 1594-1604. 
Zhou, Y.T., Shimabukuro, M., Wang, M.Y., Lee, Y., Higa, M., Milburn, J.L., Newgard, 
C.B., and Unger, R.H. 1998b. Role of peroxisome proliferator-activated receptor 
alpha in disease of pancreatic beta cells. Proc Natl Acad Sci U S A 95(15): 8898-
8903. 
Zhu, Y., Kan, L., Qi, C., Kanwar, Y.S., Yeldandi, A.V., Rao, M.S., and Reddy, J.K. 2000. 
Isolation and characterization of peroxisome proliferator-activated receptor 
(PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem 
275(18): 13510-13516. 
Zhu, Y., Qi, C., Cao, W.Q., Yeldandi, A.V., Rao, M.S., and Reddy, J.K. 2001. Cloning 
and characterization of PIMT, a protein with a methyltransferase domain, which 
interacts with and enhances nuclear receptor coactivator PRIP function. Proc Natl 
Acad Sci U S A 98(18): 10380-10385. 
Zhu, Y., Qi, C., Jain, S., Rao, M.S., and Reddy, J.K. 1997. Isolation and characterization 
of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J 
Biol Chem 272(41): 25500-25506. 
Zhu, Y., Qi, C., Korenberg, J.R., Chen, X.N., Noya, D., Rao, M.S., and Reddy, J.K. 1995. 
Structural organization of mouse peroxisome proliferator-activated receptor 
gamma (mPPAR gamma) gene: alternative promoter use and different splicing 








Transactivation activity of PPARα V227A variant on a consensus CYP4A6-PPRE and the 
mitochondria HMGCS2 promoter in the adenovirus expression system 
 
HepG2 cells were infected with adenovirus expressing WT PPARα, V227A or LacZ before 
transfection with CYP4A6-PPRE-Luc (100ng) (A), or HMGCS2-Luc (100ng) (B) and treatment 
with WY14,643 as indicated. PPARα and actin protein levels from total protein lysates (20-25μg) 
of representative replicates were detected with specific antibodies. Values are mean ± SD of three 
replicates, and expressed as percentage of maximal WT activity. * p<0.05; **p<0.01.  
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